[
  {
    "id": "moa.assertion:66",
    "description": "T315I mutant ABL1 in p210 BCR-ABL cells resulted in retained high levels of phosphotyrosine at increasing concentrations of inhibitor STI-571, whereas wildtype appropriately received inhibition.",
    "type": "VariantTherapeuticResponseStudy",
    "predicate": "predictsResistanceTo",
    "direction": "none",
    "qualifiers": {
      "alleleOrigin": "somatic",
      "geneContext": {
        "id": "moa.normalize.gene:ABL1",
        "label": "ABL1",
        "extensions": [
          {
            "type": "Extension",
            "name": "gene_normalizer_id",
            "value": "hgnc:76"
          }
        ],
        "type": "Gene"
      }
    },
    "variant": "variants.json#/moa.variant:66",
    "specifiedBy": "methods.json#/moa.variant:66",
    "isReportedIn": [
      "documents.json#/moa.source:43"
    ],
    "strength": "strengths.json#/vicc.e000009",
    "therapeutic": "therapeutics.json#/moa.normalize.therapy.rxcui:282388",
    "tumorType": "tumorTypes.json#/moa.normalize.disease.ncit:C3174"
  },
  {
    "id": "moa.assertion:68",
    "description": "Secondary mutations in BCR-ABL may suggest resistance to imatinib in CML. ABL [T315I, V299L, T315A, F317L/V/I/C] are known to be less sensitive to dasatinib.",
    "type": "VariantTherapeuticResponseStudy",
    "predicate": "predictsResistanceTo",
    "direction": "none",
    "qualifiers": {
      "alleleOrigin": "somatic",
      "geneContext": {
        "id": "moa.normalize.gene:ABL1",
        "label": "ABL1",
        "extensions": [
          {
            "type": "Extension",
            "name": "gene_normalizer_id",
            "value": "hgnc:76"
          }
        ],
        "type": "Gene"
      }
    },
    "variant": "variants.json#/moa.variant:68",
    "specifiedBy": "methods.json#/moa.variant:68",
    "isReportedIn": [
      "documents.json#/moa.source:44"
    ],
    "strength": "strengths.json#/vicc.e000007",
    "therapeutic": "therapeutics.json#/moa.normalize.therapy.rxcui:1546019",
    "tumorType": "tumorTypes.json#/moa.normalize.disease.ncit:C3174"
  },
  {
    "id": "moa.assertion:69",
    "description": "Secondary mutations in BCR-ABL may suggest resistance to imatinib in CML. ABL [T315I, V299L, T315A, F317L/V/I/C] are known to be less sensitive to dasatinib.",
    "type": "VariantTherapeuticResponseStudy",
    "predicate": "predictsResistanceTo",
    "direction": "none",
    "qualifiers": {
      "alleleOrigin": "somatic",
      "geneContext": {
        "id": "moa.normalize.gene:ABL1",
        "label": "ABL1",
        "extensions": [
          {
            "type": "Extension",
            "name": "gene_normalizer_id",
            "value": "hgnc:76"
          }
        ],
        "type": "Gene"
      }
    },
    "variant": "variants.json#/moa.variant:66",
    "specifiedBy": "methods.json#/moa.variant:66",
    "isReportedIn": [
      "documents.json#/moa.source:44"
    ],
    "strength": "strengths.json#/vicc.e000007",
    "therapeutic": "therapeutics.json#/moa.normalize.therapy.rxcui:1546019",
    "tumorType": "tumorTypes.json#/moa.normalize.disease.ncit:C3174"
  },
  {
    "id": "moa.assertion:70",
    "description": "Secondary mutations in BCR-ABL may suggest resistance to imatinib in CML. ABL [T315I, V299L, T315A, F317L/V/I/C] are known to be less sensitive to dasatinib.",
    "type": "VariantTherapeuticResponseStudy",
    "predicate": "predictsResistanceTo",
    "direction": "none",
    "qualifiers": {
      "alleleOrigin": "somatic",
      "geneContext": {
        "id": "moa.normalize.gene:ABL1",
        "label": "ABL1",
        "extensions": [
          {
            "type": "Extension",
            "name": "gene_normalizer_id",
            "value": "hgnc:76"
          }
        ],
        "type": "Gene"
      }
    },
    "variant": "variants.json#/moa.variant:70",
    "specifiedBy": "methods.json#/moa.variant:70",
    "isReportedIn": [
      "documents.json#/moa.source:44"
    ],
    "strength": "strengths.json#/vicc.e000007",
    "therapeutic": "therapeutics.json#/moa.normalize.therapy.rxcui:1546019",
    "tumorType": "tumorTypes.json#/moa.normalize.disease.ncit:C3174"
  },
  {
    "id": "moa.assertion:71",
    "description": "Secondary mutations in BCR-ABL may suggest resistance to imatinib in CML. ABL [T315I, V299L, T315A, F317L/V/I/C] are known to be less sensitive to dasatinib.",
    "type": "VariantTherapeuticResponseStudy",
    "predicate": "predictsResistanceTo",
    "direction": "none",
    "qualifiers": {
      "alleleOrigin": "somatic",
      "geneContext": {
        "id": "moa.normalize.gene:ABL1",
        "label": "ABL1",
        "extensions": [
          {
            "type": "Extension",
            "name": "gene_normalizer_id",
            "value": "hgnc:76"
          }
        ],
        "type": "Gene"
      }
    },
    "variant": "variants.json#/moa.variant:71",
    "specifiedBy": "methods.json#/moa.variant:71",
    "isReportedIn": [
      "documents.json#/moa.source:44"
    ],
    "strength": "strengths.json#/vicc.e000007",
    "therapeutic": "therapeutics.json#/moa.normalize.therapy.rxcui:1546019",
    "tumorType": "tumorTypes.json#/moa.normalize.disease.ncit:C3174"
  },
  {
    "id": "moa.assertion:72",
    "description": "Secondary mutations in BCR-ABL may suggest resistance to imatinib in CML. ABL [T315I, V299L, T315A, F317L/V/I/C] are known to be less sensitive to dasatinib.",
    "type": "VariantTherapeuticResponseStudy",
    "predicate": "predictsResistanceTo",
    "direction": "none",
    "qualifiers": {
      "alleleOrigin": "somatic",
      "geneContext": {
        "id": "moa.normalize.gene:ABL1",
        "label": "ABL1",
        "extensions": [
          {
            "type": "Extension",
            "name": "gene_normalizer_id",
            "value": "hgnc:76"
          }
        ],
        "type": "Gene"
      }
    },
    "variant": "variants.json#/moa.variant:72",
    "specifiedBy": "methods.json#/moa.variant:72",
    "isReportedIn": [
      "documents.json#/moa.source:44"
    ],
    "strength": "strengths.json#/vicc.e000007",
    "therapeutic": "therapeutics.json#/moa.normalize.therapy.rxcui:1546019",
    "tumorType": "tumorTypes.json#/moa.normalize.disease.ncit:C3174"
  },
  {
    "id": "moa.assertion:73",
    "description": "Secondary mutations in BCR-ABL may suggest resistance to imatinib in CML. ABL [T315I, V299L, T315A, F317L/V/I/C] are known to be less sensitive to dasatinib.",
    "type": "VariantTherapeuticResponseStudy",
    "predicate": "predictsResistanceTo",
    "direction": "none",
    "qualifiers": {
      "alleleOrigin": "somatic",
      "geneContext": {
        "id": "moa.normalize.gene:ABL1",
        "label": "ABL1",
        "extensions": [
          {
            "type": "Extension",
            "name": "gene_normalizer_id",
            "value": "hgnc:76"
          }
        ],
        "type": "Gene"
      }
    },
    "variant": "variants.json#/moa.variant:73",
    "specifiedBy": "methods.json#/moa.variant:73",
    "isReportedIn": [
      "documents.json#/moa.source:44"
    ],
    "strength": "strengths.json#/vicc.e000007",
    "therapeutic": "therapeutics.json#/moa.normalize.therapy.rxcui:1546019",
    "tumorType": "tumorTypes.json#/moa.normalize.disease.ncit:C3174"
  },
  {
    "id": "moa.assertion:75",
    "description": "Secondary mutations in BCR-ABL may suggest resistance to imatinib in CML. ABL [E255K/V, Y253H, F359V/C/I] are known to be less sensitive to Nilotinib.",
    "type": "VariantTherapeuticResponseStudy",
    "predicate": "predictsResistanceTo",
    "direction": "none",
    "qualifiers": {
      "alleleOrigin": "somatic",
      "geneContext": {
        "id": "moa.normalize.gene:ABL1",
        "label": "ABL1",
        "extensions": [
          {
            "type": "Extension",
            "name": "gene_normalizer_id",
            "value": "hgnc:76"
          }
        ],
        "type": "Gene"
      }
    },
    "variant": "variants.json#/moa.variant:75",
    "specifiedBy": "methods.json#/moa.variant:75",
    "isReportedIn": [
      "documents.json#/moa.source:44"
    ],
    "strength": "strengths.json#/vicc.e000007",
    "therapeutic": "therapeutics.json#/moa.normalize.therapy.rxcui:662281",
    "tumorType": "tumorTypes.json#/moa.normalize.disease.ncit:C3174"
  },
  {
    "id": "moa.assertion:76",
    "description": "Secondary mutations in BCR-ABL may suggest resistance to imatinib in CML. ABL [E255K/V, Y253H, F359V/C/I] are known to be less sensitive to Nilotinib.",
    "type": "VariantTherapeuticResponseStudy",
    "predicate": "predictsResistanceTo",
    "direction": "none",
    "qualifiers": {
      "alleleOrigin": "somatic",
      "geneContext": {
        "id": "moa.normalize.gene:ABL1",
        "label": "ABL1",
        "extensions": [
          {
            "type": "Extension",
            "name": "gene_normalizer_id",
            "value": "hgnc:76"
          }
        ],
        "type": "Gene"
      }
    },
    "variant": "variants.json#/moa.variant:76",
    "specifiedBy": "methods.json#/moa.variant:76",
    "isReportedIn": [
      "documents.json#/moa.source:44"
    ],
    "strength": "strengths.json#/vicc.e000007",
    "therapeutic": "therapeutics.json#/moa.normalize.therapy.rxcui:662281",
    "tumorType": "tumorTypes.json#/moa.normalize.disease.ncit:C3174"
  },
  {
    "id": "moa.assertion:77",
    "description": "Secondary mutations in BCR-ABL may suggest resistance to imatinib in CML. ABL [E255K/V, Y253H, F359V/C/I] are known to be less sensitive to Nilotinib.",
    "type": "VariantTherapeuticResponseStudy",
    "predicate": "predictsResistanceTo",
    "direction": "none",
    "qualifiers": {
      "alleleOrigin": "somatic",
      "geneContext": {
        "id": "moa.normalize.gene:ABL1",
        "label": "ABL1",
        "extensions": [
          {
            "type": "Extension",
            "name": "gene_normalizer_id",
            "value": "hgnc:76"
          }
        ],
        "type": "Gene"
      }
    },
    "variant": "variants.json#/moa.variant:77",
    "specifiedBy": "methods.json#/moa.variant:77",
    "isReportedIn": [
      "documents.json#/moa.source:44"
    ],
    "strength": "strengths.json#/vicc.e000007",
    "therapeutic": "therapeutics.json#/moa.normalize.therapy.rxcui:662281",
    "tumorType": "tumorTypes.json#/moa.normalize.disease.ncit:C3174"
  },
  {
    "id": "moa.assertion:78",
    "description": "Secondary mutations in BCR-ABL may suggest resistance to imatinib in CML. ABL [E255K/V, Y253H, F359V/C/I] are known to be less sensitive to Nilotinib.",
    "type": "VariantTherapeuticResponseStudy",
    "predicate": "predictsResistanceTo",
    "direction": "none",
    "qualifiers": {
      "alleleOrigin": "somatic",
      "geneContext": {
        "id": "moa.normalize.gene:ABL1",
        "label": "ABL1",
        "extensions": [
          {
            "type": "Extension",
            "name": "gene_normalizer_id",
            "value": "hgnc:76"
          }
        ],
        "type": "Gene"
      }
    },
    "variant": "variants.json#/moa.variant:78",
    "specifiedBy": "methods.json#/moa.variant:78",
    "isReportedIn": [
      "documents.json#/moa.source:44"
    ],
    "strength": "strengths.json#/vicc.e000007",
    "therapeutic": "therapeutics.json#/moa.normalize.therapy.rxcui:662281",
    "tumorType": "tumorTypes.json#/moa.normalize.disease.ncit:C3174"
  },
  {
    "id": "moa.assertion:79",
    "description": "Secondary mutations in BCR-ABL may suggest resistance to imatinib in CML. ABL [E255K/V, Y253H, F359V/C/I] are known to be less sensitive to Nilotinib.",
    "type": "VariantTherapeuticResponseStudy",
    "predicate": "predictsResistanceTo",
    "direction": "none",
    "qualifiers": {
      "alleleOrigin": "somatic",
      "geneContext": {
        "id": "moa.normalize.gene:ABL1",
        "label": "ABL1",
        "extensions": [
          {
            "type": "Extension",
            "name": "gene_normalizer_id",
            "value": "hgnc:76"
          }
        ],
        "type": "Gene"
      }
    },
    "variant": "variants.json#/moa.variant:79",
    "specifiedBy": "methods.json#/moa.variant:79",
    "isReportedIn": [
      "documents.json#/moa.source:44"
    ],
    "strength": "strengths.json#/vicc.e000007",
    "therapeutic": "therapeutics.json#/moa.normalize.therapy.rxcui:662281",
    "tumorType": "tumorTypes.json#/moa.normalize.disease.ncit:C3174"
  },
  {
    "id": "moa.assertion:80",
    "description": "Secondary mutations in BCR-ABL may suggest resistance to imatinib in CML. ABL [E255K/V, Y253H, F359V/C/I] are known to be less sensitive to Nilotinib.",
    "type": "VariantTherapeuticResponseStudy",
    "predicate": "predictsResistanceTo",
    "direction": "none",
    "qualifiers": {
      "alleleOrigin": "somatic",
      "geneContext": {
        "id": "moa.normalize.gene:ABL1",
        "label": "ABL1",
        "extensions": [
          {
            "type": "Extension",
            "name": "gene_normalizer_id",
            "value": "hgnc:76"
          }
        ],
        "type": "Gene"
      }
    },
    "variant": "variants.json#/moa.variant:80",
    "specifiedBy": "methods.json#/moa.variant:80",
    "isReportedIn": [
      "documents.json#/moa.source:44"
    ],
    "strength": "strengths.json#/vicc.e000007",
    "therapeutic": "therapeutics.json#/moa.normalize.therapy.rxcui:662281",
    "tumorType": "tumorTypes.json#/moa.normalize.disease.ncit:C3174"
  },
  {
    "id": "moa.assertion:81",
    "description": "Dasatinib (Sprycel) is not recommended by the National Comprehensive Cancer Network\u00ae (NCCN\u00ae) as a treatment option for patients with CML in the context of secondary resistance variants. Selection of an alternate TKI in the context of TKI-resistant or possible-TKI resistant BCR::ABL1 mutant CML may be based on mutantion profile.",
    "type": "VariantTherapeuticResponseStudy",
    "predicate": "predictsResistanceTo",
    "direction": "none",
    "qualifiers": {
      "alleleOrigin": "somatic",
      "geneContext": {
        "id": "moa.normalize.gene:ABL1",
        "label": "ABL1",
        "extensions": [
          {
            "type": "Extension",
            "name": "gene_normalizer_id",
            "value": "hgnc:76"
          }
        ],
        "type": "Gene"
      }
    },
    "variant": "variants.json#/moa.variant:77",
    "specifiedBy": "methods.json#/moa.variant:77",
    "isReportedIn": [
      "documents.json#/moa.source:45"
    ],
    "strength": "strengths.json#/vicc.e000003",
    "therapeutic": "therapeutics.json#/moa.normalize.therapy.rxcui:1546019",
    "tumorType": "tumorTypes.json#/moa.normalize.disease.ncit:C3174"
  },
  {
    "id": "moa.assertion:82",
    "description": "Dasatinib (Sprycel) is not recommended by the National Comprehensive Cancer Network\u00ae (NCCN\u00ae) as a treatment option for patients with CML in the context of secondary resistance variants. Selection of an alternate TKI in the context of TKI-resistant or possible-TKI resistant BCR::ABL1 mutant CML may be based on mutantion profile.",
    "type": "VariantTherapeuticResponseStudy",
    "predicate": "predictsResistanceTo",
    "direction": "none",
    "qualifiers": {
      "alleleOrigin": "somatic",
      "geneContext": {
        "id": "moa.normalize.gene:ABL1",
        "label": "ABL1",
        "extensions": [
          {
            "type": "Extension",
            "name": "gene_normalizer_id",
            "value": "hgnc:76"
          }
        ],
        "type": "Gene"
      }
    },
    "variant": "variants.json#/moa.variant:75",
    "specifiedBy": "methods.json#/moa.variant:75",
    "isReportedIn": [
      "documents.json#/moa.source:45"
    ],
    "strength": "strengths.json#/vicc.e000003",
    "therapeutic": "therapeutics.json#/moa.normalize.therapy.rxcui:1546019",
    "tumorType": "tumorTypes.json#/moa.normalize.disease.ncit:C3174"
  },
  {
    "id": "moa.assertion:83",
    "description": "Dasatinib (Sprycel) is not recommended by the National Comprehensive Cancer Network\u00ae (NCCN\u00ae) as a treatment option for patients with CML in the context of secondary resistance variants. Selection of an alternate TKI in the context of TKI-resistant or possible-TKI resistant BCR::ABL1 mutant CML may be based on mutantion profile.",
    "type": "VariantTherapeuticResponseStudy",
    "predicate": "predictsResistanceTo",
    "direction": "none",
    "qualifiers": {
      "alleleOrigin": "somatic",
      "geneContext": {
        "id": "moa.normalize.gene:ABL1",
        "label": "ABL1",
        "extensions": [
          {
            "type": "Extension",
            "name": "gene_normalizer_id",
            "value": "hgnc:76"
          }
        ],
        "type": "Gene"
      }
    },
    "variant": "variants.json#/moa.variant:76",
    "specifiedBy": "methods.json#/moa.variant:76",
    "isReportedIn": [
      "documents.json#/moa.source:45"
    ],
    "strength": "strengths.json#/vicc.e000003",
    "therapeutic": "therapeutics.json#/moa.normalize.therapy.rxcui:1546019",
    "tumorType": "tumorTypes.json#/moa.normalize.disease.ncit:C3174"
  },
  {
    "id": "moa.assertion:84",
    "description": "Dasatinib (Sprycel) is not recommended by the National Comprehensive Cancer Network\u00ae (NCCN\u00ae) as a treatment option for patients with CML in the context of secondary resistance variants. Selection of an alternate TKI in the context of TKI-resistant or possible-TKI resistant BCR::ABL1 mutant CML may be based on mutantion profile.",
    "type": "VariantTherapeuticResponseStudy",
    "predicate": "predictsResistanceTo",
    "direction": "none",
    "qualifiers": {
      "alleleOrigin": "somatic",
      "geneContext": {
        "id": "moa.normalize.gene:ABL1",
        "label": "ABL1",
        "extensions": [
          {
            "type": "Extension",
            "name": "gene_normalizer_id",
            "value": "hgnc:76"
          }
        ],
        "type": "Gene"
      }
    },
    "variant": "variants.json#/moa.variant:78",
    "specifiedBy": "methods.json#/moa.variant:78",
    "isReportedIn": [
      "documents.json#/moa.source:45"
    ],
    "strength": "strengths.json#/vicc.e000003",
    "therapeutic": "therapeutics.json#/moa.normalize.therapy.rxcui:1546019",
    "tumorType": "tumorTypes.json#/moa.normalize.disease.ncit:C3174"
  },
  {
    "id": "moa.assertion:85",
    "description": "Dasatinib (Sprycel) is not recommended by the National Comprehensive Cancer Network\u00ae (NCCN\u00ae) as a treatment option for patients with CML in the context of secondary resistance variants. Selection of an alternate TKI in the context of TKI-resistant or possible-TKI resistant BCR::ABL1 mutant CML may be based on mutantion profile.",
    "type": "VariantTherapeuticResponseStudy",
    "predicate": "predictsResistanceTo",
    "direction": "none",
    "qualifiers": {
      "alleleOrigin": "somatic",
      "geneContext": {
        "id": "moa.normalize.gene:ABL1",
        "label": "ABL1",
        "extensions": [
          {
            "type": "Extension",
            "name": "gene_normalizer_id",
            "value": "hgnc:76"
          }
        ],
        "type": "Gene"
      }
    },
    "variant": "variants.json#/moa.variant:79",
    "specifiedBy": "methods.json#/moa.variant:79",
    "isReportedIn": [
      "documents.json#/moa.source:45"
    ],
    "strength": "strengths.json#/vicc.e000003",
    "therapeutic": "therapeutics.json#/moa.normalize.therapy.rxcui:1546019",
    "tumorType": "tumorTypes.json#/moa.normalize.disease.ncit:C3174"
  },
  {
    "id": "moa.assertion:86",
    "description": "Dasatinib (Sprycel) is not recommended by the National Comprehensive Cancer Network\u00ae (NCCN\u00ae) as a treatment option for patients with CML in the context of secondary resistance variants. Selection of an alternate TKI in the context of TKI-resistant or possible-TKI resistant BCR::ABL1 mutant CML may be based on mutantion profile.",
    "type": "VariantTherapeuticResponseStudy",
    "predicate": "predictsResistanceTo",
    "direction": "none",
    "qualifiers": {
      "alleleOrigin": "somatic",
      "geneContext": {
        "id": "moa.normalize.gene:ABL1",
        "label": "ABL1",
        "extensions": [
          {
            "type": "Extension",
            "name": "gene_normalizer_id",
            "value": "hgnc:76"
          }
        ],
        "type": "Gene"
      }
    },
    "variant": "variants.json#/moa.variant:80",
    "specifiedBy": "methods.json#/moa.variant:80",
    "isReportedIn": [
      "documents.json#/moa.source:45"
    ],
    "strength": "strengths.json#/vicc.e000003",
    "therapeutic": "therapeutics.json#/moa.normalize.therapy.rxcui:1546019",
    "tumorType": "tumorTypes.json#/moa.normalize.disease.ncit:C3174"
  },
  {
    "id": "moa.assertion:87",
    "description": "Nilotinib (Tasigna) is not recommended by the National Comprehensive Cancer Network\u00ae (NCCN\u00ae) as a treatment option for patients with CML in the context of secondary resistance variants. Selection of an alternate TKI in the context of TKI-resistant or possible-TKI resistant BCR::ABL1 mutant CML may be based on mutantion profile.",
    "type": "VariantTherapeuticResponseStudy",
    "predicate": "predictsResistanceTo",
    "direction": "none",
    "qualifiers": {
      "alleleOrigin": "somatic",
      "geneContext": {
        "id": "moa.normalize.gene:ABL1",
        "label": "ABL1",
        "extensions": [
          {
            "type": "Extension",
            "name": "gene_normalizer_id",
            "value": "hgnc:76"
          }
        ],
        "type": "Gene"
      }
    },
    "variant": "variants.json#/moa.variant:70",
    "specifiedBy": "methods.json#/moa.variant:70",
    "isReportedIn": [
      "documents.json#/moa.source:45"
    ],
    "strength": "strengths.json#/vicc.e000003",
    "therapeutic": "therapeutics.json#/moa.normalize.therapy.rxcui:662281",
    "tumorType": "tumorTypes.json#/moa.normalize.disease.ncit:C3174"
  },
  {
    "id": "moa.assertion:88",
    "description": "Nilotinib (Tasigna) is not recommended by the National Comprehensive Cancer Network\u00ae (NCCN\u00ae) as a treatment option for patients with CML in the context of secondary resistance variants. Selection of an alternate TKI in the context of TKI-resistant or possible-TKI resistant BCR::ABL1 mutant CML may be based on mutantion profile.",
    "type": "VariantTherapeuticResponseStudy",
    "predicate": "predictsResistanceTo",
    "direction": "none",
    "qualifiers": {
      "alleleOrigin": "somatic",
      "geneContext": {
        "id": "moa.normalize.gene:ABL1",
        "label": "ABL1",
        "extensions": [
          {
            "type": "Extension",
            "name": "gene_normalizer_id",
            "value": "hgnc:76"
          }
        ],
        "type": "Gene"
      }
    },
    "variant": "variants.json#/moa.variant:71",
    "specifiedBy": "methods.json#/moa.variant:71",
    "isReportedIn": [
      "documents.json#/moa.source:45"
    ],
    "strength": "strengths.json#/vicc.e000003",
    "therapeutic": "therapeutics.json#/moa.normalize.therapy.rxcui:662281",
    "tumorType": "tumorTypes.json#/moa.normalize.disease.ncit:C3174"
  },
  {
    "id": "moa.assertion:89",
    "description": "Nilotinib (Tasigna) is not recommended by the National Comprehensive Cancer Network\u00ae (NCCN\u00ae) as a treatment option for patients with CML in the context of secondary resistance variants. Selection of an alternate TKI in the context of TKI-resistant or possible-TKI resistant BCR::ABL1 mutant CML may be based on mutantion profile.",
    "type": "VariantTherapeuticResponseStudy",
    "predicate": "predictsResistanceTo",
    "direction": "none",
    "qualifiers": {
      "alleleOrigin": "somatic",
      "geneContext": {
        "id": "moa.normalize.gene:ABL1",
        "label": "ABL1",
        "extensions": [
          {
            "type": "Extension",
            "name": "gene_normalizer_id",
            "value": "hgnc:76"
          }
        ],
        "type": "Gene"
      }
    },
    "variant": "variants.json#/moa.variant:72",
    "specifiedBy": "methods.json#/moa.variant:72",
    "isReportedIn": [
      "documents.json#/moa.source:45"
    ],
    "strength": "strengths.json#/vicc.e000003",
    "therapeutic": "therapeutics.json#/moa.normalize.therapy.rxcui:662281",
    "tumorType": "tumorTypes.json#/moa.normalize.disease.ncit:C3174"
  },
  {
    "id": "moa.assertion:90",
    "description": "Nilotinib (Tasigna) is not recommended by the National Comprehensive Cancer Network\u00ae (NCCN\u00ae) as a treatment option for patients with CML in the context of secondary resistance variants. Selection of an alternate TKI in the context of TKI-resistant or possible-TKI resistant BCR::ABL1 mutant CML may be based on mutantion profile.",
    "type": "VariantTherapeuticResponseStudy",
    "predicate": "predictsResistanceTo",
    "direction": "none",
    "qualifiers": {
      "alleleOrigin": "somatic",
      "geneContext": {
        "id": "moa.normalize.gene:ABL1",
        "label": "ABL1",
        "extensions": [
          {
            "type": "Extension",
            "name": "gene_normalizer_id",
            "value": "hgnc:76"
          }
        ],
        "type": "Gene"
      }
    },
    "variant": "variants.json#/moa.variant:73",
    "specifiedBy": "methods.json#/moa.variant:73",
    "isReportedIn": [
      "documents.json#/moa.source:45"
    ],
    "strength": "strengths.json#/vicc.e000003",
    "therapeutic": "therapeutics.json#/moa.normalize.therapy.rxcui:662281",
    "tumorType": "tumorTypes.json#/moa.normalize.disease.ncit:C3174"
  },
  {
    "id": "moa.assertion:91",
    "description": "Nilotinib (Tasigna) is not recommended by the National Comprehensive Cancer Network\u00ae (NCCN\u00ae) as a treatment option for patients with CML in the context of secondary resistance variants. Selection of an alternate TKI in the context of TKI-resistant or possible-TKI resistant BCR::ABL1 mutant CML may be based on mutantion profile.",
    "type": "VariantTherapeuticResponseStudy",
    "predicate": "predictsResistanceTo",
    "direction": "none",
    "qualifiers": {
      "alleleOrigin": "somatic",
      "geneContext": {
        "id": "moa.normalize.gene:ABL1",
        "label": "ABL1",
        "extensions": [
          {
            "type": "Extension",
            "name": "gene_normalizer_id",
            "value": "hgnc:76"
          }
        ],
        "type": "Gene"
      }
    },
    "variant": "variants.json#/moa.variant:68",
    "specifiedBy": "methods.json#/moa.variant:68",
    "isReportedIn": [
      "documents.json#/moa.source:45"
    ],
    "strength": "strengths.json#/vicc.e000003",
    "therapeutic": "therapeutics.json#/moa.normalize.therapy.rxcui:662281",
    "tumorType": "tumorTypes.json#/moa.normalize.disease.ncit:C3174"
  },
  {
    "id": "moa.assertion:92",
    "description": "Nilotinib (Tasigna) is not recommended by the National Comprehensive Cancer Network\u00ae (NCCN\u00ae) as a treatment option for patients with CML in the context of secondary resistance variants. Selection of an alternate TKI in the context of TKI-resistant or possible-TKI resistant BCR::ABL1 mutant CML may be based on mutantion profile.",
    "type": "VariantTherapeuticResponseStudy",
    "predicate": "predictsResistanceTo",
    "direction": "none",
    "qualifiers": {
      "alleleOrigin": "somatic",
      "geneContext": {
        "id": "moa.normalize.gene:ABL1",
        "label": "ABL1",
        "extensions": [
          {
            "type": "Extension",
            "name": "gene_normalizer_id",
            "value": "hgnc:76"
          }
        ],
        "type": "Gene"
      }
    },
    "variant": "variants.json#/moa.variant:92",
    "specifiedBy": "methods.json#/moa.variant:92",
    "isReportedIn": [
      "documents.json#/moa.source:45"
    ],
    "strength": "strengths.json#/vicc.e000003",
    "therapeutic": "therapeutics.json#/moa.normalize.therapy.rxcui:662281",
    "tumorType": "tumorTypes.json#/moa.normalize.disease.ncit:C3174"
  },
  {
    "id": "moa.assertion:93",
    "description": "Bosutinib (Bosulif) is not recommended by the National Comprehensive Cancer Network\u00ae (NCCN\u00ae) as a treatment option for patients with CML in the context of secondary resistance variants. Selection of an alternate TKI in the context of TKI-resistant or possible-TKI resistant BCR::ABL1 mutant CML may be based on mutantion profile.",
    "type": "VariantTherapeuticResponseStudy",
    "predicate": "predictsResistanceTo",
    "direction": "none",
    "qualifiers": {
      "alleleOrigin": "somatic",
      "geneContext": {
        "id": "moa.normalize.gene:ABL1",
        "label": "ABL1",
        "extensions": [
          {
            "type": "Extension",
            "name": "gene_normalizer_id",
            "value": "hgnc:76"
          }
        ],
        "type": "Gene"
      }
    },
    "variant": "variants.json#/moa.variant:75",
    "specifiedBy": "methods.json#/moa.variant:75",
    "isReportedIn": [
      "documents.json#/moa.source:45"
    ],
    "strength": "strengths.json#/vicc.e000003",
    "therapeutic": "therapeutics.json#/moa.normalize.therapy.rxcui:1307619",
    "tumorType": "tumorTypes.json#/moa.normalize.disease.ncit:C3174"
  },
  {
    "id": "moa.assertion:94",
    "description": "Bosutinib (Bosulif) is not recommended by the National Comprehensive Cancer Network\u00ae (NCCN\u00ae) as a treatment option for patients with CML in the context of secondary resistance variants. Selection of an alternate TKI in the context of TKI-resistant or possible-TKI resistant BCR::ABL1 mutant CML may be based on mutantion profile.",
    "type": "VariantTherapeuticResponseStudy",
    "predicate": "predictsResistanceTo",
    "direction": "none",
    "qualifiers": {
      "alleleOrigin": "somatic",
      "geneContext": {
        "id": "moa.normalize.gene:ABL1",
        "label": "ABL1",
        "extensions": [
          {
            "type": "Extension",
            "name": "gene_normalizer_id",
            "value": "hgnc:76"
          }
        ],
        "type": "Gene"
      }
    },
    "variant": "variants.json#/moa.variant:76",
    "specifiedBy": "methods.json#/moa.variant:76",
    "isReportedIn": [
      "documents.json#/moa.source:45"
    ],
    "strength": "strengths.json#/vicc.e000003",
    "therapeutic": "therapeutics.json#/moa.normalize.therapy.rxcui:1307619",
    "tumorType": "tumorTypes.json#/moa.normalize.disease.ncit:C3174"
  },
  {
    "id": "moa.assertion:95",
    "description": "Bosutinib (Bosulif) is not recommended by the National Comprehensive Cancer Network\u00ae (NCCN\u00ae) as a treatment option for patients with CML in the context of secondary resistance variants. Selection of an alternate TKI in the context of TKI-resistant or possible-TKI resistant BCR::ABL1 mutant CML may be based on mutantion profile.",
    "type": "VariantTherapeuticResponseStudy",
    "predicate": "predictsResistanceTo",
    "direction": "none",
    "qualifiers": {
      "alleleOrigin": "somatic",
      "geneContext": {
        "id": "moa.normalize.gene:ABL1",
        "label": "ABL1",
        "extensions": [
          {
            "type": "Extension",
            "name": "gene_normalizer_id",
            "value": "hgnc:76"
          }
        ],
        "type": "Gene"
      }
    },
    "variant": "variants.json#/moa.variant:70",
    "specifiedBy": "methods.json#/moa.variant:70",
    "isReportedIn": [
      "documents.json#/moa.source:45"
    ],
    "strength": "strengths.json#/vicc.e000003",
    "therapeutic": "therapeutics.json#/moa.normalize.therapy.rxcui:1307619",
    "tumorType": "tumorTypes.json#/moa.normalize.disease.ncit:C3174"
  },
  {
    "id": "moa.assertion:96",
    "description": "Bosutinib (Bosulif) is not recommended by the National Comprehensive Cancer Network\u00ae (NCCN\u00ae) as a treatment option for patients with CML in the context of secondary resistance variants. Selection of an alternate TKI in the context of TKI-resistant or possible-TKI resistant BCR::ABL1 mutant CML may be based on mutantion profile.",
    "type": "VariantTherapeuticResponseStudy",
    "predicate": "predictsResistanceTo",
    "direction": "none",
    "qualifiers": {
      "alleleOrigin": "somatic",
      "geneContext": {
        "id": "moa.normalize.gene:ABL1",
        "label": "ABL1",
        "extensions": [
          {
            "type": "Extension",
            "name": "gene_normalizer_id",
            "value": "hgnc:76"
          }
        ],
        "type": "Gene"
      }
    },
    "variant": "variants.json#/moa.variant:71",
    "specifiedBy": "methods.json#/moa.variant:71",
    "isReportedIn": [
      "documents.json#/moa.source:45"
    ],
    "strength": "strengths.json#/vicc.e000003",
    "therapeutic": "therapeutics.json#/moa.normalize.therapy.rxcui:1307619",
    "tumorType": "tumorTypes.json#/moa.normalize.disease.ncit:C3174"
  },
  {
    "id": "moa.assertion:97",
    "description": "Bosutinib (Bosulif) is not recommended by the National Comprehensive Cancer Network\u00ae (NCCN\u00ae) as a treatment option for patients with CML in the context of secondary resistance variants. Selection of an alternate TKI in the context of TKI-resistant or possible-TKI resistant BCR::ABL1 mutant CML may be based on mutantion profile.",
    "type": "VariantTherapeuticResponseStudy",
    "predicate": "predictsResistanceTo",
    "direction": "none",
    "qualifiers": {
      "alleleOrigin": "somatic",
      "geneContext": {
        "id": "moa.normalize.gene:ABL1",
        "label": "ABL1",
        "extensions": [
          {
            "type": "Extension",
            "name": "gene_normalizer_id",
            "value": "hgnc:76"
          }
        ],
        "type": "Gene"
      }
    },
    "variant": "variants.json#/moa.variant:72",
    "specifiedBy": "methods.json#/moa.variant:72",
    "isReportedIn": [
      "documents.json#/moa.source:45"
    ],
    "strength": "strengths.json#/vicc.e000003",
    "therapeutic": "therapeutics.json#/moa.normalize.therapy.rxcui:1307619",
    "tumorType": "tumorTypes.json#/moa.normalize.disease.ncit:C3174"
  },
  {
    "id": "moa.assertion:98",
    "description": "Bosutinib (Bosulif) is not recommended by the National Comprehensive Cancer Network\u00ae (NCCN\u00ae) as a treatment option for patients with CML in the context of secondary resistance variants. Selection of an alternate TKI in the context of TKI-resistant or possible-TKI resistant BCR::ABL1 mutant CML may be based on mutantion profile.",
    "type": "VariantTherapeuticResponseStudy",
    "predicate": "predictsResistanceTo",
    "direction": "none",
    "qualifiers": {
      "alleleOrigin": "somatic",
      "geneContext": {
        "id": "moa.normalize.gene:ABL1",
        "label": "ABL1",
        "extensions": [
          {
            "type": "Extension",
            "name": "gene_normalizer_id",
            "value": "hgnc:76"
          }
        ],
        "type": "Gene"
      }
    },
    "variant": "variants.json#/moa.variant:73",
    "specifiedBy": "methods.json#/moa.variant:73",
    "isReportedIn": [
      "documents.json#/moa.source:45"
    ],
    "strength": "strengths.json#/vicc.e000003",
    "therapeutic": "therapeutics.json#/moa.normalize.therapy.rxcui:1307619",
    "tumorType": "tumorTypes.json#/moa.normalize.disease.ncit:C3174"
  },
  {
    "id": "moa.assertion:99",
    "description": "Bosutinib (Bosulif) is not recommended by the National Comprehensive Cancer Network\u00ae (NCCN\u00ae) as a treatment option for patients with CML in the context of secondary resistance variants. Selection of an alternate TKI in the context of TKI-resistant or possible-TKI resistant BCR::ABL1 mutant CML may be based on mutantion profile.",
    "type": "VariantTherapeuticResponseStudy",
    "predicate": "predictsResistanceTo",
    "direction": "none",
    "qualifiers": {
      "alleleOrigin": "somatic",
      "geneContext": {
        "id": "moa.normalize.gene:ABL1",
        "label": "ABL1",
        "extensions": [
          {
            "type": "Extension",
            "name": "gene_normalizer_id",
            "value": "hgnc:76"
          }
        ],
        "type": "Gene"
      }
    },
    "variant": "variants.json#/moa.variant:78",
    "specifiedBy": "methods.json#/moa.variant:78",
    "isReportedIn": [
      "documents.json#/moa.source:45"
    ],
    "strength": "strengths.json#/vicc.e000003",
    "therapeutic": "therapeutics.json#/moa.normalize.therapy.rxcui:1307619",
    "tumorType": "tumorTypes.json#/moa.normalize.disease.ncit:C3174"
  },
  {
    "id": "moa.assertion:100",
    "description": "Bosutinib (Bosulif) is not recommended by the National Comprehensive Cancer Network\u00ae (NCCN\u00ae) as a treatment option for patients with CML in the context of secondary resistance variants. Selection of an alternate TKI in the context of TKI-resistant or possible-TKI resistant BCR::ABL1 mutant CML may be based on mutantion profile.",
    "type": "VariantTherapeuticResponseStudy",
    "predicate": "predictsResistanceTo",
    "direction": "none",
    "qualifiers": {
      "alleleOrigin": "somatic",
      "geneContext": {
        "id": "moa.normalize.gene:ABL1",
        "label": "ABL1",
        "extensions": [
          {
            "type": "Extension",
            "name": "gene_normalizer_id",
            "value": "hgnc:76"
          }
        ],
        "type": "Gene"
      }
    },
    "variant": "variants.json#/moa.variant:79",
    "specifiedBy": "methods.json#/moa.variant:79",
    "isReportedIn": [
      "documents.json#/moa.source:45"
    ],
    "strength": "strengths.json#/vicc.e000003",
    "therapeutic": "therapeutics.json#/moa.normalize.therapy.rxcui:1307619",
    "tumorType": "tumorTypes.json#/moa.normalize.disease.ncit:C3174"
  },
  {
    "id": "moa.assertion:101",
    "description": "Bosutinib (Bosulif) is not recommended by the National Comprehensive Cancer Network\u00ae (NCCN\u00ae) as a treatment option for patients with CML in the context of secondary resistance variants. Selection of an alternate TKI in the context of TKI-resistant or possible-TKI resistant BCR::ABL1 mutant CML may be based on mutantion profile.",
    "type": "VariantTherapeuticResponseStudy",
    "predicate": "predictsResistanceTo",
    "direction": "none",
    "qualifiers": {
      "alleleOrigin": "somatic",
      "geneContext": {
        "id": "moa.normalize.gene:ABL1",
        "label": "ABL1",
        "extensions": [
          {
            "type": "Extension",
            "name": "gene_normalizer_id",
            "value": "hgnc:76"
          }
        ],
        "type": "Gene"
      }
    },
    "variant": "variants.json#/moa.variant:68",
    "specifiedBy": "methods.json#/moa.variant:68",
    "isReportedIn": [
      "documents.json#/moa.source:45"
    ],
    "strength": "strengths.json#/vicc.e000003",
    "therapeutic": "therapeutics.json#/moa.normalize.therapy.rxcui:1307619",
    "tumorType": "tumorTypes.json#/moa.normalize.disease.ncit:C3174"
  },
  {
    "id": "moa.assertion:102",
    "description": "Bosutinib (Bosulif) is not recommended by the National Comprehensive Cancer Network\u00ae (NCCN\u00ae) as a treatment option for patients with CML in the context of secondary resistance variants. Selection of an alternate TKI in the context of TKI-resistant or possible-TKI resistant BCR::ABL1 mutant CML may be based on mutantion profile.",
    "type": "VariantTherapeuticResponseStudy",
    "predicate": "predictsResistanceTo",
    "direction": "none",
    "qualifiers": {
      "alleleOrigin": "somatic",
      "geneContext": {
        "id": "moa.normalize.gene:ABL1",
        "label": "ABL1",
        "extensions": [
          {
            "type": "Extension",
            "name": "gene_normalizer_id",
            "value": "hgnc:76"
          }
        ],
        "type": "Gene"
      }
    },
    "variant": "variants.json#/moa.variant:77",
    "specifiedBy": "methods.json#/moa.variant:77",
    "isReportedIn": [
      "documents.json#/moa.source:45"
    ],
    "strength": "strengths.json#/vicc.e000003",
    "therapeutic": "therapeutics.json#/moa.normalize.therapy.rxcui:1307619",
    "tumorType": "tumorTypes.json#/moa.normalize.disease.ncit:C3174"
  },
  {
    "id": "moa.assertion:103",
    "description": "Ponatinib (Iclusig) is not recommended by the National Comprehensive Cancer Network\u00ae (NCCN\u00ae) as a treatment option for patients with CML in the context of secondary resistance variants. Selection of an alternate TKI in the context of TKI-resistant or possible-TKI resistant BCR::ABL1 mutant CML may be based on mutantion profile.",
    "type": "VariantTherapeuticResponseStudy",
    "predicate": "predictsResistanceTo",
    "direction": "none",
    "qualifiers": {
      "alleleOrigin": "somatic",
      "geneContext": {
        "id": "moa.normalize.gene:ABL1",
        "label": "ABL1",
        "extensions": [
          {
            "type": "Extension",
            "name": "gene_normalizer_id",
            "value": "hgnc:76"
          }
        ],
        "type": "Gene"
      }
    },
    "variant": "variants.json#/moa.variant:66",
    "specifiedBy": "methods.json#/moa.variant:66",
    "isReportedIn": [
      "documents.json#/moa.source:45"
    ],
    "strength": "strengths.json#/vicc.e000003",
    "therapeutic": "therapeutics.json#/moa.normalize.therapy.rxcui:1364347",
    "tumorType": "tumorTypes.json#/moa.normalize.disease.ncit:C3174"
  },
  {
    "id": "moa.assertion:104",
    "description": "Omacetaxine is not recommended by the National Comprehensive Cancer Network\u00ae (NCCN\u00ae) as a treatment option for patients with CML in the context of secondary resistance variants. Selection of an alternate TKI in the context of TKI-resistant or possible-TKI resistant BCR::ABL1 mutant CML may be based on mutantion profile.",
    "type": "VariantTherapeuticResponseStudy",
    "predicate": "predictsResistanceTo",
    "direction": "none",
    "qualifiers": {
      "alleleOrigin": "somatic",
      "geneContext": {
        "id": "moa.normalize.gene:ABL1",
        "label": "ABL1",
        "extensions": [
          {
            "type": "Extension",
            "name": "gene_normalizer_id",
            "value": "hgnc:76"
          }
        ],
        "type": "Gene"
      }
    },
    "variant": "variants.json#/moa.variant:66",
    "specifiedBy": "methods.json#/moa.variant:66",
    "isReportedIn": [
      "documents.json#/moa.source:45"
    ],
    "strength": "strengths.json#/vicc.e000003",
    "therapeutic": "therapeutics.json#/moa.normalize.therapy.rxcui:1546446",
    "tumorType": "tumorTypes.json#/moa.normalize.disease.ncit:C3174"
  },
  {
    "id": "moa.assertion:105",
    "description": "Dasatinib (Sprycel) is not recommended by the National Comprehensive Cancer Network\u00ae (NCCN\u00ae) as a treatment option for patients with CML in the context of secondary resistance variants. Selection of an alternate TKI in the context of TKI-resistant or possible-TKI resistant BCR::ABL1 mutant CML may be based on mutantion profile.",
    "type": "VariantTherapeuticResponseStudy",
    "predicate": "predictsResistanceTo",
    "direction": "none",
    "qualifiers": {
      "alleleOrigin": "somatic",
      "geneContext": {
        "id": "moa.normalize.gene:ABL1",
        "label": "ABL1",
        "extensions": [
          {
            "type": "Extension",
            "name": "gene_normalizer_id",
            "value": "hgnc:76"
          }
        ],
        "type": "Gene"
      }
    },
    "variant": "variants.json#/moa.variant:80",
    "specifiedBy": "methods.json#/moa.variant:80",
    "isReportedIn": [
      "documents.json#/moa.source:45"
    ],
    "strength": "strengths.json#/vicc.e000003",
    "therapeutic": "therapeutics.json#/moa.normalize.therapy.rxcui:1546019",
    "tumorType": "tumorTypes.json#/moa.normalize.disease.ncit:C3174"
  },
  {
    "id": "moa.assertion:107",
    "description": "Activating mutations in AKT may predict sensitivity to direct inhibition or downstream inhibition of the PI3K/mTOR pathway. This study observed that AKT inhibitors MK-2206 and AZD5363 both caused significant growth inhibition of breast cancer explant models with AKT1 E17K mutations.",
    "type": "VariantTherapeuticResponseStudy",
    "predicate": "predictsSensitivityTo",
    "direction": "none",
    "qualifiers": {
      "alleleOrigin": "somatic",
      "geneContext": {
        "id": "moa.normalize.gene:AKT1",
        "label": "AKT1",
        "extensions": [
          {
            "type": "Extension",
            "name": "gene_normalizer_id",
            "value": "hgnc:391"
          }
        ],
        "type": "Gene"
      }
    },
    "variant": "variants.json#/moa.variant:107",
    "specifiedBy": "methods.json#/moa.variant:107",
    "isReportedIn": [
      "documents.json#/moa.source:46"
    ],
    "strength": "strengths.json#/vicc.e000009",
    "therapeutic": "therapeutics.json#/moa.normalize.therapy.iuphar.ligand:7945",
    "tumorType": "tumorTypes.json#/moa.normalize.disease.ncit:C9245"
  },
  {
    "id": "moa.assertion:110",
    "description": "Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.",
    "type": "VariantTherapeuticResponseStudy",
    "predicate": "predictsResistanceTo",
    "direction": "none",
    "qualifiers": {
      "alleleOrigin": "somatic",
      "geneContext": {
        "id": "moa.normalize.gene:ALK",
        "label": "ALK",
        "extensions": [
          {
            "type": "Extension",
            "name": "gene_normalizer_id",
            "value": "hgnc:427"
          }
        ],
        "type": "Gene"
      }
    },
    "variant": "variants.json#/moa.variant:110",
    "specifiedBy": "methods.json#/moa.variant:110",
    "isReportedIn": [
      "documents.json#/moa.source:48"
    ],
    "strength": "strengths.json#/vicc.e000009",
    "therapeutic": "therapeutics.json#/moa.normalize.therapy.rxcui:1535457",
    "tumorType": "tumorTypes.json#/moa.normalize.disease.ncit:C2926"
  },
  {
    "id": "moa.assertion:111",
    "description": "Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.",
    "type": "VariantTherapeuticResponseStudy",
    "predicate": "predictsResistanceTo",
    "direction": "none",
    "qualifiers": {
      "alleleOrigin": "somatic",
      "geneContext": {
        "id": "moa.normalize.gene:ALK",
        "label": "ALK",
        "extensions": [
          {
            "type": "Extension",
            "name": "gene_normalizer_id",
            "value": "hgnc:427"
          }
        ],
        "type": "Gene"
      }
    },
    "variant": "variants.json#/moa.variant:111",
    "specifiedBy": "methods.json#/moa.variant:111",
    "isReportedIn": [
      "documents.json#/moa.source:48"
    ],
    "strength": "strengths.json#/vicc.e000009",
    "therapeutic": "therapeutics.json#/moa.normalize.therapy.rxcui:1535457",
    "tumorType": "tumorTypes.json#/moa.normalize.disease.ncit:C2926"
  },
  {
    "id": "moa.assertion:112",
    "description": "Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.",
    "type": "VariantTherapeuticResponseStudy",
    "predicate": "predictsSensitivityTo",
    "direction": "none",
    "qualifiers": {
      "alleleOrigin": "somatic",
      "geneContext": {
        "id": "moa.normalize.gene:ALK",
        "label": "ALK",
        "extensions": [
          {
            "type": "Extension",
            "name": "gene_normalizer_id",
            "value": "hgnc:427"
          }
        ],
        "type": "Gene"
      }
    },
    "variant": "variants.json#/moa.variant:112",
    "specifiedBy": "methods.json#/moa.variant:112",
    "isReportedIn": [
      "documents.json#/moa.source:48"
    ],
    "strength": "strengths.json#/vicc.e000009",
    "therapeutic": "therapeutics.json#/moa.normalize.therapy.rxcui:1535457",
    "tumorType": "tumorTypes.json#/moa.normalize.disease.ncit:C2926"
  },
  {
    "id": "moa.assertion:113",
    "description": "Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.",
    "type": "VariantTherapeuticResponseStudy",
    "predicate": "predictsSensitivityTo",
    "direction": "none",
    "qualifiers": {
      "alleleOrigin": "somatic",
      "geneContext": {
        "id": "moa.normalize.gene:ALK",
        "label": "ALK",
        "extensions": [
          {
            "type": "Extension",
            "name": "gene_normalizer_id",
            "value": "hgnc:427"
          }
        ],
        "type": "Gene"
      }
    },
    "variant": "variants.json#/moa.variant:113",
    "specifiedBy": "methods.json#/moa.variant:113",
    "isReportedIn": [
      "documents.json#/moa.source:48"
    ],
    "strength": "strengths.json#/vicc.e000009",
    "therapeutic": "therapeutics.json#/moa.normalize.therapy.rxcui:1535457",
    "tumorType": "tumorTypes.json#/moa.normalize.disease.ncit:C2926"
  },
  {
    "id": "moa.assertion:114",
    "description": "Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.",
    "type": "VariantTherapeuticResponseStudy",
    "predicate": "predictsSensitivityTo",
    "direction": "none",
    "qualifiers": {
      "alleleOrigin": "somatic",
      "geneContext": {
        "id": "moa.normalize.gene:ALK",
        "label": "ALK",
        "extensions": [
          {
            "type": "Extension",
            "name": "gene_normalizer_id",
            "value": "hgnc:427"
          }
        ],
        "type": "Gene"
      }
    },
    "variant": "variants.json#/moa.variant:114",
    "specifiedBy": "methods.json#/moa.variant:114",
    "isReportedIn": [
      "documents.json#/moa.source:48"
    ],
    "strength": "strengths.json#/vicc.e000009",
    "therapeutic": "therapeutics.json#/moa.normalize.therapy.rxcui:1535457",
    "tumorType": "tumorTypes.json#/moa.normalize.disease.ncit:C2926"
  },
  {
    "id": "moa.assertion:115",
    "description": "Androgen receptor mutation may predict resistance to second generation androgen deprivation or direct androgen inhibitors.",
    "type": "VariantTherapeuticResponseStudy",
    "predicate": "predictsResistanceTo",
    "direction": "none",
    "qualifiers": {
      "alleleOrigin": "somatic",
      "geneContext": {
        "id": "moa.normalize.gene:AR",
        "label": "AR",
        "extensions": [
          {
            "type": "Extension",
            "name": "gene_normalizer_id",
            "value": "hgnc:644"
          }
        ],
        "type": "Gene"
      }
    },
    "variant": "variants.json#/moa.variant:115",
    "specifiedBy": "methods.json#/moa.variant:115",
    "isReportedIn": [
      "documents.json#/moa.source:49"
    ],
    "strength": "strengths.json#/vicc.e000007",
    "therapeutic": "therapeutics.json#/moa.normalize.therapy.rxcui:1100071",
    "tumorType": "tumorTypes.json#/moa.normalize.disease.ncit:C2919"
  },
  {
    "id": "moa.assertion:116",
    "description": "Androgen receptor mutation may predict resistance to second generation androgen deprivation or direct androgen inhibitors.",
    "type": "VariantTherapeuticResponseStudy",
    "predicate": "predictsResistanceTo",
    "direction": "none",
    "qualifiers": {
      "alleleOrigin": "somatic",
      "geneContext": {
        "id": "moa.normalize.gene:AR",
        "label": "AR",
        "extensions": [
          {
            "type": "Extension",
            "name": "gene_normalizer_id",
            "value": "hgnc:644"
          }
        ],
        "type": "Gene"
      }
    },
    "variant": "variants.json#/moa.variant:116",
    "specifiedBy": "methods.json#/moa.variant:116",
    "isReportedIn": [
      "documents.json#/moa.source:49"
    ],
    "strength": "strengths.json#/vicc.e000007",
    "therapeutic": "therapeutics.json#/moa.normalize.therapy.rxcui:1100071",
    "tumorType": "tumorTypes.json#/moa.normalize.disease.ncit:C2919"
  },
  {
    "id": "moa.assertion:117",
    "description": "Activating mutations in ARAF may predict sensitivity to sorafenib or other RAF inhibitors. Patient received 5 year response to sorafenib with ARAF S214C.",
    "type": "VariantTherapeuticResponseStudy",
    "predicate": "predictsSensitivityTo",
    "direction": "none",
    "qualifiers": {
      "alleleOrigin": "somatic",
      "geneContext": {
        "id": "moa.normalize.gene:ARAF",
        "label": "ARAF",
        "extensions": [
          {
            "type": "Extension",
            "name": "gene_normalizer_id",
            "value": "hgnc:646"
          }
        ],
        "type": "Gene"
      }
    },
    "variant": "variants.json#/moa.variant:117",
    "specifiedBy": "methods.json#/moa.variant:117",
    "isReportedIn": [
      "documents.json#/moa.source:50"
    ],
    "strength": "strengths.json#/vicc.e000007",
    "therapeutic": "therapeutics.json#/moa.normalize.therapy.rxcui:495881",
    "tumorType": "tumorTypes.json#/moa.normalize.disease.ncit:C2926"
  },
  {
    "id": "moa.assertion:129",
    "description": "HCT116 colorectal cancer cell lines are heterozygous for c.3380C>A and sensitive to PARP inhibition following shRNA depletion of ATM. Deletion of p53 enhances sensitivity.",
    "type": "VariantTherapeuticResponseStudy",
    "predicate": "predictsSensitivityTo",
    "direction": "none",
    "qualifiers": {
      "alleleOrigin": "somatic",
      "geneContext": {
        "id": "moa.normalize.gene:ATM",
        "label": "ATM",
        "extensions": [
          {
            "type": "Extension",
            "name": "gene_normalizer_id",
            "value": "hgnc:795"
          }
        ],
        "type": "Gene"
      }
    },
    "variant": "variants.json#/moa.variant:129",
    "specifiedBy": "methods.json#/moa.variant:129",
    "isReportedIn": [
      "documents.json#/moa.source:55"
    ],
    "strength": "strengths.json#/vicc.e000009",
    "therapeutic": "therapeutics.json#/moa.normalize.therapy.rxcui:1597582",
    "tumorType": "tumorTypes.json#/moa.normalize.disease.ncit:C5105"
  },
  {
    "id": "moa.assertion:144",
    "description": "The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib as a single agent for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E mutation, as detected by an FDA-approved test.",
    "type": "VariantTherapeuticResponseStudy",
    "predicate": "predictsSensitivityTo",
    "direction": "none",
    "qualifiers": {
      "alleleOrigin": "somatic",
      "geneContext": {
        "id": "moa.normalize.gene:BRAF",
        "label": "BRAF",
        "extensions": [
          {
            "type": "Extension",
            "name": "gene_normalizer_id",
            "value": "hgnc:1097"
          }
        ],
        "type": "Gene"
      }
    },
    "variant": "variants.json#/moa.variant:144",
    "specifiedBy": "methods.json#/moa.variant:144",
    "isReportedIn": [
      "documents.json#/moa.source:60"
    ],
    "strength": "strengths.json#/vicc.e000002",
    "therapeutic": "therapeutics.json#/moa.normalize.therapy.rxcui:1424911",
    "tumorType": "tumorTypes.json#/moa.normalize.disease.ncit:C3224"
  },
  {
    "id": "moa.assertion:145",
    "description": "The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.",
    "type": "VariantTherapeuticResponseStudy",
    "predicate": "predictsSensitivityTo",
    "direction": "none",
    "qualifiers": {
      "alleleOrigin": "somatic",
      "geneContext": {
        "id": "moa.normalize.gene:BRAF",
        "label": "BRAF",
        "extensions": [
          {
            "type": "Extension",
            "name": "gene_normalizer_id",
            "value": "hgnc:1097"
          }
        ],
        "type": "Gene"
      }
    },
    "variant": "variants.json#/moa.variant:144",
    "specifiedBy": "methods.json#/moa.variant:144",
    "isReportedIn": [
      "documents.json#/moa.source:60"
    ],
    "strength": "strengths.json#/vicc.e000002",
    "therapeutic": "therapeutics.json#/moa.ctid:mm4iftPYmDnZsAZWZwRW5l7p9lbvwqOJ",
    "tumorType": "tumorTypes.json#/moa.normalize.disease.ncit:C3224"
  },
  {
    "id": "moa.assertion:146",
    "description": "The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.",
    "type": "VariantTherapeuticResponseStudy",
    "predicate": "predictsSensitivityTo",
    "direction": "none",
    "qualifiers": {
      "alleleOrigin": "somatic",
      "geneContext": {
        "id": "moa.normalize.gene:BRAF",
        "label": "BRAF",
        "extensions": [
          {
            "type": "Extension",
            "name": "gene_normalizer_id",
            "value": "hgnc:1097"
          }
        ],
        "type": "Gene"
      }
    },
    "variant": "variants.json#/moa.variant:146",
    "specifiedBy": "methods.json#/moa.variant:146",
    "isReportedIn": [
      "documents.json#/moa.source:60"
    ],
    "strength": "strengths.json#/vicc.e000002",
    "therapeutic": "therapeutics.json#/moa.ctid:mm4iftPYmDnZsAZWZwRW5l7p9lbvwqOJ",
    "tumorType": "tumorTypes.json#/moa.normalize.disease.ncit:C3224"
  },
  {
    "id": "moa.assertion:147",
    "description": "The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the adjuvant treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test, and involvement of lymph node(s), following complete resection.",
    "type": "VariantTherapeuticResponseStudy",
    "predicate": "predictsSensitivityTo",
    "direction": "none",
    "qualifiers": {
      "alleleOrigin": "somatic",
      "geneContext": {
        "id": "moa.normalize.gene:BRAF",
        "label": "BRAF",
        "extensions": [
          {
            "type": "Extension",
            "name": "gene_normalizer_id",
            "value": "hgnc:1097"
          }
        ],
        "type": "Gene"
      }
    },
    "variant": "variants.json#/moa.variant:144",
    "specifiedBy": "methods.json#/moa.variant:144",
    "isReportedIn": [
      "documents.json#/moa.source:60"
    ],
    "strength": "strengths.json#/vicc.e000002",
    "therapeutic": "therapeutics.json#/moa.ctid:mm4iftPYmDnZsAZWZwRW5l7p9lbvwqOJ",
    "tumorType": "tumorTypes.json#/moa.normalize.disease.ncit:C3224"
  },
  {
    "id": "moa.assertion:148",
    "description": "The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the adjuvant treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test, and involvement of lymph node(s), following complete resection.",
    "type": "VariantTherapeuticResponseStudy",
    "predicate": "predictsSensitivityTo",
    "direction": "none",
    "qualifiers": {
      "alleleOrigin": "somatic",
      "geneContext": {
        "id": "moa.normalize.gene:BRAF",
        "label": "BRAF",
        "extensions": [
          {
            "type": "Extension",
            "name": "gene_normalizer_id",
            "value": "hgnc:1097"
          }
        ],
        "type": "Gene"
      }
    },
    "variant": "variants.json#/moa.variant:146",
    "specifiedBy": "methods.json#/moa.variant:146",
    "isReportedIn": [
      "documents.json#/moa.source:60"
    ],
    "strength": "strengths.json#/vicc.e000002",
    "therapeutic": "therapeutics.json#/moa.ctid:mm4iftPYmDnZsAZWZwRW5l7p9lbvwqOJ",
    "tumorType": "tumorTypes.json#/moa.normalize.disease.ncit:C3224"
  },
  {
    "id": "moa.assertion:149",
    "description": "The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with metastatic non-small cell lung cancer (NSCLC) with BRAF V600E, as detected by an FDA-approved test.",
    "type": "VariantTherapeuticResponseStudy",
    "predicate": "predictsSensitivityTo",
    "direction": "none",
    "qualifiers": {
      "alleleOrigin": "somatic",
      "geneContext": {
        "id": "moa.normalize.gene:BRAF",
        "label": "BRAF",
        "extensions": [
          {
            "type": "Extension",
            "name": "gene_normalizer_id",
            "value": "hgnc:1097"
          }
        ],
        "type": "Gene"
      }
    },
    "variant": "variants.json#/moa.variant:144",
    "specifiedBy": "methods.json#/moa.variant:144",
    "isReportedIn": [
      "documents.json#/moa.source:60"
    ],
    "strength": "strengths.json#/vicc.e000002",
    "therapeutic": "therapeutics.json#/moa.ctid:mm4iftPYmDnZsAZWZwRW5l7p9lbvwqOJ",
    "tumorType": "tumorTypes.json#/moa.normalize.disease.ncit:C2926"
  },
  {
    "id": "moa.assertion:150",
    "description": "The U.S. Food and Drug Administration (FDA) granted approval to trametinib as a single agent for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.",
    "type": "VariantTherapeuticResponseStudy",
    "predicate": "predictsSensitivityTo",
    "direction": "none",
    "qualifiers": {
      "alleleOrigin": "somatic",
      "geneContext": {
        "id": "moa.normalize.gene:BRAF",
        "label": "BRAF",
        "extensions": [
          {
            "type": "Extension",
            "name": "gene_normalizer_id",
            "value": "hgnc:1097"
          }
        ],
        "type": "Gene"
      }
    },
    "variant": "variants.json#/moa.variant:144",
    "specifiedBy": "methods.json#/moa.variant:144",
    "isReportedIn": [
      "documents.json#/moa.source:61"
    ],
    "strength": "strengths.json#/vicc.e000002",
    "therapeutic": "therapeutics.json#/moa.normalize.therapy.rxcui:1425098",
    "tumorType": "tumorTypes.json#/moa.normalize.disease.ncit:C3224"
  },
  {
    "id": "moa.assertion:151",
    "description": "The U.S. Food and Drug Administration (FDA) granted approval to trametinib as a single agent for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.",
    "type": "VariantTherapeuticResponseStudy",
    "predicate": "predictsSensitivityTo",
    "direction": "none",
    "qualifiers": {
      "alleleOrigin": "somatic",
      "geneContext": {
        "id": "moa.normalize.gene:BRAF",
        "label": "BRAF",
        "extensions": [
          {
            "type": "Extension",
            "name": "gene_normalizer_id",
            "value": "hgnc:1097"
          }
        ],
        "type": "Gene"
      }
    },
    "variant": "variants.json#/moa.variant:146",
    "specifiedBy": "methods.json#/moa.variant:146",
    "isReportedIn": [
      "documents.json#/moa.source:61"
    ],
    "strength": "strengths.json#/vicc.e000002",
    "therapeutic": "therapeutics.json#/moa.normalize.therapy.rxcui:1425098",
    "tumorType": "tumorTypes.json#/moa.normalize.disease.ncit:C3224"
  },
  {
    "id": "moa.assertion:152",
    "description": "The U.S. Food and Drug Administration (FDA) granted regular approval to encorafenib for the treatment of patients with unresectable or metastatic melanoma (MEL) with BRAF V600K mutation, as detected by an FDA-approved test.",
    "type": "VariantTherapeuticResponseStudy",
    "predicate": "predictsSensitivityTo",
    "direction": "none",
    "qualifiers": {
      "alleleOrigin": "somatic",
      "geneContext": {
        "id": "moa.normalize.gene:BRAF",
        "label": "BRAF",
        "extensions": [
          {
            "type": "Extension",
            "name": "gene_normalizer_id",
            "value": "hgnc:1097"
          }
        ],
        "type": "Gene"
      }
    },
    "variant": "variants.json#/moa.variant:146",
    "specifiedBy": "methods.json#/moa.variant:146",
    "isReportedIn": [
      "documents.json#/moa.source:62"
    ],
    "strength": "strengths.json#/vicc.e000002",
    "therapeutic": "therapeutics.json#/moa.normalize.therapy.rxcui:2049106",
    "tumorType": "tumorTypes.json#/moa.normalize.disease.ncit:C3224"
  },
  {
    "id": "moa.assertion:153",
    "description": "The U.S. Food and Drug Administration (FDA) granted regular approval to encorafenib for the treatment of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E mutation, as detected by an FDA-approved test.",
    "type": "VariantTherapeuticResponseStudy",
    "predicate": "predictsSensitivityTo",
    "direction": "none",
    "qualifiers": {
      "alleleOrigin": "somatic",
      "geneContext": {
        "id": "moa.normalize.gene:BRAF",
        "label": "BRAF",
        "extensions": [
          {
            "type": "Extension",
            "name": "gene_normalizer_id",
            "value": "hgnc:1097"
          }
        ],
        "type": "Gene"
      }
    },
    "variant": "variants.json#/moa.variant:144",
    "specifiedBy": "methods.json#/moa.variant:144",
    "isReportedIn": [
      "documents.json#/moa.source:62"
    ],
    "strength": "strengths.json#/vicc.e000002",
    "therapeutic": "therapeutics.json#/moa.normalize.therapy.rxcui:2049106",
    "tumorType": "tumorTypes.json#/moa.normalize.disease.ncit:C3224"
  },
  {
    "id": "moa.assertion:154",
    "description": "The U.S. Food and Drug Administration (FDA) granted regular approval to encorafenib in combination with cetuximab for the treatment of adult patients with metastatic colorectal cancer (CRC) with BRAF V600E mutation, as detected by an FDA-approved test, after prior therapy.",
    "type": "VariantTherapeuticResponseStudy",
    "predicate": "predictsSensitivityTo",
    "direction": "none",
    "qualifiers": {
      "alleleOrigin": "somatic",
      "geneContext": {
        "id": "moa.normalize.gene:BRAF",
        "label": "BRAF",
        "extensions": [
          {
            "type": "Extension",
            "name": "gene_normalizer_id",
            "value": "hgnc:1097"
          }
        ],
        "type": "Gene"
      }
    },
    "variant": "variants.json#/moa.variant:144",
    "specifiedBy": "methods.json#/moa.variant:144",
    "isReportedIn": [
      "documents.json#/moa.source:62"
    ],
    "strength": "strengths.json#/vicc.e000002",
    "therapeutic": "therapeutics.json#/moa.ctid:zBda4sO3iQLExj5SB8VTPzPLaPoWefiP",
    "tumorType": "tumorTypes.json#/moa.normalize.disease.ncit:C5105"
  },
  {
    "id": "moa.assertion:155",
    "description": "The U.S. Food and Drug Administration (FDA) granted regular approval to vemurafenib for the treatment of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E mutation, as detected by an FDA-approved test.",
    "type": "VariantTherapeuticResponseStudy",
    "predicate": "predictsSensitivityTo",
    "direction": "none",
    "qualifiers": {
      "alleleOrigin": "somatic",
      "geneContext": {
        "id": "moa.normalize.gene:BRAF",
        "label": "BRAF",
        "extensions": [
          {
            "type": "Extension",
            "name": "gene_normalizer_id",
            "value": "hgnc:1097"
          }
        ],
        "type": "Gene"
      }
    },
    "variant": "variants.json#/moa.variant:144",
    "specifiedBy": "methods.json#/moa.variant:144",
    "isReportedIn": [
      "documents.json#/moa.source:63"
    ],
    "strength": "strengths.json#/vicc.e000002",
    "therapeutic": "therapeutics.json#/moa.normalize.therapy.rxcui:1147220",
    "tumorType": "tumorTypes.json#/moa.normalize.disease.ncit:C3224"
  },
  {
    "id": "moa.assertion:156",
    "description": "Panitumumab (Vectibix) is not recommended by the National Comprehensive Cancer Network\u00ae (NCCN\u00ae) as a treatment option for patients with metastatic colorectal cancer, BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor. ",
    "type": "VariantTherapeuticResponseStudy",
    "predicate": "predictsResistanceTo",
    "direction": "none",
    "qualifiers": {
      "alleleOrigin": "somatic",
      "geneContext": {
        "id": "moa.normalize.gene:BRAF",
        "label": "BRAF",
        "extensions": [
          {
            "type": "Extension",
            "name": "gene_normalizer_id",
            "value": "hgnc:1097"
          }
        ],
        "type": "Gene"
      }
    },
    "variant": "variants.json#/moa.variant:144",
    "specifiedBy": "methods.json#/moa.variant:144",
    "isReportedIn": [
      "documents.json#/moa.source:64"
    ],
    "strength": "strengths.json#/vicc.e000003",
    "therapeutic": "therapeutics.json#/moa.normalize.therapy.rxcui:263034",
    "tumorType": "tumorTypes.json#/moa.normalize.disease.ncit:C5105"
  },
  {
    "id": "moa.assertion:158",
    "description": "Vemurafenib (Zelboraf) is recommended by the National Comprehensive Cancer Network\u00ae (NCCN\u00ae) as a treatment option for patients with BRAF p.V600E mutant melanoma. Activating BRAF mutations are associated with an increased sensitivity to BRAF inhibitors. Co-administration with a MEK inhibitor may potentiate the effects of BRAF inhibitors.",
    "type": "VariantTherapeuticResponseStudy",
    "predicate": "predictsSensitivityTo",
    "direction": "none",
    "qualifiers": {
      "alleleOrigin": "somatic",
      "geneContext": {
        "id": "moa.normalize.gene:BRAF",
        "label": "BRAF",
        "extensions": [
          {
            "type": "Extension",
            "name": "gene_normalizer_id",
            "value": "hgnc:1097"
          }
        ],
        "type": "Gene"
      }
    },
    "variant": "variants.json#/moa.variant:144",
    "specifiedBy": "methods.json#/moa.variant:144",
    "isReportedIn": [
      "documents.json#/moa.source:66"
    ],
    "strength": "strengths.json#/vicc.e000003",
    "therapeutic": "therapeutics.json#/moa.normalize.therapy.rxcui:1147220",
    "tumorType": "tumorTypes.json#/moa.normalize.disease.ncit:C3224"
  },
  {
    "id": "moa.assertion:159",
    "description": "Dabrafenib (Tafinlar) is recommended by the National Comprehensive Cancer Network\u00ae (NCCN\u00ae) as a treatment option for patients with BRAF p.V600E mutant melanoma. Activating BRAF mutations are associated with an increased sensitivity to BRAF inhibitors. Co-administration with a MEK inhibitor may potentiate the effects of BRAF inhibitors.",
    "type": "VariantTherapeuticResponseStudy",
    "predicate": "predictsSensitivityTo",
    "direction": "none",
    "qualifiers": {
      "alleleOrigin": "somatic",
      "geneContext": {
        "id": "moa.normalize.gene:BRAF",
        "label": "BRAF",
        "extensions": [
          {
            "type": "Extension",
            "name": "gene_normalizer_id",
            "value": "hgnc:1097"
          }
        ],
        "type": "Gene"
      }
    },
    "variant": "variants.json#/moa.variant:144",
    "specifiedBy": "methods.json#/moa.variant:144",
    "isReportedIn": [
      "documents.json#/moa.source:66"
    ],
    "strength": "strengths.json#/vicc.e000003",
    "therapeutic": "therapeutics.json#/moa.normalize.therapy.rxcui:1424911",
    "tumorType": "tumorTypes.json#/moa.normalize.disease.ncit:C3224"
  },
  {
    "id": "moa.assertion:160",
    "description": "Vemurafenib (Zelboraf) in combination with Cobimetinib (Coltellic) is recommended by the National Comprehensive Cancer Network\u00ae (NCCN\u00ae) as a treatment option for patients with BRAF p.V600E mutant melanoma. Activating BRAF mutations are associated with an increased sensitivity to BRAF inhibitors. Co-administration with a MEK inhibitor may potentiate the effects of BRAF inhibitors.",
    "type": "VariantTherapeuticResponseStudy",
    "predicate": "predictsSensitivityTo",
    "direction": "none",
    "qualifiers": {
      "alleleOrigin": "somatic",
      "geneContext": {
        "id": "moa.normalize.gene:BRAF",
        "label": "BRAF",
        "extensions": [
          {
            "type": "Extension",
            "name": "gene_normalizer_id",
            "value": "hgnc:1097"
          }
        ],
        "type": "Gene"
      }
    },
    "variant": "variants.json#/moa.variant:144",
    "specifiedBy": "methods.json#/moa.variant:144",
    "isReportedIn": [
      "documents.json#/moa.source:66"
    ],
    "strength": "strengths.json#/vicc.e000003",
    "therapeutic": "therapeutics.json#/moa.ctid:dhs2LkZmpoTUpE6XlcACT7zTBbnvfnX9",
    "tumorType": "tumorTypes.json#/moa.normalize.disease.ncit:C3224"
  },
  {
    "id": "moa.assertion:161",
    "description": "Dabrafenib (Tafinlar) in combination with Trametinib (Mekinist) is recommended by the National Comprehensive Cancer Network\u00ae (NCCN\u00ae) as a treatment option for patients with BRAF p.V600E mutant melanoma. Activating BRAF mutations are associated with an increased sensitivity to BRAF inhibitors. Co-administration with a MEK inhibitor may potentiate the effects of BRAF inhibitors.",
    "type": "VariantTherapeuticResponseStudy",
    "predicate": "predictsSensitivityTo",
    "direction": "none",
    "qualifiers": {
      "alleleOrigin": "somatic",
      "geneContext": {
        "id": "moa.normalize.gene:BRAF",
        "label": "BRAF",
        "extensions": [
          {
            "type": "Extension",
            "name": "gene_normalizer_id",
            "value": "hgnc:1097"
          }
        ],
        "type": "Gene"
      }
    },
    "variant": "variants.json#/moa.variant:144",
    "specifiedBy": "methods.json#/moa.variant:144",
    "isReportedIn": [
      "documents.json#/moa.source:66"
    ],
    "strength": "strengths.json#/vicc.e000003",
    "therapeutic": "therapeutics.json#/moa.ctid:mm4iftPYmDnZsAZWZwRW5l7p9lbvwqOJ",
    "tumorType": "tumorTypes.json#/moa.normalize.disease.ncit:C3224"
  },
  {
    "id": "moa.assertion:162",
    "description": "The combination of ipilimumab and vemurafenib in a sequencing strategy showed limited efficacy in a phase II study.",
    "type": "VariantTherapeuticResponseStudy",
    "predicate": "predictsSensitivityTo",
    "direction": "none",
    "qualifiers": {
      "alleleOrigin": "somatic",
      "geneContext": {
        "id": "moa.normalize.gene:BRAF",
        "label": "BRAF",
        "extensions": [
          {
            "type": "Extension",
            "name": "gene_normalizer_id",
            "value": "hgnc:1097"
          }
        ],
        "type": "Gene"
      }
    },
    "variant": "variants.json#/moa.variant:144",
    "specifiedBy": "methods.json#/moa.variant:144",
    "isReportedIn": [
      "documents.json#/moa.source:67"
    ],
    "strength": "strengths.json#/vicc.e000006",
    "therapeutic": "therapeutics.json#/moa.ctid:FKTdlTdqAvhIQciAr34sdnBlday3jJMR",
    "tumorType": "tumorTypes.json#/moa.normalize.disease.ncit:C3224"
  },
  {
    "id": "moa.assertion:163",
    "description": "The combination of ipilimumab and vemurafenib in a sequencing strategy showed limited efficacy in a phase II study.",
    "type": "VariantTherapeuticResponseStudy",
    "predicate": "predictsSensitivityTo",
    "direction": "none",
    "qualifiers": {
      "alleleOrigin": "somatic",
      "geneContext": {
        "id": "moa.normalize.gene:BRAF",
        "label": "BRAF",
        "extensions": [
          {
            "type": "Extension",
            "name": "gene_normalizer_id",
            "value": "hgnc:1097"
          }
        ],
        "type": "Gene"
      }
    },
    "variant": "variants.json#/moa.variant:144",
    "specifiedBy": "methods.json#/moa.variant:144",
    "isReportedIn": [
      "documents.json#/moa.source:67"
    ],
    "strength": "strengths.json#/vicc.e000006",
    "therapeutic": "therapeutics.json#/moa.ctid:FKTdlTdqAvhIQciAr34sdnBlday3jJMR",
    "tumorType": "tumorTypes.json#/moa.normalize.disease.ncit:C3224"
  },
  {
    "id": "moa.assertion:164",
    "description": "Administration of bevacizumab in a dabrafenib-resistant melanoma cancer cell line (A375R) counteracted the tumor growth stimulating effect of administering dabrafenib post-resistance. This study suggests that a regime which combines BRAFi with bevacizumab or inhibitors of PI3K/Akt/mTOR may be more effective than BRAFi monotherapy in the setting of resistance.",
    "type": "VariantTherapeuticResponseStudy",
    "predicate": "predictsSensitivityTo",
    "direction": "none",
    "qualifiers": {
      "alleleOrigin": "somatic",
      "geneContext": {
        "id": "moa.normalize.gene:BRAF",
        "label": "BRAF",
        "extensions": [
          {
            "type": "Extension",
            "name": "gene_normalizer_id",
            "value": "hgnc:1097"
          }
        ],
        "type": "Gene"
      }
    },
    "variant": "variants.json#/moa.variant:144",
    "specifiedBy": "methods.json#/moa.variant:144",
    "isReportedIn": [
      "documents.json#/moa.source:68"
    ],
    "strength": "strengths.json#/vicc.e000009",
    "therapeutic": "therapeutics.json#/moa.ctid:Q8MsBWnZEz9Ibgy9CFdvvd735aqANV8t",
    "tumorType": "tumorTypes.json#/moa.normalize.disease.ncit:C3224"
  },
  {
    "id": "moa.assertion:165",
    "description": "Administration of GSK2126458A, a PI3K/AKT/mTOR pathway inhibitor, in a dabrafenib-resistant cell line counteracted the tumor growth stimulating effect of administering dabrafenib post-resistance. This study suggests that a regime which combines BRAFi with bevacizumab or inhibitors of PI3K/Akt/mTOR may be more effective than BRAFi monotherapy in the setting of resistance.",
    "type": "VariantTherapeuticResponseStudy",
    "predicate": "predictsSensitivityTo",
    "direction": "none",
    "qualifiers": {
      "alleleOrigin": "somatic",
      "geneContext": {
        "id": "moa.normalize.gene:BRAF",
        "label": "BRAF",
        "extensions": [
          {
            "type": "Extension",
            "name": "gene_normalizer_id",
            "value": "hgnc:1097"
          }
        ],
        "type": "Gene"
      }
    },
    "variant": "variants.json#/moa.variant:144",
    "specifiedBy": "methods.json#/moa.variant:144",
    "isReportedIn": [
      "documents.json#/moa.source:68"
    ],
    "strength": "strengths.json#/vicc.e000009",
    "therapeutic": "therapeutics.json#/moa.ctid:reZr1erbRlUj4i9sapm6pr2OzpdbGeWq",
    "tumorType": "tumorTypes.json#/moa.normalize.disease.ncit:C3224"
  },
  {
    "id": "moa.assertion:167",
    "description": "Three human melanoma cell lines displayed sensitivity to bleomycin, particularly when co-administered with human interferon-beta gene or herpes simplex virus thymidine kinase/ganciclovir suicide gene lipofection.",
    "type": "VariantTherapeuticResponseStudy",
    "predicate": "predictsSensitivityTo",
    "direction": "none",
    "qualifiers": {
      "alleleOrigin": "somatic",
      "geneContext": {
        "id": "moa.normalize.gene:BRAF",
        "label": "BRAF",
        "extensions": [
          {
            "type": "Extension",
            "name": "gene_normalizer_id",
            "value": "hgnc:1097"
          }
        ],
        "type": "Gene"
      }
    },
    "variant": "variants.json#/moa.variant:144",
    "specifiedBy": "methods.json#/moa.variant:144",
    "isReportedIn": [
      "documents.json#/moa.source:70"
    ],
    "strength": "strengths.json#/vicc.e000009",
    "therapeutic": "therapeutics.json#/moa.normalize.therapy.rxcui:1622",
    "tumorType": "tumorTypes.json#/moa.normalize.disease.ncit:C3224"
  },
  {
    "id": "moa.assertion:169",
    "description": "Activating BRAF mutations are associated with an increased sensitivity to BRAF inhibitors. Co-administration with a MEK inhibitor may potentiate the effects of BRAF inhibitors.",
    "type": "VariantTherapeuticResponseStudy",
    "predicate": "predictsSensitivityTo",
    "direction": "none",
    "qualifiers": {
      "alleleOrigin": "somatic",
      "geneContext": {
        "id": "moa.normalize.gene:BRAF",
        "label": "BRAF",
        "extensions": [
          {
            "type": "Extension",
            "name": "gene_normalizer_id",
            "value": "hgnc:1097"
          }
        ],
        "type": "Gene"
      }
    },
    "variant": "variants.json#/moa.variant:144",
    "specifiedBy": "methods.json#/moa.variant:144",
    "isReportedIn": [
      "documents.json#/moa.source:72"
    ],
    "strength": "strengths.json#/vicc.e000006",
    "therapeutic": "therapeutics.json#/moa.normalize.therapy.rxcui:1147220",
    "tumorType": "tumorTypes.json#/moa.normalize.disease.ncit:C3107"
  },
  {
    "id": "moa.assertion:170",
    "description": "Activating BRAF mutations are associated with an increased sensitivity to BRAF inhibitors. Co-administration with a MEK inhibitor may potentiate the effects of BRAF inhibitors.",
    "type": "VariantTherapeuticResponseStudy",
    "predicate": "predictsSensitivityTo",
    "direction": "none",
    "qualifiers": {
      "alleleOrigin": "somatic",
      "geneContext": {
        "id": "moa.normalize.gene:BRAF",
        "label": "BRAF",
        "extensions": [
          {
            "type": "Extension",
            "name": "gene_normalizer_id",
            "value": "hgnc:1097"
          }
        ],
        "type": "Gene"
      }
    },
    "variant": "variants.json#/moa.variant:144",
    "specifiedBy": "methods.json#/moa.variant:144",
    "isReportedIn": [
      "documents.json#/moa.source:72"
    ],
    "strength": "strengths.json#/vicc.e000006",
    "therapeutic": "therapeutics.json#/moa.normalize.therapy.rxcui:1147220",
    "tumorType": "tumorTypes.json#/moa.normalize.disease.ncit:C53972"
  },
  {
    "id": "moa.assertion:171",
    "description": "Activating BRAF mutations are associated with an increased sensitivity to BRAF inhibitors. Co-administration with a MEK inhibitor may potentiate the effects of BRAF inhibitors.",
    "type": "VariantTherapeuticResponseStudy",
    "predicate": "predictsSensitivityTo",
    "direction": "none",
    "qualifiers": {
      "alleleOrigin": "somatic",
      "geneContext": {
        "id": "moa.normalize.gene:BRAF",
        "label": "BRAF",
        "extensions": [
          {
            "type": "Extension",
            "name": "gene_normalizer_id",
            "value": "hgnc:1097"
          }
        ],
        "type": "Gene"
      }
    },
    "variant": "variants.json#/moa.variant:144",
    "specifiedBy": "methods.json#/moa.variant:144",
    "isReportedIn": [
      "documents.json#/moa.source:72"
    ],
    "strength": "strengths.json#/vicc.e000006",
    "therapeutic": "therapeutics.json#/moa.normalize.therapy.rxcui:1147220",
    "tumorType": "tumorTypes.json#/moa.normalize.disease.ncit:C2926"
  },
  {
    "id": "moa.assertion:172",
    "description": "Study of a patient-derived orthotopic xenograft (PDOX) model suggests some vemurafenib-resistant BRAF-V600E-mutated melanomas may be sensitive to trametinib (but not cobimetinib) treatment.",
    "type": "VariantTherapeuticResponseStudy",
    "predicate": "predictsSensitivityTo",
    "direction": "none",
    "qualifiers": {
      "alleleOrigin": "somatic",
      "geneContext": {
        "id": "moa.normalize.gene:BRAF",
        "label": "BRAF",
        "extensions": [
          {
            "type": "Extension",
            "name": "gene_normalizer_id",
            "value": "hgnc:1097"
          }
        ],
        "type": "Gene"
      }
    },
    "variant": "variants.json#/moa.variant:144",
    "specifiedBy": "methods.json#/moa.variant:144",
    "isReportedIn": [
      "documents.json#/moa.source:73"
    ],
    "strength": "strengths.json#/vicc.e000009",
    "therapeutic": "therapeutics.json#/moa.normalize.therapy.rxcui:1425098",
    "tumorType": "tumorTypes.json#/moa.normalize.disease.ncit:C3224"
  },
  {
    "id": "moa.assertion:173",
    "description": "Two patients with metastatic colorectal neuroendocrine tumors refractory to treatment exhibited a durable response to combined BRAF-MEK inhibition. One patient with BRAF V600E observed ongoing response lasting over 7 months when treated with dabrafenib and trametinib in combination.",
    "type": "VariantTherapeuticResponseStudy",
    "predicate": "predictsSensitivityTo",
    "direction": "none",
    "qualifiers": {
      "alleleOrigin": "somatic",
      "geneContext": {
        "id": "moa.normalize.gene:BRAF",
        "label": "BRAF",
        "extensions": [
          {
            "type": "Extension",
            "name": "gene_normalizer_id",
            "value": "hgnc:1097"
          }
        ],
        "type": "Gene"
      }
    },
    "variant": "variants.json#/moa.variant:144",
    "specifiedBy": "methods.json#/moa.variant:144",
    "isReportedIn": [
      "documents.json#/moa.source:74"
    ],
    "strength": "strengths.json#/vicc.e000007",
    "therapeutic": "therapeutics.json#/moa.ctid:mm4iftPYmDnZsAZWZwRW5l7p9lbvwqOJ",
    "tumorType": "tumorTypes.json#/moa.normalize.disease.oncotree:HGNEC"
  },
  {
    "id": "moa.assertion:174",
    "description": "Two patients with metastatic colorectal neuroendocrine tumors refractory to treatment exhibited a durable response to combined BRAF-MEK inhibition. One patient with BRAF V600E observed ongoing response lasting 9 months when treated with vemurafenib and trametinib in combination.",
    "type": "VariantTherapeuticResponseStudy",
    "predicate": "predictsSensitivityTo",
    "direction": "none",
    "qualifiers": {
      "alleleOrigin": "somatic",
      "geneContext": {
        "id": "moa.normalize.gene:BRAF",
        "label": "BRAF",
        "extensions": [
          {
            "type": "Extension",
            "name": "gene_normalizer_id",
            "value": "hgnc:1097"
          }
        ],
        "type": "Gene"
      }
    },
    "variant": "variants.json#/moa.variant:144",
    "specifiedBy": "methods.json#/moa.variant:144",
    "isReportedIn": [
      "documents.json#/moa.source:74"
    ],
    "strength": "strengths.json#/vicc.e000007",
    "therapeutic": "therapeutics.json#/moa.ctid:xQv-2m99rVOprssTMAjOqFqgoYXQuioO",
    "tumorType": "tumorTypes.json#/moa.normalize.disease.oncotree:HGNEC"
  },
  {
    "id": "moa.assertion:175",
    "description": "Preclinical evidence suggests the combination of proteasome inhibitor ixazomib with interferon-alpha may negatively impact tumor cell viability in melanoma, particularly in patients with BRAF V600E mutations.",
    "type": "VariantTherapeuticResponseStudy",
    "predicate": "predictsSensitivityTo",
    "direction": "none",
    "qualifiers": {
      "alleleOrigin": "somatic",
      "geneContext": {
        "id": "moa.normalize.gene:BRAF",
        "label": "BRAF",
        "extensions": [
          {
            "type": "Extension",
            "name": "gene_normalizer_id",
            "value": "hgnc:1097"
          }
        ],
        "type": "Gene"
      }
    },
    "variant": "variants.json#/moa.variant:144",
    "specifiedBy": "methods.json#/moa.variant:144",
    "isReportedIn": [
      "documents.json#/moa.source:75"
    ],
    "strength": "strengths.json#/vicc.e000009",
    "therapeutic": "therapeutics.json#/moa.ctid:NmGaX2IchyPJJ5hrP9xxsLPbTPlUBTWc",
    "tumorType": "tumorTypes.json#/moa.normalize.disease.ncit:C3224"
  },
  {
    "id": "moa.assertion:180",
    "description": "BRAF V600E mutations were associated with sensitivity to the BRAF inhibitor PLX-4032 in a study of 109 microdissected pancreatic ductal adenocarcinoma patients.",
    "type": "VariantTherapeuticResponseStudy",
    "predicate": "predictsSensitivityTo",
    "direction": "none",
    "qualifiers": {
      "alleleOrigin": "somatic",
      "geneContext": {
        "id": "moa.normalize.gene:BRAF",
        "label": "BRAF",
        "extensions": [
          {
            "type": "Extension",
            "name": "gene_normalizer_id",
            "value": "hgnc:1097"
          }
        ],
        "type": "Gene"
      }
    },
    "variant": "variants.json#/moa.variant:144",
    "specifiedBy": "methods.json#/moa.variant:144",
    "isReportedIn": [
      "documents.json#/moa.source:52"
    ],
    "strength": "strengths.json#/vicc.e000007",
    "therapeutic": "therapeutics.json#/moa.normalize.therapy.rxcui:1147220",
    "tumorType": "tumorTypes.json#/moa.normalize.disease.ncit:C8294"
  },
  {
    "id": "moa.assertion:181",
    "description": "Vemurafenib monotherapy is efficacious in preclinical models of pediatric gliomas harboring BRAF V600E mutations, but resistance quickly develops. EGFR inhibition appears to rescue the effects of vemurafenib in these models.",
    "type": "VariantTherapeuticResponseStudy",
    "predicate": "predictsSensitivityTo",
    "direction": "none",
    "qualifiers": {
      "alleleOrigin": "somatic",
      "geneContext": {
        "id": "moa.normalize.gene:BRAF",
        "label": "BRAF",
        "extensions": [
          {
            "type": "Extension",
            "name": "gene_normalizer_id",
            "value": "hgnc:1097"
          }
        ],
        "type": "Gene"
      }
    },
    "variant": "variants.json#/moa.variant:144",
    "specifiedBy": "methods.json#/moa.variant:144",
    "isReportedIn": [
      "documents.json#/moa.source:77"
    ],
    "strength": "strengths.json#/vicc.e000009",
    "therapeutic": "therapeutics.json#/moa.ctid:0trcUgfHzHFLIvacsRpjWHnI1eN8XvQc",
    "tumorType": "tumorTypes.json#/moa.normalize.disease.oncotree:GNOS"
  },
  {
    "id": "moa.assertion:182",
    "description": "Cetuximab (Erbitux) is not recommended by the National Comprehensive Cancer Network\u00ae (NCCN\u00ae) as a treatment option for patients with metastatic colorectal cancer, BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor. ",
    "type": "VariantTherapeuticResponseStudy",
    "predicate": "predictsResistanceTo",
    "direction": "none",
    "qualifiers": {
      "alleleOrigin": "somatic",
      "geneContext": {
        "id": "moa.normalize.gene:BRAF",
        "label": "BRAF",
        "extensions": [
          {
            "type": "Extension",
            "name": "gene_normalizer_id",
            "value": "hgnc:1097"
          }
        ],
        "type": "Gene"
      }
    },
    "variant": "variants.json#/moa.variant:144",
    "specifiedBy": "methods.json#/moa.variant:144",
    "isReportedIn": [
      "documents.json#/moa.source:64"
    ],
    "strength": "strengths.json#/vicc.e000003",
    "therapeutic": "therapeutics.json#/moa.normalize.therapy.rxcui:318341",
    "tumorType": "tumorTypes.json#/moa.normalize.disease.ncit:C5105"
  },
  {
    "id": "moa.assertion:184",
    "description": "Vemurafenib alone had insufficient activity in BRAF V600E mutant colorectal cancer patients. Of patients who received vemurafenib and cetuximab, one response was observed; however, approximately half of the patients had tumor regression that did not meet the standard criteria of partial response.",
    "type": "VariantTherapeuticResponseStudy",
    "predicate": "predictsSensitivityTo",
    "direction": "none",
    "qualifiers": {
      "alleleOrigin": "somatic",
      "geneContext": {
        "id": "moa.normalize.gene:BRAF",
        "label": "BRAF",
        "extensions": [
          {
            "type": "Extension",
            "name": "gene_normalizer_id",
            "value": "hgnc:1097"
          }
        ],
        "type": "Gene"
      }
    },
    "variant": "variants.json#/moa.variant:144",
    "specifiedBy": "methods.json#/moa.variant:144",
    "isReportedIn": [
      "documents.json#/moa.source:72"
    ],
    "strength": "strengths.json#/vicc.e000006",
    "therapeutic": "therapeutics.json#/moa.ctid:Xu3LpnoQkk74JyWy2b90_Y6KSgb4Gdst",
    "tumorType": "tumorTypes.json#/moa.normalize.disease.ncit:C5105"
  },
  {
    "id": "moa.assertion:242",
    "description": "Osimertinib is a kinase inhibitor indicated for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation positive non-small cell lung cancer (NSCLC), as detected by an FDA approved test, whose disease has progressed on or after EGFR TKI therapy.",
    "type": "VariantTherapeuticResponseStudy",
    "predicate": "predictsSensitivityTo",
    "direction": "none",
    "qualifiers": {
      "alleleOrigin": "somatic",
      "geneContext": {
        "id": "moa.normalize.gene:EGFR",
        "label": "EGFR",
        "extensions": [
          {
            "type": "Extension",
            "name": "gene_normalizer_id",
            "value": "hgnc:3236"
          }
        ],
        "type": "Gene"
      }
    },
    "variant": "variants.json#/moa.variant:242",
    "specifiedBy": "methods.json#/moa.variant:242",
    "isReportedIn": [
      "documents.json#/moa.source:89"
    ],
    "strength": "strengths.json#/vicc.e000002",
    "therapeutic": "therapeutics.json#/moa.normalize.therapy.rxcui:1721560",
    "tumorType": "tumorTypes.json#/moa.normalize.disease.ncit:C2926"
  },
  {
    "id": "moa.assertion:245",
    "description": "Gefitinib (Iressa) is not recommended by the National Comprehensive Cancer Network\u00ae (NCCN\u00ae) as a treatment option for patients with second-site mutations within the EGFR kinase domain, such as p.T790M, as they are associated with acquired resistance to EGFR TKIs.",
    "type": "VariantTherapeuticResponseStudy",
    "predicate": "predictsResistanceTo",
    "direction": "none",
    "qualifiers": {
      "alleleOrigin": "somatic",
      "geneContext": {
        "id": "moa.normalize.gene:EGFR",
        "label": "EGFR",
        "extensions": [
          {
            "type": "Extension",
            "name": "gene_normalizer_id",
            "value": "hgnc:3236"
          }
        ],
        "type": "Gene"
      }
    },
    "variant": "variants.json#/moa.variant:242",
    "specifiedBy": "methods.json#/moa.variant:242",
    "isReportedIn": [
      "documents.json#/moa.source:20"
    ],
    "strength": "strengths.json#/vicc.e000003",
    "therapeutic": "therapeutics.json#/moa.normalize.therapy.rxcui:328134",
    "tumorType": "tumorTypes.json#/moa.normalize.disease.ncit:C2926"
  },
  {
    "id": "moa.assertion:249",
    "description": "Durvalumab (a PD-L1 inhibitor), is being evaluated in combination with Osimertinib (an EGFR-TKI) in patients with sensitizing EGFR mutations or T790M.",
    "type": "VariantTherapeuticResponseStudy",
    "predicate": "predictsSensitivityTo",
    "direction": "none",
    "qualifiers": {
      "alleleOrigin": "somatic",
      "geneContext": {
        "id": "moa.normalize.gene:EGFR",
        "label": "EGFR",
        "extensions": [
          {
            "type": "Extension",
            "name": "gene_normalizer_id",
            "value": "hgnc:3236"
          }
        ],
        "type": "Gene"
      }
    },
    "variant": "variants.json#/moa.variant:242",
    "specifiedBy": "methods.json#/moa.variant:242",
    "isReportedIn": [
      "documents.json#/moa.source:90"
    ],
    "strength": "strengths.json#/vicc.e000006",
    "therapeutic": "therapeutics.json#/moa.ctid:9vUH8jAN_UCLGblx4LtQdsL8c_EHtvE_",
    "tumorType": "tumorTypes.json#/moa.normalize.disease.ncit:C2926"
  },
  {
    "id": "moa.assertion:250",
    "description": "HM61713 showed clinical activity in patients with an EGFR T790M mutation in a Phase I trial.",
    "type": "VariantTherapeuticResponseStudy",
    "predicate": "predictsSensitivityTo",
    "direction": "none",
    "qualifiers": {
      "alleleOrigin": "somatic",
      "geneContext": {
        "id": "moa.normalize.gene:EGFR",
        "label": "EGFR",
        "extensions": [
          {
            "type": "Extension",
            "name": "gene_normalizer_id",
            "value": "hgnc:3236"
          }
        ],
        "type": "Gene"
      }
    },
    "variant": "variants.json#/moa.variant:242",
    "specifiedBy": "methods.json#/moa.variant:242",
    "isReportedIn": [
      "documents.json#/moa.source:91"
    ],
    "strength": "strengths.json#/vicc.e000006",
    "therapeutic": "therapeutics.json#/moa.normalize.therapy.ncit:C101791",
    "tumorType": "tumorTypes.json#/moa.normalize.disease.ncit:C2926"
  },
  {
    "id": "moa.assertion:254",
    "description": "Dacomitinib is being evaluated in comparison with gefitinib for the treatment of locally advanced or metastatic non-small cell lung cancer.",
    "type": "VariantTherapeuticResponseStudy",
    "predicate": "predictsSensitivityTo",
    "direction": "none",
    "qualifiers": {
      "alleleOrigin": "somatic",
      "geneContext": {
        "id": "moa.normalize.gene:EGFR",
        "label": "EGFR",
        "extensions": [
          {
            "type": "Extension",
            "name": "gene_normalizer_id",
            "value": "hgnc:3236"
          }
        ],
        "type": "Gene"
      }
    },
    "variant": "variants.json#/moa.variant:254",
    "specifiedBy": "methods.json#/moa.variant:254",
    "isReportedIn": [
      "documents.json#/moa.source:92"
    ],
    "strength": "strengths.json#/vicc.e000006",
    "therapeutic": "therapeutics.json#/moa.normalize.therapy.rxcui:2058848",
    "tumorType": "tumorTypes.json#/moa.normalize.disease.ncit:C2926"
  },
  {
    "id": "moa.assertion:256",
    "description": "Osimertinib is being evaluated in patients who have progressed following treatment with an EGFR TKI.",
    "type": "VariantTherapeuticResponseStudy",
    "predicate": "predictsSensitivityTo",
    "direction": "none",
    "qualifiers": {
      "alleleOrigin": "somatic",
      "geneContext": {
        "id": "moa.normalize.gene:EGFR",
        "label": "EGFR",
        "extensions": [
          {
            "type": "Extension",
            "name": "gene_normalizer_id",
            "value": "hgnc:3236"
          }
        ],
        "type": "Gene"
      }
    },
    "variant": "variants.json#/moa.variant:242",
    "specifiedBy": "methods.json#/moa.variant:242",
    "isReportedIn": [
      "documents.json#/moa.source:92"
    ],
    "strength": "strengths.json#/vicc.e000006",
    "therapeutic": "therapeutics.json#/moa.normalize.therapy.rxcui:1721560",
    "tumorType": "tumorTypes.json#/moa.normalize.disease.ncit:C2926"
  },
  {
    "id": "moa.assertion:257",
    "description": "Rociletinib was found to be effective in some patients in a 130-patient trial.",
    "type": "VariantTherapeuticResponseStudy",
    "predicate": "predictsSensitivityTo",
    "direction": "none",
    "qualifiers": {
      "alleleOrigin": "somatic",
      "geneContext": {
        "id": "moa.normalize.gene:EGFR",
        "label": "EGFR",
        "extensions": [
          {
            "type": "Extension",
            "name": "gene_normalizer_id",
            "value": "hgnc:3236"
          }
        ],
        "type": "Gene"
      }
    },
    "variant": "variants.json#/moa.variant:242",
    "specifiedBy": "methods.json#/moa.variant:242",
    "isReportedIn": [
      "documents.json#/moa.source:93"
    ],
    "strength": "strengths.json#/vicc.e000006",
    "therapeutic": "therapeutics.json#/moa.normalize.therapy.ncit:C99905",
    "tumorType": "tumorTypes.json#/moa.normalize.disease.ncit:C2926"
  },
  {
    "id": "moa.assertion:259",
    "description": "Osimertinib is FDA-Approved for metastatic non-small cell lung cancer patients with EGFR T790M mutations.",
    "type": "VariantTherapeuticResponseStudy",
    "predicate": "predictsSensitivityTo",
    "direction": "none",
    "qualifiers": {
      "alleleOrigin": "somatic",
      "geneContext": {
        "id": "moa.normalize.gene:EGFR",
        "label": "EGFR",
        "extensions": [
          {
            "type": "Extension",
            "name": "gene_normalizer_id",
            "value": "hgnc:3236"
          }
        ],
        "type": "Gene"
      }
    },
    "variant": "variants.json#/moa.variant:242",
    "specifiedBy": "methods.json#/moa.variant:242",
    "isReportedIn": [
      "documents.json#/moa.source:95"
    ],
    "strength": "strengths.json#/vicc.e000007",
    "therapeutic": "therapeutics.json#/moa.normalize.therapy.rxcui:1721560",
    "tumorType": "tumorTypes.json#/moa.normalize.disease.ncit:C2926"
  },
  {
    "id": "moa.assertion:260",
    "description": "EGF816 demonstrated clinical activity in a Phase 1 trial of patients with L858R and T790M mutations.",
    "type": "VariantTherapeuticResponseStudy",
    "predicate": "predictsSensitivityTo",
    "direction": "none",
    "qualifiers": {
      "alleleOrigin": "somatic",
      "geneContext": {
        "id": "moa.normalize.gene:EGFR",
        "label": "EGFR",
        "extensions": [
          {
            "type": "Extension",
            "name": "gene_normalizer_id",
            "value": "hgnc:3236"
          }
        ],
        "type": "Gene"
      }
    },
    "variant": "variants.json#/moa.variant:254",
    "specifiedBy": "methods.json#/moa.variant:254",
    "isReportedIn": [
      "documents.json#/moa.source:95"
    ],
    "strength": "strengths.json#/vicc.e000007",
    "therapeutic": "therapeutics.json#/moa.normalize.therapy.ncit:C115109",
    "tumorType": "tumorTypes.json#/moa.normalize.disease.ncit:C2926"
  },
  {
    "id": "moa.assertion:261",
    "description": "EGF816 demonstrated clinical activity in a Phase 1 trial of patients with L858R and T790M mutations.",
    "type": "VariantTherapeuticResponseStudy",
    "predicate": "predictsSensitivityTo",
    "direction": "none",
    "qualifiers": {
      "alleleOrigin": "somatic",
      "geneContext": {
        "id": "moa.normalize.gene:EGFR",
        "label": "EGFR",
        "extensions": [
          {
            "type": "Extension",
            "name": "gene_normalizer_id",
            "value": "hgnc:3236"
          }
        ],
        "type": "Gene"
      }
    },
    "variant": "variants.json#/moa.variant:242",
    "specifiedBy": "methods.json#/moa.variant:242",
    "isReportedIn": [
      "documents.json#/moa.source:95"
    ],
    "strength": "strengths.json#/vicc.e000007",
    "therapeutic": "therapeutics.json#/moa.normalize.therapy.ncit:C115109",
    "tumorType": "tumorTypes.json#/moa.normalize.disease.ncit:C2926"
  },
  {
    "id": "moa.assertion:262",
    "description": "PF-06747775, a small molecule inhibitor of EGFR T790M, is being evaluated in advanced NSCLC patients with EGFR mutations (del 19 and L858R with or without T790M).",
    "type": "VariantTherapeuticResponseStudy",
    "predicate": "predictsSensitivityTo",
    "direction": "none",
    "qualifiers": {
      "alleleOrigin": "somatic",
      "geneContext": {
        "id": "moa.normalize.gene:EGFR",
        "label": "EGFR",
        "extensions": [
          {
            "type": "Extension",
            "name": "gene_normalizer_id",
            "value": "hgnc:3236"
          }
        ],
        "type": "Gene"
      }
    },
    "variant": "variants.json#/moa.variant:254",
    "specifiedBy": "methods.json#/moa.variant:254",
    "isReportedIn": [
      "documents.json#/moa.source:95"
    ],
    "strength": "strengths.json#/vicc.e000007",
    "therapeutic": "therapeutics.json#/moa.normalize.therapy.ncit:C120307",
    "tumorType": "tumorTypes.json#/moa.normalize.disease.ncit:C2926"
  },
  {
    "id": "moa.assertion:263",
    "description": "PF-06747775, a small molecule inhibitor of EGFR T790M, is being evaluated in advanced NSCLC patients with EGFR mutations (del 19 and L858R with or without T790M).",
    "type": "VariantTherapeuticResponseStudy",
    "predicate": "predictsSensitivityTo",
    "direction": "none",
    "qualifiers": {
      "alleleOrigin": "somatic",
      "geneContext": {
        "id": "moa.normalize.gene:EGFR",
        "label": "EGFR",
        "extensions": [
          {
            "type": "Extension",
            "name": "gene_normalizer_id",
            "value": "hgnc:3236"
          }
        ],
        "type": "Gene"
      }
    },
    "variant": "variants.json#/moa.variant:242",
    "specifiedBy": "methods.json#/moa.variant:242",
    "isReportedIn": [
      "documents.json#/moa.source:95"
    ],
    "strength": "strengths.json#/vicc.e000007",
    "therapeutic": "therapeutics.json#/moa.normalize.therapy.ncit:C120307",
    "tumorType": "tumorTypes.json#/moa.normalize.disease.ncit:C2926"
  },
  {
    "id": "moa.assertion:264",
    "description": "TKI therapy for patients with T790M has limited benefit.",
    "type": "VariantTherapeuticResponseStudy",
    "predicate": "predictsResistanceTo",
    "direction": "none",
    "qualifiers": {
      "alleleOrigin": "somatic",
      "geneContext": {
        "id": "moa.normalize.gene:EGFR",
        "label": "EGFR",
        "extensions": [
          {
            "type": "Extension",
            "name": "gene_normalizer_id",
            "value": "hgnc:3236"
          }
        ],
        "type": "Gene"
      }
    },
    "variant": "variants.json#/moa.variant:242",
    "specifiedBy": "methods.json#/moa.variant:242",
    "isReportedIn": [
      "documents.json#/moa.source:96"
    ],
    "strength": "strengths.json#/vicc.e000007",
    "therapeutic": "therapeutics.json#/moa.normalize.therapy.rxcui:337525",
    "tumorType": "tumorTypes.json#/moa.normalize.disease.ncit:C2926"
  },
  {
    "id": "moa.assertion:265",
    "description": "TKI therapy for patients with T790M has limited benefit.",
    "type": "VariantTherapeuticResponseStudy",
    "predicate": "predictsResistanceTo",
    "direction": "none",
    "qualifiers": {
      "alleleOrigin": "somatic",
      "geneContext": {
        "id": "moa.normalize.gene:EGFR",
        "label": "EGFR",
        "extensions": [
          {
            "type": "Extension",
            "name": "gene_normalizer_id",
            "value": "hgnc:3236"
          }
        ],
        "type": "Gene"
      }
    },
    "variant": "variants.json#/moa.variant:242",
    "specifiedBy": "methods.json#/moa.variant:242",
    "isReportedIn": [
      "documents.json#/moa.source:96"
    ],
    "strength": "strengths.json#/vicc.e000007",
    "therapeutic": "therapeutics.json#/moa.normalize.therapy.rxcui:1430438",
    "tumorType": "tumorTypes.json#/moa.normalize.disease.ncit:C2926"
  },
  {
    "id": "moa.assertion:268",
    "description": "The U.S. Food and Drug Administration (FDA) granted approval for afatinib for treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have non-resistant EGFR mutations as detected by an FDA-approved test. Safety and efficacy were not established for tumors with resistant EGFR mutations. Most common non-resistant mutations were exon 21 L858R and exon 19 deletions.",
    "type": "VariantTherapeuticResponseStudy",
    "predicate": "predictsSensitivityTo",
    "direction": "none",
    "qualifiers": {
      "alleleOrigin": "somatic",
      "geneContext": {
        "id": "moa.normalize.gene:EGFR",
        "label": "EGFR",
        "extensions": [
          {
            "type": "Extension",
            "name": "gene_normalizer_id",
            "value": "hgnc:3236"
          }
        ],
        "type": "Gene"
      }
    },
    "variant": "variants.json#/moa.variant:254",
    "specifiedBy": "methods.json#/moa.variant:254",
    "isReportedIn": [
      "documents.json#/moa.source:97"
    ],
    "strength": "strengths.json#/vicc.e000002",
    "therapeutic": "therapeutics.json#/moa.normalize.therapy.rxcui:1430438",
    "tumorType": "tumorTypes.json#/moa.normalize.disease.ncit:C2926"
  },
  {
    "id": "moa.assertion:271",
    "description": "In a phase 3 trial, EGFR mutant positive advanced NSCLC (n=556) patients observed significantly longer PFS when treated with osimertinib instead of standard EGFR-TKIs.",
    "type": "VariantTherapeuticResponseStudy",
    "predicate": "predictsSensitivityTo",
    "direction": "none",
    "qualifiers": {
      "alleleOrigin": "somatic",
      "geneContext": {
        "id": "moa.normalize.gene:EGFR",
        "label": "EGFR",
        "extensions": [
          {
            "type": "Extension",
            "name": "gene_normalizer_id",
            "value": "hgnc:3236"
          }
        ],
        "type": "Gene"
      }
    },
    "variant": "variants.json#/moa.variant:254",
    "specifiedBy": "methods.json#/moa.variant:254",
    "isReportedIn": [
      "documents.json#/moa.source:98"
    ],
    "strength": "strengths.json#/vicc.e000006",
    "therapeutic": "therapeutics.json#/moa.normalize.therapy.rxcui:1721560",
    "tumorType": "tumorTypes.json#/moa.normalize.disease.ncit:C2926"
  },
  {
    "id": "moa.assertion:273",
    "description": "The U.S. Food and Drug Administration (FDA) granted approval for osimertinib for adjuvant therapy after tumor resection in patients with non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 21 L858R mutations, as detected by an FDA-approved test.",
    "type": "VariantTherapeuticResponseStudy",
    "predicate": "predictsSensitivityTo",
    "direction": "none",
    "qualifiers": {
      "alleleOrigin": "somatic",
      "geneContext": {
        "id": "moa.normalize.gene:EGFR",
        "label": "EGFR",
        "extensions": [
          {
            "type": "Extension",
            "name": "gene_normalizer_id",
            "value": "hgnc:3236"
          }
        ],
        "type": "Gene"
      }
    },
    "variant": "variants.json#/moa.variant:254",
    "specifiedBy": "methods.json#/moa.variant:254",
    "isReportedIn": [
      "documents.json#/moa.source:99"
    ],
    "strength": "strengths.json#/vicc.e000002",
    "therapeutic": "therapeutics.json#/moa.normalize.therapy.rxcui:1721560",
    "tumorType": "tumorTypes.json#/moa.normalize.disease.ncit:C2926"
  },
  {
    "id": "moa.assertion:281",
    "description": "Rapid disease regression was notd in a patient with a ERFFI1 p.E384X nonsense variant when treated with erlotinib.",
    "type": "VariantTherapeuticResponseStudy",
    "predicate": "predictsSensitivityTo",
    "direction": "none",
    "qualifiers": {
      "alleleOrigin": "somatic",
      "geneContext": {
        "id": "moa.normalize.gene:ERRFI1",
        "label": "ERRFI1",
        "extensions": [
          {
            "type": "Extension",
            "name": "gene_normalizer_id",
            "value": "hgnc:18185"
          }
        ],
        "type": "Gene"
      }
    },
    "variant": "variants.json#/moa.variant:281",
    "specifiedBy": "methods.json#/moa.variant:281",
    "isReportedIn": [
      "documents.json#/moa.source:23"
    ],
    "strength": "strengths.json#/vicc.e000007",
    "therapeutic": "therapeutics.json#/moa.normalize.therapy.rxcui:337525",
    "tumorType": "tumorTypes.json#/moa.normalize.disease.ncit:C4436"
  },
  {
    "id": "moa.assertion:287",
    "description": "The U.S. Food and Drug Administration (FDA) granted accelerated approval to tazemetostat, an EZH2 inhibitor, for adult patients with relapsed or refactory (R/R) follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies, and for adult patients with R/R FL who have no satisfactory alternative treatment options.",
    "type": "VariantTherapeuticResponseStudy",
    "predicate": "predictsSensitivityTo",
    "direction": "none",
    "qualifiers": {
      "alleleOrigin": "somatic",
      "geneContext": {
        "id": "moa.normalize.gene:EZH2",
        "label": "EZH2",
        "extensions": [
          {
            "type": "Extension",
            "name": "gene_normalizer_id",
            "value": "hgnc:3527"
          }
        ],
        "type": "Gene"
      }
    },
    "variant": "variants.json#/moa.variant:287",
    "specifiedBy": "methods.json#/moa.variant:287",
    "isReportedIn": [
      "documents.json#/moa.source:106"
    ],
    "strength": "strengths.json#/vicc.e000002",
    "therapeutic": "therapeutics.json#/moa.normalize.therapy.rxcui:2274378",
    "tumorType": "tumorTypes.json#/moa.normalize.disease.ncit:C3209"
  },
  {
    "id": "moa.assertion:288",
    "description": "The U.S. Food and Drug Administration (FDA) granted accelerated approval to tazemetostat, an EZH2 inhibitor, for adult patients with relapsed or refactory (R/R) follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies, and for adult patients with R/R FL who have no satisfactory alternative treatment options.",
    "type": "VariantTherapeuticResponseStudy",
    "predicate": "predictsSensitivityTo",
    "direction": "none",
    "qualifiers": {
      "alleleOrigin": "somatic",
      "geneContext": {
        "id": "moa.normalize.gene:EZH2",
        "label": "EZH2",
        "extensions": [
          {
            "type": "Extension",
            "name": "gene_normalizer_id",
            "value": "hgnc:3527"
          }
        ],
        "type": "Gene"
      }
    },
    "variant": "variants.json#/moa.variant:288",
    "specifiedBy": "methods.json#/moa.variant:288",
    "isReportedIn": [
      "documents.json#/moa.source:106"
    ],
    "strength": "strengths.json#/vicc.e000002",
    "therapeutic": "therapeutics.json#/moa.normalize.therapy.rxcui:2274378",
    "tumorType": "tumorTypes.json#/moa.normalize.disease.ncit:C3209"
  },
  {
    "id": "moa.assertion:289",
    "description": "The U.S. Food and Drug Administration (FDA) granted accelerated approval to tazemetostat, an EZH2 inhibitor, for adult patients with relapsed or refactory (R/R) follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies, and for adult patients with R/R FL who have no satisfactory alternative treatment options.",
    "type": "VariantTherapeuticResponseStudy",
    "predicate": "predictsSensitivityTo",
    "direction": "none",
    "qualifiers": {
      "alleleOrigin": "somatic",
      "geneContext": {
        "id": "moa.normalize.gene:EZH2",
        "label": "EZH2",
        "extensions": [
          {
            "type": "Extension",
            "name": "gene_normalizer_id",
            "value": "hgnc:3527"
          }
        ],
        "type": "Gene"
      }
    },
    "variant": "variants.json#/moa.variant:289",
    "specifiedBy": "methods.json#/moa.variant:289",
    "isReportedIn": [
      "documents.json#/moa.source:106"
    ],
    "strength": "strengths.json#/vicc.e000002",
    "therapeutic": "therapeutics.json#/moa.normalize.therapy.rxcui:2274378",
    "tumorType": "tumorTypes.json#/moa.normalize.disease.ncit:C3209"
  },
  {
    "id": "moa.assertion:290",
    "description": "The U.S. Food and Drug Administration (FDA) granted accelerated approval to tazemetostat, an EZH2 inhibitor, for adult patients with relapsed or refactory (R/R) follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies, and for adult patients with R/R FL who have no satisfactory alternative treatment options.",
    "type": "VariantTherapeuticResponseStudy",
    "predicate": "predictsSensitivityTo",
    "direction": "none",
    "qualifiers": {
      "alleleOrigin": "somatic",
      "geneContext": {
        "id": "moa.normalize.gene:EZH2",
        "label": "EZH2",
        "extensions": [
          {
            "type": "Extension",
            "name": "gene_normalizer_id",
            "value": "hgnc:3527"
          }
        ],
        "type": "Gene"
      }
    },
    "variant": "variants.json#/moa.variant:290",
    "specifiedBy": "methods.json#/moa.variant:290",
    "isReportedIn": [
      "documents.json#/moa.source:106"
    ],
    "strength": "strengths.json#/vicc.e000002",
    "therapeutic": "therapeutics.json#/moa.normalize.therapy.rxcui:2274378",
    "tumorType": "tumorTypes.json#/moa.normalize.disease.ncit:C3209"
  },
  {
    "id": "moa.assertion:291",
    "description": "The U.S. Food and Drug Administration (FDA) granted accelerated approval to tazemetostat, an EZH2 inhibitor, for adult patients with relapsed or refactory (R/R) follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies, and for adult patients with R/R FL who have no satisfactory alternative treatment options.",
    "type": "VariantTherapeuticResponseStudy",
    "predicate": "predictsSensitivityTo",
    "direction": "none",
    "qualifiers": {
      "alleleOrigin": "somatic",
      "geneContext": {
        "id": "moa.normalize.gene:EZH2",
        "label": "EZH2",
        "extensions": [
          {
            "type": "Extension",
            "name": "gene_normalizer_id",
            "value": "hgnc:3527"
          }
        ],
        "type": "Gene"
      }
    },
    "variant": "variants.json#/moa.variant:291",
    "specifiedBy": "methods.json#/moa.variant:291",
    "isReportedIn": [
      "documents.json#/moa.source:106"
    ],
    "strength": "strengths.json#/vicc.e000002",
    "therapeutic": "therapeutics.json#/moa.normalize.therapy.rxcui:2274378",
    "tumorType": "tumorTypes.json#/moa.normalize.disease.ncit:C3209"
  },
  {
    "id": "moa.assertion:294",
    "description": "The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy.",
    "type": "VariantTherapeuticResponseStudy",
    "predicate": "predictsSensitivityTo",
    "direction": "none",
    "qualifiers": {
      "alleleOrigin": "somatic",
      "geneContext": {
        "id": "moa.normalize.gene:FGFR3",
        "label": "FGFR3",
        "extensions": [
          {
            "type": "Extension",
            "name": "gene_normalizer_id",
            "value": "hgnc:3690"
          }
        ],
        "type": "Gene"
      }
    },
    "variant": "variants.json#/moa.variant:294",
    "specifiedBy": "methods.json#/moa.variant:294",
    "isReportedIn": [
      "documents.json#/moa.source:26"
    ],
    "strength": "strengths.json#/vicc.e000002",
    "therapeutic": "therapeutics.json#/moa.normalize.therapy.rxcui:2123125",
    "tumorType": "tumorTypes.json#/moa.normalize.disease.ncit:C39851"
  },
  {
    "id": "moa.assertion:295",
    "description": "The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy.",
    "type": "VariantTherapeuticResponseStudy",
    "predicate": "predictsSensitivityTo",
    "direction": "none",
    "qualifiers": {
      "alleleOrigin": "somatic",
      "geneContext": {
        "id": "moa.normalize.gene:FGFR3",
        "label": "FGFR3",
        "extensions": [
          {
            "type": "Extension",
            "name": "gene_normalizer_id",
            "value": "hgnc:3690"
          }
        ],
        "type": "Gene"
      }
    },
    "variant": "variants.json#/moa.variant:295",
    "specifiedBy": "methods.json#/moa.variant:295",
    "isReportedIn": [
      "documents.json#/moa.source:26"
    ],
    "strength": "strengths.json#/vicc.e000002",
    "therapeutic": "therapeutics.json#/moa.normalize.therapy.rxcui:2123125",
    "tumorType": "tumorTypes.json#/moa.normalize.disease.ncit:C39851"
  },
  {
    "id": "moa.assertion:296",
    "description": "The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy.",
    "type": "VariantTherapeuticResponseStudy",
    "predicate": "predictsSensitivityTo",
    "direction": "none",
    "qualifiers": {
      "alleleOrigin": "somatic",
      "geneContext": {
        "id": "moa.normalize.gene:FGFR3",
        "label": "FGFR3",
        "extensions": [
          {
            "type": "Extension",
            "name": "gene_normalizer_id",
            "value": "hgnc:3690"
          }
        ],
        "type": "Gene"
      }
    },
    "variant": "variants.json#/moa.variant:296",
    "specifiedBy": "methods.json#/moa.variant:296",
    "isReportedIn": [
      "documents.json#/moa.source:26"
    ],
    "strength": "strengths.json#/vicc.e000002",
    "therapeutic": "therapeutics.json#/moa.normalize.therapy.rxcui:2123125",
    "tumorType": "tumorTypes.json#/moa.normalize.disease.ncit:C39851"
  },
  {
    "id": "moa.assertion:297",
    "description": "The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy.",
    "type": "VariantTherapeuticResponseStudy",
    "predicate": "predictsSensitivityTo",
    "direction": "none",
    "qualifiers": {
      "alleleOrigin": "somatic",
      "geneContext": {
        "id": "moa.normalize.gene:FGFR3",
        "label": "FGFR3",
        "extensions": [
          {
            "type": "Extension",
            "name": "gene_normalizer_id",
            "value": "hgnc:3690"
          }
        ],
        "type": "Gene"
      }
    },
    "variant": "variants.json#/moa.variant:297",
    "specifiedBy": "methods.json#/moa.variant:297",
    "isReportedIn": [
      "documents.json#/moa.source:26"
    ],
    "strength": "strengths.json#/vicc.e000002",
    "therapeutic": "therapeutics.json#/moa.normalize.therapy.rxcui:2123125",
    "tumorType": "tumorTypes.json#/moa.normalize.disease.ncit:C39851"
  },
  {
    "id": "moa.assertion:304",
    "description": "A second FTL3 internal tanden duplication mutation (FTL3 p.F691L) was detected in a patient with acute myeloid leukemia at the time of relapse followed Quizartinib (AC220) treatment. Normal karyotype of NPM1 and FLT3-ITD was observed before treatment.",
    "type": "VariantTherapeuticResponseStudy",
    "predicate": "predictsResistanceTo",
    "direction": "none",
    "qualifiers": {
      "alleleOrigin": "somatic",
      "geneContext": {
        "id": "moa.normalize.gene:FLT3",
        "label": "FLT3",
        "extensions": [
          {
            "type": "Extension",
            "name": "gene_normalizer_id",
            "value": "hgnc:3765"
          }
        ],
        "type": "Gene"
      }
    },
    "variant": "variants.json#/moa.variant:304",
    "specifiedBy": "methods.json#/moa.variant:304",
    "isReportedIn": [
      "documents.json#/moa.source:110"
    ],
    "strength": "strengths.json#/vicc.e000007",
    "therapeutic": "therapeutics.json#/moa.normalize.therapy.ncit:C68936",
    "tumorType": "tumorTypes.json#/moa.normalize.disease.ncit:C3171"
  },
  {
    "id": "moa.assertion:305",
    "description": "Sunitinib successfully inhibits cellular proliferation of cells Ba/F3 FLT3 K663Q cells in a dose-dependent manner.",
    "type": "VariantTherapeuticResponseStudy",
    "predicate": "predictsSensitivityTo",
    "direction": "none",
    "qualifiers": {
      "alleleOrigin": "somatic",
      "geneContext": {
        "id": "moa.normalize.gene:FLT3",
        "label": "FLT3",
        "extensions": [
          {
            "type": "Extension",
            "name": "gene_normalizer_id",
            "value": "hgnc:3765"
          }
        ],
        "type": "Gene"
      }
    },
    "variant": "variants.json#/moa.variant:305",
    "specifiedBy": "methods.json#/moa.variant:305",
    "isReportedIn": [
      "documents.json#/moa.source:111"
    ],
    "strength": "strengths.json#/vicc.e000009",
    "therapeutic": "therapeutics.json#/moa.normalize.therapy.rxcui:357977",
    "tumorType": "tumorTypes.json#/moa.normalize.disease.ncit:C3171"
  },
  {
    "id": "moa.assertion:306",
    "description": "GATA3 mutation did not influence baseline Ki67 levels but was enriched in samples exhibiting greater percentage of Ki67 decline. While this requires further validation, it suggests that GATA3 mutation may be a positive marker for aromatase inhibitor response.",
    "type": "VariantTherapeuticResponseStudy",
    "predicate": "predictsSensitivityTo",
    "direction": "none",
    "qualifiers": {
      "alleleOrigin": "somatic",
      "geneContext": {
        "id": "moa.normalize.gene:GATA3",
        "label": "GATA3",
        "extensions": [
          {
            "type": "Extension",
            "name": "gene_normalizer_id",
            "value": "hgnc:4172"
          }
        ],
        "type": "Gene"
      }
    },
    "variant": "variants.json#/moa.variant:306",
    "specifiedBy": "methods.json#/moa.variant:306",
    "isReportedIn": [
      "documents.json#/moa.source:112"
    ],
    "strength": "strengths.json#/vicc.e000007",
    "therapeutic": "therapeutics.json#/moa.normalize.therapy.rxcui:72965",
    "tumorType": "tumorTypes.json#/moa.normalize.disease.ncit:C9245"
  },
  {
    "id": "moa.assertion:310",
    "description": "The U.S. Food and Drug Administration (FDA) granted approval to ivosidenib, an isocitrate dehydrogenase-1 (IDH1) inhibitor, indicated for the treatment of adult patients with a susceptible IDH1 mutation as detected by an FDA approved test with newly-diagnosed AML who are greater than or equal to 75 years old or who have comorbidities that preclude the use of intensive induction chemotherapy as well as relapsed or refractory AML.",
    "type": "VariantTherapeuticResponseStudy",
    "predicate": "predictsSensitivityTo",
    "direction": "none",
    "qualifiers": {
      "alleleOrigin": "somatic",
      "geneContext": {
        "id": "moa.normalize.gene:IDH1",
        "label": "IDH1",
        "extensions": [
          {
            "type": "Extension",
            "name": "gene_normalizer_id",
            "value": "hgnc:5382"
          }
        ],
        "type": "Gene"
      }
    },
    "variant": "variants.json#/moa.variant:310",
    "specifiedBy": "methods.json#/moa.variant:310",
    "isReportedIn": [
      "documents.json#/moa.source:115"
    ],
    "strength": "strengths.json#/vicc.e000002",
    "therapeutic": "therapeutics.json#/moa.normalize.therapy.rxcui:2049873",
    "tumorType": "tumorTypes.json#/moa.normalize.disease.ncit:C3171"
  },
  {
    "id": "moa.assertion:311",
    "description": "The U.S. Food and Drug Administration (FDA) granted approval to ivosidenib, an isocitrate dehydrogenase-1 (IDH1) inhibitor, indicated for the treatment of adult patients with a susceptible IDH1 mutation as detected by an FDA approved test with newly-diagnosed AML who are greater than or equal to 75 years old or who have comorbidities that preclude the use of intensive induction chemotherapy as well as relapsed or refractory AML.",
    "type": "VariantTherapeuticResponseStudy",
    "predicate": "predictsSensitivityTo",
    "direction": "none",
    "qualifiers": {
      "alleleOrigin": "somatic",
      "geneContext": {
        "id": "moa.normalize.gene:IDH1",
        "label": "IDH1",
        "extensions": [
          {
            "type": "Extension",
            "name": "gene_normalizer_id",
            "value": "hgnc:5382"
          }
        ],
        "type": "Gene"
      }
    },
    "variant": "variants.json#/moa.variant:311",
    "specifiedBy": "methods.json#/moa.variant:311",
    "isReportedIn": [
      "documents.json#/moa.source:115"
    ],
    "strength": "strengths.json#/vicc.e000002",
    "therapeutic": "therapeutics.json#/moa.normalize.therapy.rxcui:2049873",
    "tumorType": "tumorTypes.json#/moa.normalize.disease.ncit:C3171"
  },
  {
    "id": "moa.assertion:312",
    "description": "The U.S. Food and Drug Administration (FDA) granted approval to ivosidenib, an isocitrate dehydrogenase-1 (IDH1) inhibitor, indicated for the treatment of adult patients with a susceptible IDH1 mutation as detected by an FDA approved test with locally advanced or metastatic cholangiocarcinoma who have been previously treated.",
    "type": "VariantTherapeuticResponseStudy",
    "predicate": "predictsSensitivityTo",
    "direction": "none",
    "qualifiers": {
      "alleleOrigin": "somatic",
      "geneContext": {
        "id": "moa.normalize.gene:IDH1",
        "label": "IDH1",
        "extensions": [
          {
            "type": "Extension",
            "name": "gene_normalizer_id",
            "value": "hgnc:5382"
          }
        ],
        "type": "Gene"
      }
    },
    "variant": "variants.json#/moa.variant:310",
    "specifiedBy": "methods.json#/moa.variant:310",
    "isReportedIn": [
      "documents.json#/moa.source:115"
    ],
    "strength": "strengths.json#/vicc.e000002",
    "therapeutic": "therapeutics.json#/moa.normalize.therapy.rxcui:2049873",
    "tumorType": "tumorTypes.json#/moa.normalize.disease.ncit:C4436"
  },
  {
    "id": "moa.assertion:313",
    "description": "The U.S. Food and Drug Administration (FDA) granted approval to ivosidenib, an isocitrate dehydrogenase-1 (IDH1) inhibitor, indicated for the treatment of adult patients with a susceptible IDH1 mutation as detected by an FDA approved test with locally advanced or metastatic cholangiocarcinoma who have been previously treated.",
    "type": "VariantTherapeuticResponseStudy",
    "predicate": "predictsSensitivityTo",
    "direction": "none",
    "qualifiers": {
      "alleleOrigin": "somatic",
      "geneContext": {
        "id": "moa.normalize.gene:IDH1",
        "label": "IDH1",
        "extensions": [
          {
            "type": "Extension",
            "name": "gene_normalizer_id",
            "value": "hgnc:5382"
          }
        ],
        "type": "Gene"
      }
    },
    "variant": "variants.json#/moa.variant:311",
    "specifiedBy": "methods.json#/moa.variant:311",
    "isReportedIn": [
      "documents.json#/moa.source:115"
    ],
    "strength": "strengths.json#/vicc.e000002",
    "therapeutic": "therapeutics.json#/moa.normalize.therapy.rxcui:2049873",
    "tumorType": "tumorTypes.json#/moa.normalize.disease.ncit:C4436"
  },
  {
    "id": "moa.assertion:316",
    "description": "The U.S. Food and Drug Administration (FDA) granted regular approval to enasidenib for the treatment of adult patients with relapsed or refractory acute myeloid leukemia with an isocitrate dehydrogenase-2 (IDH2) mutation as detected by an FDA-approved test.",
    "type": "VariantTherapeuticResponseStudy",
    "predicate": "predictsSensitivityTo",
    "direction": "none",
    "qualifiers": {
      "alleleOrigin": "somatic",
      "geneContext": {
        "id": "moa.normalize.gene:IDH2",
        "label": "IDH2",
        "extensions": [
          {
            "type": "Extension",
            "name": "gene_normalizer_id",
            "value": "hgnc:5383"
          }
        ],
        "type": "Gene"
      }
    },
    "variant": "variants.json#/moa.variant:316",
    "specifiedBy": "methods.json#/moa.variant:316",
    "isReportedIn": [
      "documents.json#/moa.source:116"
    ],
    "strength": "strengths.json#/vicc.e000002",
    "therapeutic": "therapeutics.json#/moa.normalize.therapy.rxcui:1940332",
    "tumorType": "tumorTypes.json#/moa.normalize.disease.ncit:C3171"
  },
  {
    "id": "moa.assertion:317",
    "description": "The U.S. Food and Drug Administration (FDA) granted regular approval to enasidenib for the treatment of adult patients with relapsed or refractory acute myeloid leukemia with an isocitrate dehydrogenase-2 (IDH2) mutation as detected by an FDA-approved test.",
    "type": "VariantTherapeuticResponseStudy",
    "predicate": "predictsSensitivityTo",
    "direction": "none",
    "qualifiers": {
      "alleleOrigin": "somatic",
      "geneContext": {
        "id": "moa.normalize.gene:IDH2",
        "label": "IDH2",
        "extensions": [
          {
            "type": "Extension",
            "name": "gene_normalizer_id",
            "value": "hgnc:5383"
          }
        ],
        "type": "Gene"
      }
    },
    "variant": "variants.json#/moa.variant:317",
    "specifiedBy": "methods.json#/moa.variant:317",
    "isReportedIn": [
      "documents.json#/moa.source:116"
    ],
    "strength": "strengths.json#/vicc.e000002",
    "therapeutic": "therapeutics.json#/moa.normalize.therapy.rxcui:1940332",
    "tumorType": "tumorTypes.json#/moa.normalize.disease.ncit:C3171"
  },
  {
    "id": "moa.assertion:318",
    "description": "The U.S. Food and Drug Administration (FDA) granted regular approval to enasidenib for the treatment of adult patients with relapsed or refractory acute myeloid leukemia with an isocitrate dehydrogenase-2 (IDH2) mutation as detected by an FDA-approved test.",
    "type": "VariantTherapeuticResponseStudy",
    "predicate": "predictsSensitivityTo",
    "direction": "none",
    "qualifiers": {
      "alleleOrigin": "somatic",
      "geneContext": {
        "id": "moa.normalize.gene:IDH2",
        "label": "IDH2",
        "extensions": [
          {
            "type": "Extension",
            "name": "gene_normalizer_id",
            "value": "hgnc:5383"
          }
        ],
        "type": "Gene"
      }
    },
    "variant": "variants.json#/moa.variant:318",
    "specifiedBy": "methods.json#/moa.variant:318",
    "isReportedIn": [
      "documents.json#/moa.source:116"
    ],
    "strength": "strengths.json#/vicc.e000002",
    "therapeutic": "therapeutics.json#/moa.normalize.therapy.rxcui:1940332",
    "tumorType": "tumorTypes.json#/moa.normalize.disease.ncit:C3171"
  },
  {
    "id": "moa.assertion:325",
    "description": "MOHITO JAK1 V658F transplated mice were highly sensitive to growth inhibition by PU-H71.",
    "type": "VariantTherapeuticResponseStudy",
    "predicate": "predictsSensitivityTo",
    "direction": "none",
    "qualifiers": {
      "alleleOrigin": "somatic",
      "geneContext": {
        "id": "moa.normalize.gene:JAK1",
        "label": "JAK1",
        "extensions": [
          {
            "type": "Extension",
            "name": "gene_normalizer_id",
            "value": "hgnc:6190"
          }
        ],
        "type": "Gene"
      }
    },
    "variant": "variants.json#/moa.variant:325",
    "specifiedBy": "methods.json#/moa.variant:325",
    "isReportedIn": [
      "documents.json#/moa.source:118"
    ],
    "strength": "strengths.json#/vicc.e000009",
    "therapeutic": "therapeutics.json#/moa.normalize.therapy.drugbank:DB12638",
    "tumorType": "tumorTypes.json#/moa.normalize.disease.ncit:C3167"
  },
  {
    "id": "moa.assertion:326",
    "description": "MOHITO JAK1 A634D transplated mice were highly sensitive to growth inhibition by PU-H71.",
    "type": "VariantTherapeuticResponseStudy",
    "predicate": "predictsSensitivityTo",
    "direction": "none",
    "qualifiers": {
      "alleleOrigin": "somatic",
      "geneContext": {
        "id": "moa.normalize.gene:JAK1",
        "label": "JAK1",
        "extensions": [
          {
            "type": "Extension",
            "name": "gene_normalizer_id",
            "value": "hgnc:6190"
          }
        ],
        "type": "Gene"
      }
    },
    "variant": "variants.json#/moa.variant:326",
    "specifiedBy": "methods.json#/moa.variant:326",
    "isReportedIn": [
      "documents.json#/moa.source:118"
    ],
    "strength": "strengths.json#/vicc.e000009",
    "therapeutic": "therapeutics.json#/moa.normalize.therapy.drugbank:DB12638",
    "tumorType": "tumorTypes.json#/moa.normalize.disease.ncit:C3167"
  },
  {
    "id": "moa.assertion:339",
    "description": "FDA-approved for locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate.",
    "type": "VariantTherapeuticResponseStudy",
    "predicate": "predictsSensitivityTo",
    "direction": "none",
    "qualifiers": {
      "alleleOrigin": "somatic",
      "geneContext": {
        "id": "moa.normalize.gene:KIT",
        "label": "KIT",
        "extensions": [
          {
            "type": "Extension",
            "name": "gene_normalizer_id",
            "value": "hgnc:6342"
          }
        ],
        "type": "Gene"
      }
    },
    "variant": "variants.json#/moa.variant:339",
    "specifiedBy": "methods.json#/moa.variant:339",
    "isReportedIn": [
      "documents.json#/moa.source:121"
    ],
    "strength": "strengths.json#/vicc.e000002",
    "therapeutic": "therapeutics.json#/moa.normalize.therapy.rxcui:1312397",
    "tumorType": "tumorTypes.json#/moa.normalize.disease.ncit:C3868"
  },
  {
    "id": "moa.assertion:340",
    "description": "FDA-approved for locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate.",
    "type": "VariantTherapeuticResponseStudy",
    "predicate": "predictsSensitivityTo",
    "direction": "none",
    "qualifiers": {
      "alleleOrigin": "somatic",
      "geneContext": {
        "id": "moa.normalize.gene:KIT",
        "label": "KIT",
        "extensions": [
          {
            "type": "Extension",
            "name": "gene_normalizer_id",
            "value": "hgnc:6342"
          }
        ],
        "type": "Gene"
      }
    },
    "variant": "variants.json#/moa.variant:340",
    "specifiedBy": "methods.json#/moa.variant:340",
    "isReportedIn": [
      "documents.json#/moa.source:121"
    ],
    "strength": "strengths.json#/vicc.e000002",
    "therapeutic": "therapeutics.json#/moa.normalize.therapy.rxcui:1312397",
    "tumorType": "tumorTypes.json#/moa.normalize.disease.ncit:C3868"
  },
  {
    "id": "moa.assertion:342",
    "description": "The U.S. Food and Drug Administration (FDA) granted approval to Sunitinib for the treatment of gastrointestinal stromal tumor (GIST) after disease progression on or intolerance of imatinib mesylate.",
    "type": "VariantTherapeuticResponseStudy",
    "predicate": "predictsSensitivityTo",
    "direction": "none",
    "qualifiers": {
      "alleleOrigin": "somatic",
      "geneContext": {
        "id": "moa.normalize.gene:KIT",
        "label": "KIT",
        "extensions": [
          {
            "type": "Extension",
            "name": "gene_normalizer_id",
            "value": "hgnc:6342"
          }
        ],
        "type": "Gene"
      }
    },
    "variant": "variants.json#/moa.variant:339",
    "specifiedBy": "methods.json#/moa.variant:339",
    "isReportedIn": [
      "documents.json#/moa.source:122"
    ],
    "strength": "strengths.json#/vicc.e000002",
    "therapeutic": "therapeutics.json#/moa.normalize.therapy.rxcui:357977",
    "tumorType": "tumorTypes.json#/moa.normalize.disease.ncit:C3868"
  },
  {
    "id": "moa.assertion:343",
    "description": "The U.S. Food and Drug Administration (FDA) granted approval to Sunitinib for the treatment of gastrointestinal stromal tumor (GIST) after disease progression on or intolerance of imatinib mesylate.",
    "type": "VariantTherapeuticResponseStudy",
    "predicate": "predictsSensitivityTo",
    "direction": "none",
    "qualifiers": {
      "alleleOrigin": "somatic",
      "geneContext": {
        "id": "moa.normalize.gene:KIT",
        "label": "KIT",
        "extensions": [
          {
            "type": "Extension",
            "name": "gene_normalizer_id",
            "value": "hgnc:6342"
          }
        ],
        "type": "Gene"
      }
    },
    "variant": "variants.json#/moa.variant:340",
    "specifiedBy": "methods.json#/moa.variant:340",
    "isReportedIn": [
      "documents.json#/moa.source:122"
    ],
    "strength": "strengths.json#/vicc.e000002",
    "therapeutic": "therapeutics.json#/moa.normalize.therapy.rxcui:357977",
    "tumorType": "tumorTypes.json#/moa.normalize.disease.ncit:C3868"
  },
  {
    "id": "moa.assertion:347",
    "description": "Imatinib (Gleevec) is recommended by the National Comprehensive Cancer Network\u00ae (NCCN\u00ae) as a treatment option for patients with melanoma and KIT exon 11 and 13 variants; p.W557, p.V559, p.L576P, and p.K642E appear to have high level of sensitivity to KIT inhibition.",
    "type": "VariantTherapeuticResponseStudy",
    "predicate": "predictsSensitivityTo",
    "direction": "none",
    "qualifiers": {
      "alleleOrigin": "somatic",
      "geneContext": {
        "id": "moa.normalize.gene:KIT",
        "label": "KIT",
        "extensions": [
          {
            "type": "Extension",
            "name": "gene_normalizer_id",
            "value": "hgnc:6342"
          }
        ],
        "type": "Gene"
      }
    },
    "variant": "variants.json#/moa.variant:347",
    "specifiedBy": "methods.json#/moa.variant:347",
    "isReportedIn": [
      "documents.json#/moa.source:124"
    ],
    "strength": "strengths.json#/vicc.e000003",
    "therapeutic": "therapeutics.json#/moa.normalize.therapy.rxcui:282388",
    "tumorType": "tumorTypes.json#/moa.normalize.disease.ncit:C3224"
  },
  {
    "id": "moa.assertion:348",
    "description": "Imatinib (Gleevec) is recommended by the National Comprehensive Cancer Network\u00ae (NCCN\u00ae) as a treatment option for patients with melanoma and KIT exon 11 and 13 variants; p.W557, p.V559, p.L576P, and p.K642E appear to have high level of sensitivity to KIT inhibition.",
    "type": "VariantTherapeuticResponseStudy",
    "predicate": "predictsSensitivityTo",
    "direction": "none",
    "qualifiers": {
      "alleleOrigin": "somatic",
      "geneContext": {
        "id": "moa.normalize.gene:KIT",
        "label": "KIT",
        "extensions": [
          {
            "type": "Extension",
            "name": "gene_normalizer_id",
            "value": "hgnc:6342"
          }
        ],
        "type": "Gene"
      }
    },
    "variant": "variants.json#/moa.variant:348",
    "specifiedBy": "methods.json#/moa.variant:348",
    "isReportedIn": [
      "documents.json#/moa.source:124"
    ],
    "strength": "strengths.json#/vicc.e000003",
    "therapeutic": "therapeutics.json#/moa.normalize.therapy.rxcui:282388",
    "tumorType": "tumorTypes.json#/moa.normalize.disease.ncit:C3224"
  },
  {
    "id": "moa.assertion:349",
    "description": "Imatinib (Gleevec) is recommended by the National Comprehensive Cancer Network\u00ae (NCCN\u00ae) as a treatment option for patients with melanoma and KIT exon 11 and 13 variants; p.W557, p.V559, p.L576P, and p.K642E appear to have high level of sensitivity to KIT inhibition.",
    "type": "VariantTherapeuticResponseStudy",
    "predicate": "predictsSensitivityTo",
    "direction": "none",
    "qualifiers": {
      "alleleOrigin": "somatic",
      "geneContext": {
        "id": "moa.normalize.gene:KIT",
        "label": "KIT",
        "extensions": [
          {
            "type": "Extension",
            "name": "gene_normalizer_id",
            "value": "hgnc:6342"
          }
        ],
        "type": "Gene"
      }
    },
    "variant": "variants.json#/moa.variant:349",
    "specifiedBy": "methods.json#/moa.variant:349",
    "isReportedIn": [
      "documents.json#/moa.source:124"
    ],
    "strength": "strengths.json#/vicc.e000003",
    "therapeutic": "therapeutics.json#/moa.normalize.therapy.rxcui:282388",
    "tumorType": "tumorTypes.json#/moa.normalize.disease.ncit:C3224"
  },
  {
    "id": "moa.assertion:350",
    "description": "Imatinib (Gleevec) is recommended by the National Comprehensive Cancer Network\u00ae (NCCN\u00ae) as a treatment option for patients with melanoma and KIT exon 11 and 13 variants; p.W557, p.V559, p.L576P, and p.K642E appear to have high level of sensitivity to KIT inhibition.",
    "type": "VariantTherapeuticResponseStudy",
    "predicate": "predictsSensitivityTo",
    "direction": "none",
    "qualifiers": {
      "alleleOrigin": "somatic",
      "geneContext": {
        "id": "moa.normalize.gene:KIT",
        "label": "KIT",
        "extensions": [
          {
            "type": "Extension",
            "name": "gene_normalizer_id",
            "value": "hgnc:6342"
          }
        ],
        "type": "Gene"
      }
    },
    "variant": "variants.json#/moa.variant:350",
    "specifiedBy": "methods.json#/moa.variant:350",
    "isReportedIn": [
      "documents.json#/moa.source:124"
    ],
    "strength": "strengths.json#/vicc.e000003",
    "therapeutic": "therapeutics.json#/moa.normalize.therapy.rxcui:282388",
    "tumorType": "tumorTypes.json#/moa.normalize.disease.ncit:C3224"
  },
  {
    "id": "moa.assertion:351",
    "description": "Imatinib (Gleevec) is recommended by the National Comprehensive Cancer Network\u00ae (NCCN\u00ae) as a treatment option for patients with melanoma and KIT exon 11 and 13 variants; p.W557, p.V559, p.L576P, and p.K642E appear to have high level of sensitivity to KIT inhibition.",
    "type": "VariantTherapeuticResponseStudy",
    "predicate": "predictsSensitivityTo",
    "direction": "none",
    "qualifiers": {
      "alleleOrigin": "somatic",
      "geneContext": {
        "id": "moa.normalize.gene:KIT",
        "label": "KIT",
        "extensions": [
          {
            "type": "Extension",
            "name": "gene_normalizer_id",
            "value": "hgnc:6342"
          }
        ],
        "type": "Gene"
      }
    },
    "variant": "variants.json#/moa.variant:351",
    "specifiedBy": "methods.json#/moa.variant:351",
    "isReportedIn": [
      "documents.json#/moa.source:124"
    ],
    "strength": "strengths.json#/vicc.e000003",
    "therapeutic": "therapeutics.json#/moa.normalize.therapy.rxcui:282388",
    "tumorType": "tumorTypes.json#/moa.normalize.disease.ncit:C3224"
  },
  {
    "id": "moa.assertion:352",
    "description": "Imatinib (Gleevec) is recommended by the National Comprehensive Cancer Network\u00ae (NCCN\u00ae) as a treatment option for patients with melanoma and KIT exon 11 and 13 variants; p.W557, p.V559, p.L576P, and p.K642E appear to have high level of sensitivity to KIT inhibition.",
    "type": "VariantTherapeuticResponseStudy",
    "predicate": "predictsSensitivityTo",
    "direction": "none",
    "qualifiers": {
      "alleleOrigin": "somatic",
      "geneContext": {
        "id": "moa.normalize.gene:KIT",
        "label": "KIT",
        "extensions": [
          {
            "type": "Extension",
            "name": "gene_normalizer_id",
            "value": "hgnc:6342"
          }
        ],
        "type": "Gene"
      }
    },
    "variant": "variants.json#/moa.variant:352",
    "specifiedBy": "methods.json#/moa.variant:352",
    "isReportedIn": [
      "documents.json#/moa.source:124"
    ],
    "strength": "strengths.json#/vicc.e000003",
    "therapeutic": "therapeutics.json#/moa.normalize.therapy.rxcui:282388",
    "tumorType": "tumorTypes.json#/moa.normalize.disease.ncit:C3224"
  },
  {
    "id": "moa.assertion:353",
    "description": "Imatinib (Gleevec) is recommended by the National Comprehensive Cancer Network\u00ae (NCCN\u00ae) as a treatment option for patients with melanoma and KIT exon 11 and 13 variants; p.W557, p.V559, p.L576P, and p.K642E appear to have high level of sensitivity to KIT inhibition.",
    "type": "VariantTherapeuticResponseStudy",
    "predicate": "predictsSensitivityTo",
    "direction": "none",
    "qualifiers": {
      "alleleOrigin": "somatic",
      "geneContext": {
        "id": "moa.normalize.gene:KIT",
        "label": "KIT",
        "extensions": [
          {
            "type": "Extension",
            "name": "gene_normalizer_id",
            "value": "hgnc:6342"
          }
        ],
        "type": "Gene"
      }
    },
    "variant": "variants.json#/moa.variant:353",
    "specifiedBy": "methods.json#/moa.variant:353",
    "isReportedIn": [
      "documents.json#/moa.source:124"
    ],
    "strength": "strengths.json#/vicc.e000003",
    "therapeutic": "therapeutics.json#/moa.normalize.therapy.rxcui:282388",
    "tumorType": "tumorTypes.json#/moa.normalize.disease.ncit:C3224"
  },
  {
    "id": "moa.assertion:360",
    "description": "Avapritnib inhibited the autophosphorylation of KIT p.D816V in cellular assays relative to wild-type KIT.",
    "type": "VariantTherapeuticResponseStudy",
    "predicate": "predictsSensitivityTo",
    "direction": "none",
    "qualifiers": {
      "alleleOrigin": "somatic",
      "geneContext": {
        "id": "moa.normalize.gene:KIT",
        "label": "KIT",
        "extensions": [
          {
            "type": "Extension",
            "name": "gene_normalizer_id",
            "value": "hgnc:6342"
          }
        ],
        "type": "Gene"
      }
    },
    "variant": "variants.json#/moa.variant:360",
    "specifiedBy": "methods.json#/moa.variant:360",
    "isReportedIn": [
      "documents.json#/moa.source:127"
    ],
    "strength": "strengths.json#/vicc.e000009",
    "therapeutic": "therapeutics.json#/moa.normalize.therapy.rxcui:2272107",
    "tumorType": "tumorTypes.json#/moa.normalize.disease.ncit:C3868"
  },
  {
    "id": "moa.assertion:372",
    "description": "The U.S. Food and Drug Administration (FDA) has granted accelerated approval to sotorasib, a RAS GTPase family inhibitor, for adult patients with KRAS G12C mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), as determined by an FDA approved test, who have received at least one prior systemic therapy.",
    "type": "VariantTherapeuticResponseStudy",
    "predicate": "predictsSensitivityTo",
    "direction": "none",
    "qualifiers": {
      "alleleOrigin": "somatic",
      "geneContext": {
        "id": "moa.normalize.gene:KRAS",
        "label": "KRAS",
        "extensions": [
          {
            "type": "Extension",
            "name": "gene_normalizer_id",
            "value": "hgnc:6407"
          }
        ],
        "type": "Gene"
      }
    },
    "variant": "variants.json#/moa.variant:372",
    "specifiedBy": "methods.json#/moa.variant:372",
    "isReportedIn": [
      "documents.json#/moa.source:130"
    ],
    "strength": "strengths.json#/vicc.e000002",
    "therapeutic": "therapeutics.json#/moa.normalize.therapy.rxcui:2550714",
    "tumorType": "tumorTypes.json#/moa.normalize.disease.ncit:C2926"
  },
  {
    "id": "moa.assertion:386",
    "description": "Presence of this variant in vitro suggests resistance to PLX4720, a precursor to Vemurafenib, in metastatic melanoma.",
    "type": "VariantTherapeuticResponseStudy",
    "predicate": "predictsResistanceTo",
    "direction": "none",
    "qualifiers": {
      "alleleOrigin": "somatic",
      "geneContext": {
        "id": "moa.normalize.gene:MAP2K1",
        "label": "MAP2K1",
        "extensions": [
          {
            "type": "Extension",
            "name": "gene_normalizer_id",
            "value": "hgnc:6840"
          }
        ],
        "type": "Gene"
      }
    },
    "variant": "variants.json#/moa.variant:386",
    "specifiedBy": "methods.json#/moa.variant:386",
    "isReportedIn": [
      "documents.json#/moa.source:69"
    ],
    "strength": "strengths.json#/vicc.e000009",
    "therapeutic": "therapeutics.json#/moa.normalize.therapy.rxcui:1147220",
    "tumorType": "tumorTypes.json#/moa.normalize.disease.ncit:C3224"
  },
  {
    "id": "moa.assertion:387",
    "description": "Presence of this variant in vitro suggests resistance to PLX4720, a precursor to Vemurafenib, in metastatic melanoma.",
    "type": "VariantTherapeuticResponseStudy",
    "predicate": "predictsResistanceTo",
    "direction": "none",
    "qualifiers": {
      "alleleOrigin": "somatic",
      "geneContext": {
        "id": "moa.normalize.gene:MAP2K1",
        "label": "MAP2K1",
        "extensions": [
          {
            "type": "Extension",
            "name": "gene_normalizer_id",
            "value": "hgnc:6840"
          }
        ],
        "type": "Gene"
      }
    },
    "variant": "variants.json#/moa.variant:387",
    "specifiedBy": "methods.json#/moa.variant:387",
    "isReportedIn": [
      "documents.json#/moa.source:69"
    ],
    "strength": "strengths.json#/vicc.e000009",
    "therapeutic": "therapeutics.json#/moa.normalize.therapy.rxcui:1147220",
    "tumorType": "tumorTypes.json#/moa.normalize.disease.ncit:C3224"
  },
  {
    "id": "moa.assertion:388",
    "description": "Presence of this variant may suggest resistance to Selumetinib.",
    "type": "VariantTherapeuticResponseStudy",
    "predicate": "predictsResistanceTo",
    "direction": "none",
    "qualifiers": {
      "alleleOrigin": "somatic",
      "geneContext": {
        "id": "moa.normalize.gene:MAP2K1",
        "label": "MAP2K1",
        "extensions": [
          {
            "type": "Extension",
            "name": "gene_normalizer_id",
            "value": "hgnc:6840"
          }
        ],
        "type": "Gene"
      }
    },
    "variant": "variants.json#/moa.variant:386",
    "specifiedBy": "methods.json#/moa.variant:386",
    "isReportedIn": [
      "documents.json#/moa.source:69"
    ],
    "strength": "strengths.json#/vicc.e000007",
    "therapeutic": "therapeutics.json#/moa.normalize.therapy.rxcui:2289380",
    "tumorType": "tumorTypes.json#/moa.normalize.disease.ncit:C3224"
  },
  {
    "id": "moa.assertion:389",
    "description": "Cell line NCI-H1437 harbors MAP2K1 p.Q56P, a known transformation-component allele of MEK1 originally identified in rat fibroblasts, and is sensitive to treatment with Selumetinib (AZD6244).",
    "type": "VariantTherapeuticResponseStudy",
    "predicate": "predictsSensitivityTo",
    "direction": "none",
    "qualifiers": {
      "alleleOrigin": "somatic",
      "geneContext": {
        "id": "moa.normalize.gene:MAP2K1",
        "label": "MAP2K1",
        "extensions": [
          {
            "type": "Extension",
            "name": "gene_normalizer_id",
            "value": "hgnc:6840"
          }
        ],
        "type": "Gene"
      }
    },
    "variant": "variants.json#/moa.variant:387",
    "specifiedBy": "methods.json#/moa.variant:387",
    "isReportedIn": [
      "documents.json#/moa.source:138"
    ],
    "strength": "strengths.json#/vicc.e000009",
    "therapeutic": "therapeutics.json#/moa.normalize.therapy.rxcui:2289380",
    "tumorType": "tumorTypes.json#/moa.normalize.disease.ncit:C2926"
  },
  {
    "id": "moa.assertion:390",
    "description": "MEK1 Q56P confers resistance to monotherapy with RAF or MEK inhibitors in vitro.",
    "type": "VariantTherapeuticResponseStudy",
    "predicate": "predictsResistanceTo",
    "direction": "none",
    "qualifiers": {
      "alleleOrigin": "somatic",
      "geneContext": {
        "id": "moa.normalize.gene:MAP2K1",
        "label": "MAP2K1",
        "extensions": [
          {
            "type": "Extension",
            "name": "gene_normalizer_id",
            "value": "hgnc:6840"
          }
        ],
        "type": "Gene"
      }
    },
    "variant": "variants.json#/moa.variant:387",
    "specifiedBy": "methods.json#/moa.variant:387",
    "isReportedIn": [
      "documents.json#/moa.source:139"
    ],
    "strength": "strengths.json#/vicc.e000009",
    "therapeutic": "therapeutics.json#/moa.normalize.therapy.rxcui:1147220",
    "tumorType": "tumorTypes.json#/moa.normalize.disease.ncit:C3224"
  },
  {
    "id": "moa.assertion:391",
    "description": "MEK1 Q56P confers resistance to monotherapy with RAF or MEK inhibitors in vitro.",
    "type": "VariantTherapeuticResponseStudy",
    "predicate": "predictsResistanceTo",
    "direction": "none",
    "qualifiers": {
      "alleleOrigin": "somatic",
      "geneContext": {
        "id": "moa.normalize.gene:MAP2K1",
        "label": "MAP2K1",
        "extensions": [
          {
            "type": "Extension",
            "name": "gene_normalizer_id",
            "value": "hgnc:6840"
          }
        ],
        "type": "Gene"
      }
    },
    "variant": "variants.json#/moa.variant:387",
    "specifiedBy": "methods.json#/moa.variant:387",
    "isReportedIn": [
      "documents.json#/moa.source:139"
    ],
    "strength": "strengths.json#/vicc.e000009",
    "therapeutic": "therapeutics.json#/moa.normalize.therapy.rxcui:2289380",
    "tumorType": "tumorTypes.json#/moa.normalize.disease.ncit:C3224"
  },
  {
    "id": "moa.assertion:392",
    "description": "MEK1 C121S confers resistance to monotherapy with RAF or MEK inhibitors in vitro.",
    "type": "VariantTherapeuticResponseStudy",
    "predicate": "predictsResistanceTo",
    "direction": "none",
    "qualifiers": {
      "alleleOrigin": "somatic",
      "geneContext": {
        "id": "moa.normalize.gene:MAP2K1",
        "label": "MAP2K1",
        "extensions": [
          {
            "type": "Extension",
            "name": "gene_normalizer_id",
            "value": "hgnc:6840"
          }
        ],
        "type": "Gene"
      }
    },
    "variant": "variants.json#/moa.variant:392",
    "specifiedBy": "methods.json#/moa.variant:392",
    "isReportedIn": [
      "documents.json#/moa.source:140"
    ],
    "strength": "strengths.json#/vicc.e000009",
    "therapeutic": "therapeutics.json#/moa.normalize.therapy.rxcui:1147220",
    "tumorType": "tumorTypes.json#/moa.normalize.disease.ncit:C3224"
  },
  {
    "id": "moa.assertion:393",
    "description": "MEK1 C121S confers resistance to monotherapy with RAF or MEK inhibitors in vitro.",
    "type": "VariantTherapeuticResponseStudy",
    "predicate": "predictsResistanceTo",
    "direction": "none",
    "qualifiers": {
      "alleleOrigin": "somatic",
      "geneContext": {
        "id": "moa.normalize.gene:MAP2K1",
        "label": "MAP2K1",
        "extensions": [
          {
            "type": "Extension",
            "name": "gene_normalizer_id",
            "value": "hgnc:6840"
          }
        ],
        "type": "Gene"
      }
    },
    "variant": "variants.json#/moa.variant:392",
    "specifiedBy": "methods.json#/moa.variant:392",
    "isReportedIn": [
      "documents.json#/moa.source:140"
    ],
    "strength": "strengths.json#/vicc.e000009",
    "therapeutic": "therapeutics.json#/moa.normalize.therapy.rxcui:2289380",
    "tumorType": "tumorTypes.json#/moa.normalize.disease.ncit:C3224"
  },
  {
    "id": "moa.assertion:394",
    "description": "MEK2 Q60P was observed in a patient's trametinib resistant tumor but not pretreatment tumor.",
    "type": "VariantTherapeuticResponseStudy",
    "predicate": "predictsResistanceTo",
    "direction": "none",
    "qualifiers": {
      "alleleOrigin": "somatic",
      "geneContext": {
        "id": "moa.normalize.gene:MAP2K2",
        "label": "MAP2K2",
        "extensions": [
          {
            "type": "Extension",
            "name": "gene_normalizer_id",
            "value": "hgnc:6842"
          }
        ],
        "type": "Gene"
      }
    },
    "variant": "variants.json#/moa.variant:394",
    "specifiedBy": "methods.json#/moa.variant:394",
    "isReportedIn": [
      "documents.json#/moa.source:76"
    ],
    "strength": "strengths.json#/vicc.e000007",
    "therapeutic": "therapeutics.json#/moa.normalize.therapy.rxcui:1425098",
    "tumorType": "tumorTypes.json#/moa.normalize.disease.ncit:C3224"
  },
  {
    "id": "moa.assertion:395",
    "description": "In an exceptional responder, erlotinib resulted in complete and rapid response in MAPK1 mutant HNSCC",
    "type": "VariantTherapeuticResponseStudy",
    "predicate": "predictsSensitivityTo",
    "direction": "none",
    "qualifiers": {
      "alleleOrigin": "somatic",
      "geneContext": {
        "id": "moa.normalize.gene:MAPK1",
        "label": "MAPK1",
        "extensions": [
          {
            "type": "Extension",
            "name": "gene_normalizer_id",
            "value": "hgnc:6871"
          }
        ],
        "type": "Gene"
      }
    },
    "variant": "variants.json#/moa.variant:395",
    "specifiedBy": "methods.json#/moa.variant:395",
    "isReportedIn": [
      "documents.json#/moa.source:141"
    ],
    "strength": "strengths.json#/vicc.e000009",
    "therapeutic": "therapeutics.json#/moa.normalize.therapy.rxcui:337525",
    "tumorType": "tumorTypes.json#/moa.normalize.disease.ncit:C34447"
  },
  {
    "id": "moa.assertion:397",
    "description": "Presence of this variant may suggest sensitivity to SU11274.",
    "type": "VariantTherapeuticResponseStudy",
    "predicate": "predictsSensitivityTo",
    "direction": "none",
    "qualifiers": {
      "alleleOrigin": "somatic",
      "geneContext": {
        "id": "moa.normalize.gene:MET",
        "label": "MET",
        "extensions": [
          {
            "type": "Extension",
            "name": "gene_normalizer_id",
            "value": "hgnc:7029"
          }
        ],
        "type": "Gene"
      }
    },
    "variant": "variants.json#/moa.variant:397",
    "specifiedBy": "methods.json#/moa.variant:397",
    "isReportedIn": [
      "documents.json#/moa.source:143"
    ],
    "strength": "strengths.json#/vicc.e000009",
    "therapeutic": "therapeutics.json#/moa.normalize.therapy.iuphar.ligand:5057",
    "tumorType": "tumorTypes.json#/moa.normalize.disease.ncit:C34447"
  },
  {
    "id": "moa.assertion:427",
    "description": "Presence of this variant may suggest sensitivity to Selumetinib.",
    "type": "VariantTherapeuticResponseStudy",
    "predicate": "predictsSensitivityTo",
    "direction": "none",
    "qualifiers": {
      "alleleOrigin": "somatic",
      "geneContext": {
        "id": "moa.normalize.gene:NRAS",
        "label": "NRAS",
        "extensions": [
          {
            "type": "Extension",
            "name": "gene_normalizer_id",
            "value": "hgnc:7989"
          }
        ],
        "type": "Gene"
      }
    },
    "variant": "variants.json#/moa.variant:427",
    "specifiedBy": "methods.json#/moa.variant:427",
    "isReportedIn": [
      "documents.json#/moa.source:149"
    ],
    "strength": "strengths.json#/vicc.e000007",
    "therapeutic": "therapeutics.json#/moa.normalize.therapy.rxcui:2289380",
    "tumorType": "tumorTypes.json#/moa.normalize.disease.ncit:C3224"
  },
  {
    "id": "moa.assertion:428",
    "description": "Presence of this variant may suggest sensitivity to Selumetinib.",
    "type": "VariantTherapeuticResponseStudy",
    "predicate": "predictsSensitivityTo",
    "direction": "none",
    "qualifiers": {
      "alleleOrigin": "somatic",
      "geneContext": {
        "id": "moa.normalize.gene:NRAS",
        "label": "NRAS",
        "extensions": [
          {
            "type": "Extension",
            "name": "gene_normalizer_id",
            "value": "hgnc:7989"
          }
        ],
        "type": "Gene"
      }
    },
    "variant": "variants.json#/moa.variant:414",
    "specifiedBy": "methods.json#/moa.variant:414",
    "isReportedIn": [
      "documents.json#/moa.source:149"
    ],
    "strength": "strengths.json#/vicc.e000007",
    "therapeutic": "therapeutics.json#/moa.normalize.therapy.rxcui:2289380",
    "tumorType": "tumorTypes.json#/moa.normalize.disease.ncit:C3224"
  },
  {
    "id": "moa.assertion:429",
    "description": "Presence of this variant may suggest sensitivity to Selumetinib.",
    "type": "VariantTherapeuticResponseStudy",
    "predicate": "predictsSensitivityTo",
    "direction": "none",
    "qualifiers": {
      "alleleOrigin": "somatic",
      "geneContext": {
        "id": "moa.normalize.gene:NRAS",
        "label": "NRAS",
        "extensions": [
          {
            "type": "Extension",
            "name": "gene_normalizer_id",
            "value": "hgnc:7989"
          }
        ],
        "type": "Gene"
      }
    },
    "variant": "variants.json#/moa.variant:415",
    "specifiedBy": "methods.json#/moa.variant:415",
    "isReportedIn": [
      "documents.json#/moa.source:149"
    ],
    "strength": "strengths.json#/vicc.e000007",
    "therapeutic": "therapeutics.json#/moa.normalize.therapy.rxcui:2289380",
    "tumorType": "tumorTypes.json#/moa.normalize.disease.ncit:C3224"
  },
  {
    "id": "moa.assertion:430",
    "description": "Presence of this variant may suggest sensitivity to Selumetinib.",
    "type": "VariantTherapeuticResponseStudy",
    "predicate": "predictsSensitivityTo",
    "direction": "none",
    "qualifiers": {
      "alleleOrigin": "somatic",
      "geneContext": {
        "id": "moa.normalize.gene:NRAS",
        "label": "NRAS",
        "extensions": [
          {
            "type": "Extension",
            "name": "gene_normalizer_id",
            "value": "hgnc:7989"
          }
        ],
        "type": "Gene"
      }
    },
    "variant": "variants.json#/moa.variant:416",
    "specifiedBy": "methods.json#/moa.variant:416",
    "isReportedIn": [
      "documents.json#/moa.source:149"
    ],
    "strength": "strengths.json#/vicc.e000007",
    "therapeutic": "therapeutics.json#/moa.normalize.therapy.rxcui:2289380",
    "tumorType": "tumorTypes.json#/moa.normalize.disease.ncit:C3224"
  },
  {
    "id": "moa.assertion:431",
    "description": "Presence of this variant may suggest sensitivity to Selumetinib.",
    "type": "VariantTherapeuticResponseStudy",
    "predicate": "predictsSensitivityTo",
    "direction": "none",
    "qualifiers": {
      "alleleOrigin": "somatic",
      "geneContext": {
        "id": "moa.normalize.gene:NRAS",
        "label": "NRAS",
        "extensions": [
          {
            "type": "Extension",
            "name": "gene_normalizer_id",
            "value": "hgnc:7989"
          }
        ],
        "type": "Gene"
      }
    },
    "variant": "variants.json#/moa.variant:417",
    "specifiedBy": "methods.json#/moa.variant:417",
    "isReportedIn": [
      "documents.json#/moa.source:149"
    ],
    "strength": "strengths.json#/vicc.e000007",
    "therapeutic": "therapeutics.json#/moa.normalize.therapy.rxcui:2289380",
    "tumorType": "tumorTypes.json#/moa.normalize.disease.ncit:C3224"
  },
  {
    "id": "moa.assertion:432",
    "description": "Presence of this variant may suggest sensitivity to Selumetinib.",
    "type": "VariantTherapeuticResponseStudy",
    "predicate": "predictsSensitivityTo",
    "direction": "none",
    "qualifiers": {
      "alleleOrigin": "somatic",
      "geneContext": {
        "id": "moa.normalize.gene:NRAS",
        "label": "NRAS",
        "extensions": [
          {
            "type": "Extension",
            "name": "gene_normalizer_id",
            "value": "hgnc:7989"
          }
        ],
        "type": "Gene"
      }
    },
    "variant": "variants.json#/moa.variant:418",
    "specifiedBy": "methods.json#/moa.variant:418",
    "isReportedIn": [
      "documents.json#/moa.source:149"
    ],
    "strength": "strengths.json#/vicc.e000007",
    "therapeutic": "therapeutics.json#/moa.normalize.therapy.rxcui:2289380",
    "tumorType": "tumorTypes.json#/moa.normalize.disease.ncit:C3224"
  },
  {
    "id": "moa.assertion:433",
    "description": "Presence of this variant may suggest sensitivity to Selumetinib.",
    "type": "VariantTherapeuticResponseStudy",
    "predicate": "predictsSensitivityTo",
    "direction": "none",
    "qualifiers": {
      "alleleOrigin": "somatic",
      "geneContext": {
        "id": "moa.normalize.gene:NRAS",
        "label": "NRAS",
        "extensions": [
          {
            "type": "Extension",
            "name": "gene_normalizer_id",
            "value": "hgnc:7989"
          }
        ],
        "type": "Gene"
      }
    },
    "variant": "variants.json#/moa.variant:419",
    "specifiedBy": "methods.json#/moa.variant:419",
    "isReportedIn": [
      "documents.json#/moa.source:149"
    ],
    "strength": "strengths.json#/vicc.e000007",
    "therapeutic": "therapeutics.json#/moa.normalize.therapy.rxcui:2289380",
    "tumorType": "tumorTypes.json#/moa.normalize.disease.ncit:C3224"
  },
  {
    "id": "moa.assertion:434",
    "description": "Presence of this variant may suggest sensitivity to Selumetinib.",
    "type": "VariantTherapeuticResponseStudy",
    "predicate": "predictsSensitivityTo",
    "direction": "none",
    "qualifiers": {
      "alleleOrigin": "somatic",
      "geneContext": {
        "id": "moa.normalize.gene:NRAS",
        "label": "NRAS",
        "extensions": [
          {
            "type": "Extension",
            "name": "gene_normalizer_id",
            "value": "hgnc:7989"
          }
        ],
        "type": "Gene"
      }
    },
    "variant": "variants.json#/moa.variant:420",
    "specifiedBy": "methods.json#/moa.variant:420",
    "isReportedIn": [
      "documents.json#/moa.source:149"
    ],
    "strength": "strengths.json#/vicc.e000007",
    "therapeutic": "therapeutics.json#/moa.normalize.therapy.rxcui:2289380",
    "tumorType": "tumorTypes.json#/moa.normalize.disease.ncit:C3224"
  },
  {
    "id": "moa.assertion:435",
    "description": "Presence of this variant may suggest sensitivity to Selumetinib.",
    "type": "VariantTherapeuticResponseStudy",
    "predicate": "predictsSensitivityTo",
    "direction": "none",
    "qualifiers": {
      "alleleOrigin": "somatic",
      "geneContext": {
        "id": "moa.normalize.gene:NRAS",
        "label": "NRAS",
        "extensions": [
          {
            "type": "Extension",
            "name": "gene_normalizer_id",
            "value": "hgnc:7989"
          }
        ],
        "type": "Gene"
      }
    },
    "variant": "variants.json#/moa.variant:421",
    "specifiedBy": "methods.json#/moa.variant:421",
    "isReportedIn": [
      "documents.json#/moa.source:149"
    ],
    "strength": "strengths.json#/vicc.e000007",
    "therapeutic": "therapeutics.json#/moa.normalize.therapy.rxcui:2289380",
    "tumorType": "tumorTypes.json#/moa.normalize.disease.ncit:C3224"
  },
  {
    "id": "moa.assertion:436",
    "description": "Presence of this variant may suggest sensitivity to Selumetinib.",
    "type": "VariantTherapeuticResponseStudy",
    "predicate": "predictsSensitivityTo",
    "direction": "none",
    "qualifiers": {
      "alleleOrigin": "somatic",
      "geneContext": {
        "id": "moa.normalize.gene:NRAS",
        "label": "NRAS",
        "extensions": [
          {
            "type": "Extension",
            "name": "gene_normalizer_id",
            "value": "hgnc:7989"
          }
        ],
        "type": "Gene"
      }
    },
    "variant": "variants.json#/moa.variant:422",
    "specifiedBy": "methods.json#/moa.variant:422",
    "isReportedIn": [
      "documents.json#/moa.source:149"
    ],
    "strength": "strengths.json#/vicc.e000007",
    "therapeutic": "therapeutics.json#/moa.normalize.therapy.rxcui:2289380",
    "tumorType": "tumorTypes.json#/moa.normalize.disease.ncit:C3224"
  },
  {
    "id": "moa.assertion:437",
    "description": "Presence of this variant may suggest sensitivity to Selumetinib.",
    "type": "VariantTherapeuticResponseStudy",
    "predicate": "predictsSensitivityTo",
    "direction": "none",
    "qualifiers": {
      "alleleOrigin": "somatic",
      "geneContext": {
        "id": "moa.normalize.gene:NRAS",
        "label": "NRAS",
        "extensions": [
          {
            "type": "Extension",
            "name": "gene_normalizer_id",
            "value": "hgnc:7989"
          }
        ],
        "type": "Gene"
      }
    },
    "variant": "variants.json#/moa.variant:423",
    "specifiedBy": "methods.json#/moa.variant:423",
    "isReportedIn": [
      "documents.json#/moa.source:149"
    ],
    "strength": "strengths.json#/vicc.e000007",
    "therapeutic": "therapeutics.json#/moa.normalize.therapy.rxcui:2289380",
    "tumorType": "tumorTypes.json#/moa.normalize.disease.ncit:C3224"
  },
  {
    "id": "moa.assertion:438",
    "description": "Presence of this variant may suggest sensitivity to Selumetinib.",
    "type": "VariantTherapeuticResponseStudy",
    "predicate": "predictsSensitivityTo",
    "direction": "none",
    "qualifiers": {
      "alleleOrigin": "somatic",
      "geneContext": {
        "id": "moa.normalize.gene:NRAS",
        "label": "NRAS",
        "extensions": [
          {
            "type": "Extension",
            "name": "gene_normalizer_id",
            "value": "hgnc:7989"
          }
        ],
        "type": "Gene"
      }
    },
    "variant": "variants.json#/moa.variant:424",
    "specifiedBy": "methods.json#/moa.variant:424",
    "isReportedIn": [
      "documents.json#/moa.source:149"
    ],
    "strength": "strengths.json#/vicc.e000007",
    "therapeutic": "therapeutics.json#/moa.normalize.therapy.rxcui:2289380",
    "tumorType": "tumorTypes.json#/moa.normalize.disease.ncit:C3224"
  },
  {
    "id": "moa.assertion:439",
    "description": "Presence of this variant may suggest sensitivity to Selumetinib.",
    "type": "VariantTherapeuticResponseStudy",
    "predicate": "predictsSensitivityTo",
    "direction": "none",
    "qualifiers": {
      "alleleOrigin": "somatic",
      "geneContext": {
        "id": "moa.normalize.gene:NRAS",
        "label": "NRAS",
        "extensions": [
          {
            "type": "Extension",
            "name": "gene_normalizer_id",
            "value": "hgnc:7989"
          }
        ],
        "type": "Gene"
      }
    },
    "variant": "variants.json#/moa.variant:425",
    "specifiedBy": "methods.json#/moa.variant:425",
    "isReportedIn": [
      "documents.json#/moa.source:149"
    ],
    "strength": "strengths.json#/vicc.e000007",
    "therapeutic": "therapeutics.json#/moa.normalize.therapy.rxcui:2289380",
    "tumorType": "tumorTypes.json#/moa.normalize.disease.ncit:C3224"
  },
  {
    "id": "moa.assertion:440",
    "description": "Presence of this variant may suggest sensitivity to Selumetinib.",
    "type": "VariantTherapeuticResponseStudy",
    "predicate": "predictsSensitivityTo",
    "direction": "none",
    "qualifiers": {
      "alleleOrigin": "somatic",
      "geneContext": {
        "id": "moa.normalize.gene:NRAS",
        "label": "NRAS",
        "extensions": [
          {
            "type": "Extension",
            "name": "gene_normalizer_id",
            "value": "hgnc:7989"
          }
        ],
        "type": "Gene"
      }
    },
    "variant": "variants.json#/moa.variant:426",
    "specifiedBy": "methods.json#/moa.variant:426",
    "isReportedIn": [
      "documents.json#/moa.source:149"
    ],
    "strength": "strengths.json#/vicc.e000007",
    "therapeutic": "therapeutics.json#/moa.normalize.therapy.rxcui:2289380",
    "tumorType": "tumorTypes.json#/moa.normalize.disease.ncit:C3224"
  },
  {
    "id": "moa.assertion:441",
    "description": "Presence of this variant may suggest sensitivity to Selumetinib.",
    "type": "VariantTherapeuticResponseStudy",
    "predicate": "predictsSensitivityTo",
    "direction": "none",
    "qualifiers": {
      "alleleOrigin": "somatic",
      "geneContext": {
        "id": "moa.normalize.gene:NRAS",
        "label": "NRAS",
        "extensions": [
          {
            "type": "Extension",
            "name": "gene_normalizer_id",
            "value": "hgnc:7989"
          }
        ],
        "type": "Gene"
      }
    },
    "variant": "variants.json#/moa.variant:427",
    "specifiedBy": "methods.json#/moa.variant:427",
    "isReportedIn": [
      "documents.json#/moa.source:149"
    ],
    "strength": "strengths.json#/vicc.e000007",
    "therapeutic": "therapeutics.json#/moa.normalize.therapy.rxcui:2289380",
    "tumorType": "tumorTypes.json#/moa.normalize.disease.ncit:C3224"
  },
  {
    "id": "moa.assertion:454",
    "description": "Avapritnib inhibited the autophosphorylation of PDGFRA p.D842V in cellular assays.",
    "type": "VariantTherapeuticResponseStudy",
    "predicate": "predictsSensitivityTo",
    "direction": "none",
    "qualifiers": {
      "alleleOrigin": "somatic",
      "geneContext": {
        "id": "moa.normalize.gene:PDGFRA",
        "label": "PDGFRA",
        "extensions": [
          {
            "type": "Extension",
            "name": "gene_normalizer_id",
            "value": "hgnc:8803"
          }
        ],
        "type": "Gene"
      }
    },
    "variant": "variants.json#/moa.variant:453",
    "specifiedBy": "methods.json#/moa.variant:453",
    "isReportedIn": [
      "documents.json#/moa.source:127"
    ],
    "strength": "strengths.json#/vicc.e000009",
    "therapeutic": "therapeutics.json#/moa.normalize.therapy.rxcui:2272107",
    "tumorType": "tumorTypes.json#/moa.normalize.disease.ncit:C3868"
  },
  {
    "id": "moa.assertion:456",
    "description": "The U.S. Food and Drug Administration (FDA) granted approval to avapritinib, a KIT inhibitor, for the treatment of adults with unresectable or metastatic GIST harboring a platelet-derived growth factor alpha (PDGFRA) exon 18 variant, including PDGFRA p.D842V.",
    "type": "VariantTherapeuticResponseStudy",
    "predicate": "predictsSensitivityTo",
    "direction": "none",
    "qualifiers": {
      "alleleOrigin": "somatic",
      "geneContext": {
        "id": "moa.normalize.gene:PDGFRA",
        "label": "PDGFRA",
        "extensions": [
          {
            "type": "Extension",
            "name": "gene_normalizer_id",
            "value": "hgnc:8803"
          }
        ],
        "type": "Gene"
      }
    },
    "variant": "variants.json#/moa.variant:453",
    "specifiedBy": "methods.json#/moa.variant:453",
    "isReportedIn": [
      "documents.json#/moa.source:127"
    ],
    "strength": "strengths.json#/vicc.e000002",
    "therapeutic": "therapeutics.json#/moa.normalize.therapy.rxcui:2272107",
    "tumorType": "tumorTypes.json#/moa.normalize.disease.ncit:C3868"
  },
  {
    "id": "moa.assertion:461",
    "description": "In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.",
    "type": "VariantTherapeuticResponseStudy",
    "predicate": "predictsSensitivityTo",
    "direction": "none",
    "qualifiers": {
      "alleleOrigin": "somatic",
      "geneContext": {
        "id": "moa.normalize.gene:PIK3CA",
        "label": "PIK3CA",
        "extensions": [
          {
            "type": "Extension",
            "name": "gene_normalizer_id",
            "value": "hgnc:8975"
          }
        ],
        "type": "Gene"
      }
    },
    "variant": "variants.json#/moa.variant:461",
    "specifiedBy": "methods.json#/moa.variant:461",
    "isReportedIn": [
      "documents.json#/moa.source:58"
    ],
    "strength": "strengths.json#/vicc.e000009",
    "therapeutic": "therapeutics.json#/moa.normalize.therapy.ncit:C165479",
    "tumorType": "tumorTypes.json#/moa.normalize.disease.ncit:C9245"
  },
  {
    "id": "moa.assertion:462",
    "description": "In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.",
    "type": "VariantTherapeuticResponseStudy",
    "predicate": "predictsSensitivityTo",
    "direction": "none",
    "qualifiers": {
      "alleleOrigin": "somatic",
      "geneContext": {
        "id": "moa.normalize.gene:PIK3CA",
        "label": "PIK3CA",
        "extensions": [
          {
            "type": "Extension",
            "name": "gene_normalizer_id",
            "value": "hgnc:8975"
          }
        ],
        "type": "Gene"
      }
    },
    "variant": "variants.json#/moa.variant:462",
    "specifiedBy": "methods.json#/moa.variant:462",
    "isReportedIn": [
      "documents.json#/moa.source:58"
    ],
    "strength": "strengths.json#/vicc.e000009",
    "therapeutic": "therapeutics.json#/moa.normalize.therapy.ncit:C165479",
    "tumorType": "tumorTypes.json#/moa.normalize.disease.ncit:C9245"
  },
  {
    "id": "moa.assertion:463",
    "description": "In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.",
    "type": "VariantTherapeuticResponseStudy",
    "predicate": "predictsSensitivityTo",
    "direction": "none",
    "qualifiers": {
      "alleleOrigin": "somatic",
      "geneContext": {
        "id": "moa.normalize.gene:PIK3CA",
        "label": "PIK3CA",
        "extensions": [
          {
            "type": "Extension",
            "name": "gene_normalizer_id",
            "value": "hgnc:8975"
          }
        ],
        "type": "Gene"
      }
    },
    "variant": "variants.json#/moa.variant:463",
    "specifiedBy": "methods.json#/moa.variant:463",
    "isReportedIn": [
      "documents.json#/moa.source:58"
    ],
    "strength": "strengths.json#/vicc.e000009",
    "therapeutic": "therapeutics.json#/moa.normalize.therapy.ncit:C165479",
    "tumorType": "tumorTypes.json#/moa.normalize.disease.ncit:C9245"
  },
  {
    "id": "moa.assertion:464",
    "description": "In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.",
    "type": "VariantTherapeuticResponseStudy",
    "predicate": "predictsSensitivityTo",
    "direction": "none",
    "qualifiers": {
      "alleleOrigin": "somatic",
      "geneContext": {
        "id": "moa.normalize.gene:PIK3CA",
        "label": "PIK3CA",
        "extensions": [
          {
            "type": "Extension",
            "name": "gene_normalizer_id",
            "value": "hgnc:8975"
          }
        ],
        "type": "Gene"
      }
    },
    "variant": "variants.json#/moa.variant:464",
    "specifiedBy": "methods.json#/moa.variant:464",
    "isReportedIn": [
      "documents.json#/moa.source:58"
    ],
    "strength": "strengths.json#/vicc.e000009",
    "therapeutic": "therapeutics.json#/moa.normalize.therapy.ncit:C165479",
    "tumorType": "tumorTypes.json#/moa.normalize.disease.ncit:C9245"
  },
  {
    "id": "moa.assertion:465",
    "description": "In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.",
    "type": "VariantTherapeuticResponseStudy",
    "predicate": "predictsSensitivityTo",
    "direction": "none",
    "qualifiers": {
      "alleleOrigin": "somatic",
      "geneContext": {
        "id": "moa.normalize.gene:PIK3CA",
        "label": "PIK3CA",
        "extensions": [
          {
            "type": "Extension",
            "name": "gene_normalizer_id",
            "value": "hgnc:8975"
          }
        ],
        "type": "Gene"
      }
    },
    "variant": "variants.json#/moa.variant:465",
    "specifiedBy": "methods.json#/moa.variant:465",
    "isReportedIn": [
      "documents.json#/moa.source:58"
    ],
    "strength": "strengths.json#/vicc.e000009",
    "therapeutic": "therapeutics.json#/moa.normalize.therapy.ncit:C165479",
    "tumorType": "tumorTypes.json#/moa.normalize.disease.ncit:C9245"
  },
  {
    "id": "moa.assertion:466",
    "description": "In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.",
    "type": "VariantTherapeuticResponseStudy",
    "predicate": "predictsSensitivityTo",
    "direction": "none",
    "qualifiers": {
      "alleleOrigin": "somatic",
      "geneContext": {
        "id": "moa.normalize.gene:PIK3CA",
        "label": "PIK3CA",
        "extensions": [
          {
            "type": "Extension",
            "name": "gene_normalizer_id",
            "value": "hgnc:8975"
          }
        ],
        "type": "Gene"
      }
    },
    "variant": "variants.json#/moa.variant:466",
    "specifiedBy": "methods.json#/moa.variant:466",
    "isReportedIn": [
      "documents.json#/moa.source:58"
    ],
    "strength": "strengths.json#/vicc.e000009",
    "therapeutic": "therapeutics.json#/moa.normalize.therapy.ncit:C165479",
    "tumorType": "tumorTypes.json#/moa.normalize.disease.ncit:C9245"
  },
  {
    "id": "moa.assertion:467",
    "description": "In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.",
    "type": "VariantTherapeuticResponseStudy",
    "predicate": "predictsSensitivityTo",
    "direction": "none",
    "qualifiers": {
      "alleleOrigin": "somatic",
      "geneContext": {
        "id": "moa.normalize.gene:PIK3CA",
        "label": "PIK3CA",
        "extensions": [
          {
            "type": "Extension",
            "name": "gene_normalizer_id",
            "value": "hgnc:8975"
          }
        ],
        "type": "Gene"
      }
    },
    "variant": "variants.json#/moa.variant:466",
    "specifiedBy": "methods.json#/moa.variant:466",
    "isReportedIn": [
      "documents.json#/moa.source:58"
    ],
    "strength": "strengths.json#/vicc.e000009",
    "therapeutic": "therapeutics.json#/moa.normalize.therapy.ncit:C165479",
    "tumorType": "tumorTypes.json#/moa.normalize.disease.ncit:C9245"
  },
  {
    "id": "moa.assertion:468",
    "description": "In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.",
    "type": "VariantTherapeuticResponseStudy",
    "predicate": "predictsSensitivityTo",
    "direction": "none",
    "qualifiers": {
      "alleleOrigin": "somatic",
      "geneContext": {
        "id": "moa.normalize.gene:PIK3CA",
        "label": "PIK3CA",
        "extensions": [
          {
            "type": "Extension",
            "name": "gene_normalizer_id",
            "value": "hgnc:8975"
          }
        ],
        "type": "Gene"
      }
    },
    "variant": "variants.json#/moa.variant:468",
    "specifiedBy": "methods.json#/moa.variant:468",
    "isReportedIn": [
      "documents.json#/moa.source:58"
    ],
    "strength": "strengths.json#/vicc.e000009",
    "therapeutic": "therapeutics.json#/moa.normalize.therapy.ncit:C165479",
    "tumorType": "tumorTypes.json#/moa.normalize.disease.ncit:C9245"
  },
  {
    "id": "moa.assertion:469",
    "description": "In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.",
    "type": "VariantTherapeuticResponseStudy",
    "predicate": "predictsSensitivityTo",
    "direction": "none",
    "qualifiers": {
      "alleleOrigin": "somatic",
      "geneContext": {
        "id": "moa.normalize.gene:PIK3CA",
        "label": "PIK3CA",
        "extensions": [
          {
            "type": "Extension",
            "name": "gene_normalizer_id",
            "value": "hgnc:8975"
          }
        ],
        "type": "Gene"
      }
    },
    "variant": "variants.json#/moa.variant:469",
    "specifiedBy": "methods.json#/moa.variant:469",
    "isReportedIn": [
      "documents.json#/moa.source:58"
    ],
    "strength": "strengths.json#/vicc.e000009",
    "therapeutic": "therapeutics.json#/moa.normalize.therapy.ncit:C165479",
    "tumorType": "tumorTypes.json#/moa.normalize.disease.ncit:C9245"
  },
  {
    "id": "moa.assertion:470",
    "description": "In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.",
    "type": "VariantTherapeuticResponseStudy",
    "predicate": "predictsSensitivityTo",
    "direction": "none",
    "qualifiers": {
      "alleleOrigin": "somatic",
      "geneContext": {
        "id": "moa.normalize.gene:PIK3CA",
        "label": "PIK3CA",
        "extensions": [
          {
            "type": "Extension",
            "name": "gene_normalizer_id",
            "value": "hgnc:8975"
          }
        ],
        "type": "Gene"
      }
    },
    "variant": "variants.json#/moa.variant:470",
    "specifiedBy": "methods.json#/moa.variant:470",
    "isReportedIn": [
      "documents.json#/moa.source:58"
    ],
    "strength": "strengths.json#/vicc.e000009",
    "therapeutic": "therapeutics.json#/moa.normalize.therapy.ncit:C165479",
    "tumorType": "tumorTypes.json#/moa.normalize.disease.ncit:C9245"
  },
  {
    "id": "moa.assertion:471",
    "description": "In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.",
    "type": "VariantTherapeuticResponseStudy",
    "predicate": "predictsSensitivityTo",
    "direction": "none",
    "qualifiers": {
      "alleleOrigin": "somatic",
      "geneContext": {
        "id": "moa.normalize.gene:PIK3CA",
        "label": "PIK3CA",
        "extensions": [
          {
            "type": "Extension",
            "name": "gene_normalizer_id",
            "value": "hgnc:8975"
          }
        ],
        "type": "Gene"
      }
    },
    "variant": "variants.json#/moa.variant:471",
    "specifiedBy": "methods.json#/moa.variant:471",
    "isReportedIn": [
      "documents.json#/moa.source:58"
    ],
    "strength": "strengths.json#/vicc.e000009",
    "therapeutic": "therapeutics.json#/moa.normalize.therapy.ncit:C165479",
    "tumorType": "tumorTypes.json#/moa.normalize.disease.ncit:C9245"
  },
  {
    "id": "moa.assertion:472",
    "description": "In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.",
    "type": "VariantTherapeuticResponseStudy",
    "predicate": "predictsSensitivityTo",
    "direction": "none",
    "qualifiers": {
      "alleleOrigin": "somatic",
      "geneContext": {
        "id": "moa.normalize.gene:PIK3CA",
        "label": "PIK3CA",
        "extensions": [
          {
            "type": "Extension",
            "name": "gene_normalizer_id",
            "value": "hgnc:8975"
          }
        ],
        "type": "Gene"
      }
    },
    "variant": "variants.json#/moa.variant:472",
    "specifiedBy": "methods.json#/moa.variant:472",
    "isReportedIn": [
      "documents.json#/moa.source:58"
    ],
    "strength": "strengths.json#/vicc.e000009",
    "therapeutic": "therapeutics.json#/moa.normalize.therapy.ncit:C165479",
    "tumorType": "tumorTypes.json#/moa.normalize.disease.ncit:C9245"
  },
  {
    "id": "moa.assertion:473",
    "description": "In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.",
    "type": "VariantTherapeuticResponseStudy",
    "predicate": "predictsSensitivityTo",
    "direction": "none",
    "qualifiers": {
      "alleleOrigin": "somatic",
      "geneContext": {
        "id": "moa.normalize.gene:PIK3CA",
        "label": "PIK3CA",
        "extensions": [
          {
            "type": "Extension",
            "name": "gene_normalizer_id",
            "value": "hgnc:8975"
          }
        ],
        "type": "Gene"
      }
    },
    "variant": "variants.json#/moa.variant:473",
    "specifiedBy": "methods.json#/moa.variant:473",
    "isReportedIn": [
      "documents.json#/moa.source:58"
    ],
    "strength": "strengths.json#/vicc.e000009",
    "therapeutic": "therapeutics.json#/moa.normalize.therapy.ncit:C165479",
    "tumorType": "tumorTypes.json#/moa.normalize.disease.ncit:C9245"
  },
  {
    "id": "moa.assertion:474",
    "description": "In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.",
    "type": "VariantTherapeuticResponseStudy",
    "predicate": "predictsSensitivityTo",
    "direction": "none",
    "qualifiers": {
      "alleleOrigin": "somatic",
      "geneContext": {
        "id": "moa.normalize.gene:PIK3CA",
        "label": "PIK3CA",
        "extensions": [
          {
            "type": "Extension",
            "name": "gene_normalizer_id",
            "value": "hgnc:8975"
          }
        ],
        "type": "Gene"
      }
    },
    "variant": "variants.json#/moa.variant:474",
    "specifiedBy": "methods.json#/moa.variant:474",
    "isReportedIn": [
      "documents.json#/moa.source:58"
    ],
    "strength": "strengths.json#/vicc.e000009",
    "therapeutic": "therapeutics.json#/moa.normalize.therapy.ncit:C165479",
    "tumorType": "tumorTypes.json#/moa.normalize.disease.ncit:C9245"
  },
  {
    "id": "moa.assertion:475",
    "description": "In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.",
    "type": "VariantTherapeuticResponseStudy",
    "predicate": "predictsSensitivityTo",
    "direction": "none",
    "qualifiers": {
      "alleleOrigin": "somatic",
      "geneContext": {
        "id": "moa.normalize.gene:PIK3CA",
        "label": "PIK3CA",
        "extensions": [
          {
            "type": "Extension",
            "name": "gene_normalizer_id",
            "value": "hgnc:8975"
          }
        ],
        "type": "Gene"
      }
    },
    "variant": "variants.json#/moa.variant:475",
    "specifiedBy": "methods.json#/moa.variant:475",
    "isReportedIn": [
      "documents.json#/moa.source:58"
    ],
    "strength": "strengths.json#/vicc.e000009",
    "therapeutic": "therapeutics.json#/moa.normalize.therapy.ncit:C165479",
    "tumorType": "tumorTypes.json#/moa.normalize.disease.ncit:C9245"
  },
  {
    "id": "moa.assertion:476",
    "description": "In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.",
    "type": "VariantTherapeuticResponseStudy",
    "predicate": "predictsSensitivityTo",
    "direction": "none",
    "qualifiers": {
      "alleleOrigin": "somatic",
      "geneContext": {
        "id": "moa.normalize.gene:PIK3CA",
        "label": "PIK3CA",
        "extensions": [
          {
            "type": "Extension",
            "name": "gene_normalizer_id",
            "value": "hgnc:8975"
          }
        ],
        "type": "Gene"
      }
    },
    "variant": "variants.json#/moa.variant:476",
    "specifiedBy": "methods.json#/moa.variant:476",
    "isReportedIn": [
      "documents.json#/moa.source:58"
    ],
    "strength": "strengths.json#/vicc.e000009",
    "therapeutic": "therapeutics.json#/moa.normalize.therapy.ncit:C165479",
    "tumorType": "tumorTypes.json#/moa.normalize.disease.ncit:C9245"
  },
  {
    "id": "moa.assertion:477",
    "description": "In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.",
    "type": "VariantTherapeuticResponseStudy",
    "predicate": "predictsSensitivityTo",
    "direction": "none",
    "qualifiers": {
      "alleleOrigin": "somatic",
      "geneContext": {
        "id": "moa.normalize.gene:PIK3CA",
        "label": "PIK3CA",
        "extensions": [
          {
            "type": "Extension",
            "name": "gene_normalizer_id",
            "value": "hgnc:8975"
          }
        ],
        "type": "Gene"
      }
    },
    "variant": "variants.json#/moa.variant:476",
    "specifiedBy": "methods.json#/moa.variant:476",
    "isReportedIn": [
      "documents.json#/moa.source:58"
    ],
    "strength": "strengths.json#/vicc.e000009",
    "therapeutic": "therapeutics.json#/moa.normalize.therapy.ncit:C165479",
    "tumorType": "tumorTypes.json#/moa.normalize.disease.ncit:C9245"
  },
  {
    "id": "moa.assertion:478",
    "description": "In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.",
    "type": "VariantTherapeuticResponseStudy",
    "predicate": "predictsSensitivityTo",
    "direction": "none",
    "qualifiers": {
      "alleleOrigin": "somatic",
      "geneContext": {
        "id": "moa.normalize.gene:PIK3CA",
        "label": "PIK3CA",
        "extensions": [
          {
            "type": "Extension",
            "name": "gene_normalizer_id",
            "value": "hgnc:8975"
          }
        ],
        "type": "Gene"
      }
    },
    "variant": "variants.json#/moa.variant:478",
    "specifiedBy": "methods.json#/moa.variant:478",
    "isReportedIn": [
      "documents.json#/moa.source:58"
    ],
    "strength": "strengths.json#/vicc.e000009",
    "therapeutic": "therapeutics.json#/moa.normalize.therapy.ncit:C165479",
    "tumorType": "tumorTypes.json#/moa.normalize.disease.ncit:C9245"
  },
  {
    "id": "moa.assertion:479",
    "description": "In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.",
    "type": "VariantTherapeuticResponseStudy",
    "predicate": "predictsSensitivityTo",
    "direction": "none",
    "qualifiers": {
      "alleleOrigin": "somatic",
      "geneContext": {
        "id": "moa.normalize.gene:PIK3CA",
        "label": "PIK3CA",
        "extensions": [
          {
            "type": "Extension",
            "name": "gene_normalizer_id",
            "value": "hgnc:8975"
          }
        ],
        "type": "Gene"
      }
    },
    "variant": "variants.json#/moa.variant:479",
    "specifiedBy": "methods.json#/moa.variant:479",
    "isReportedIn": [
      "documents.json#/moa.source:58"
    ],
    "strength": "strengths.json#/vicc.e000009",
    "therapeutic": "therapeutics.json#/moa.normalize.therapy.ncit:C165479",
    "tumorType": "tumorTypes.json#/moa.normalize.disease.ncit:C9245"
  },
  {
    "id": "moa.assertion:480",
    "description": "In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.",
    "type": "VariantTherapeuticResponseStudy",
    "predicate": "predictsSensitivityTo",
    "direction": "none",
    "qualifiers": {
      "alleleOrigin": "somatic",
      "geneContext": {
        "id": "moa.normalize.gene:PIK3CA",
        "label": "PIK3CA",
        "extensions": [
          {
            "type": "Extension",
            "name": "gene_normalizer_id",
            "value": "hgnc:8975"
          }
        ],
        "type": "Gene"
      }
    },
    "variant": "variants.json#/moa.variant:480",
    "specifiedBy": "methods.json#/moa.variant:480",
    "isReportedIn": [
      "documents.json#/moa.source:58"
    ],
    "strength": "strengths.json#/vicc.e000009",
    "therapeutic": "therapeutics.json#/moa.normalize.therapy.ncit:C165479",
    "tumorType": "tumorTypes.json#/moa.normalize.disease.ncit:C9245"
  },
  {
    "id": "moa.assertion:521",
    "description": "Certain missesnse mutations may predict resistance to RET inhibitors",
    "type": "VariantTherapeuticResponseStudy",
    "predicate": "predictsResistanceTo",
    "direction": "none",
    "qualifiers": {
      "alleleOrigin": "somatic",
      "geneContext": {
        "id": "moa.normalize.gene:RET",
        "label": "RET",
        "extensions": [
          {
            "type": "Extension",
            "name": "gene_normalizer_id",
            "value": "hgnc:9967"
          }
        ],
        "type": "Gene"
      }
    },
    "variant": "variants.json#/moa.variant:521",
    "specifiedBy": "methods.json#/moa.variant:521",
    "isReportedIn": [
      "documents.json#/moa.source:159"
    ],
    "strength": "strengths.json#/vicc.e000007",
    "therapeutic": "therapeutics.json#/moa.normalize.therapy.rxcui:2370147",
    "tumorType": "tumorTypes.json#/moa.normalize.disease.ncit:C3879"
  },
  {
    "id": "moa.assertion:522",
    "description": "Certain missesnse mutations may predict sensitivity to RET inhibitors",
    "type": "VariantTherapeuticResponseStudy",
    "predicate": "predictsSensitivityTo",
    "direction": "none",
    "qualifiers": {
      "alleleOrigin": "somatic",
      "geneContext": {
        "id": "moa.normalize.gene:RET",
        "label": "RET",
        "extensions": [
          {
            "type": "Extension",
            "name": "gene_normalizer_id",
            "value": "hgnc:9967"
          }
        ],
        "type": "Gene"
      }
    },
    "variant": "variants.json#/moa.variant:522",
    "specifiedBy": "methods.json#/moa.variant:522",
    "isReportedIn": [
      "documents.json#/moa.source:159"
    ],
    "strength": "strengths.json#/vicc.e000007",
    "therapeutic": "therapeutics.json#/moa.normalize.therapy.rxcui:2370147",
    "tumorType": "tumorTypes.json#/moa.normalize.disease.ncit:C3879"
  },
  {
    "id": "moa.assertion:814",
    "description": "The U.S. Food and Drug Administration (FDA) granted approval to ivosidenib in combination with azacitidine or as a monotherapy indicated for patients with a susceptible iDH1 mutation as detected by an FDA-approved test for the treatment of newly diagnosed AML in adults 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy.",
    "type": "VariantTherapeuticResponseStudy",
    "predicate": "predictsSensitivityTo",
    "direction": "none",
    "qualifiers": {
      "alleleOrigin": "somatic",
      "geneContext": {
        "id": "moa.normalize.gene:IDH1",
        "label": "IDH1",
        "extensions": [
          {
            "type": "Extension",
            "name": "gene_normalizer_id",
            "value": "hgnc:5382"
          }
        ],
        "type": "Gene"
      }
    },
    "variant": "variants.json#/moa.variant:310",
    "specifiedBy": "methods.json#/moa.variant:310",
    "isReportedIn": [
      "documents.json#/moa.source:235"
    ],
    "strength": "strengths.json#/vicc.e000002",
    "therapeutic": "therapeutics.json#/moa.normalize.therapy.rxcui:2049873",
    "tumorType": "tumorTypes.json#/moa.normalize.disease.ncit:C3171"
  },
  {
    "id": "moa.assertion:815",
    "description": "The U.S. Food and Drug Administration (FDA) granted approval to ivosidenib in combination with azacitidine or as a monotherapy indicated for patients with a susceptible iDH1 mutation as detected by an FDA-approved test for the treatment of newly diagnosed AML in adults 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy.",
    "type": "VariantTherapeuticResponseStudy",
    "predicate": "predictsSensitivityTo",
    "direction": "none",
    "qualifiers": {
      "alleleOrigin": "somatic",
      "geneContext": {
        "id": "moa.normalize.gene:IDH1",
        "label": "IDH1",
        "extensions": [
          {
            "type": "Extension",
            "name": "gene_normalizer_id",
            "value": "hgnc:5382"
          }
        ],
        "type": "Gene"
      }
    },
    "variant": "variants.json#/moa.variant:311",
    "specifiedBy": "methods.json#/moa.variant:311",
    "isReportedIn": [
      "documents.json#/moa.source:235"
    ],
    "strength": "strengths.json#/vicc.e000002",
    "therapeutic": "therapeutics.json#/moa.normalize.therapy.rxcui:2049873",
    "tumorType": "tumorTypes.json#/moa.normalize.disease.ncit:C3171"
  },
  {
    "id": "moa.assertion:816",
    "description": "The U.S. Food and Drug Administration (FDA) granted approval to ivosidenib in combination with azacitidine or as a monotherapy indicated for patients with a susceptible iDH1 mutation as detected by an FDA-approved test for the treatment of newly diagnosed AML in adults 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy.",
    "type": "VariantTherapeuticResponseStudy",
    "predicate": "predictsSensitivityTo",
    "direction": "none",
    "qualifiers": {
      "alleleOrigin": "somatic",
      "geneContext": {
        "id": "moa.normalize.gene:IDH1",
        "label": "IDH1",
        "extensions": [
          {
            "type": "Extension",
            "name": "gene_normalizer_id",
            "value": "hgnc:5382"
          }
        ],
        "type": "Gene"
      }
    },
    "variant": "variants.json#/moa.variant:310",
    "specifiedBy": "methods.json#/moa.variant:310",
    "isReportedIn": [
      "documents.json#/moa.source:235"
    ],
    "strength": "strengths.json#/vicc.e000002",
    "therapeutic": "therapeutics.json#/moa.ctid:q8-EQ3sEvpFi9GFxwRkBI4-kW-qt4Ka0",
    "tumorType": "tumorTypes.json#/moa.normalize.disease.ncit:C3171"
  },
  {
    "id": "moa.assertion:817",
    "description": "The U.S. Food and Drug Administration (FDA) granted approval to ivosidenib in combination with azacitidine or as a monotherapy indicated for patients with a susceptible iDH1 mutation as detected by an FDA-approved test for the treatment of newly diagnosed AML in adults 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy.",
    "type": "VariantTherapeuticResponseStudy",
    "predicate": "predictsSensitivityTo",
    "direction": "none",
    "qualifiers": {
      "alleleOrigin": "somatic",
      "geneContext": {
        "id": "moa.normalize.gene:IDH1",
        "label": "IDH1",
        "extensions": [
          {
            "type": "Extension",
            "name": "gene_normalizer_id",
            "value": "hgnc:5382"
          }
        ],
        "type": "Gene"
      }
    },
    "variant": "variants.json#/moa.variant:311",
    "specifiedBy": "methods.json#/moa.variant:311",
    "isReportedIn": [
      "documents.json#/moa.source:235"
    ],
    "strength": "strengths.json#/vicc.e000002",
    "therapeutic": "therapeutics.json#/moa.ctid:q8-EQ3sEvpFi9GFxwRkBI4-kW-qt4Ka0",
    "tumorType": "tumorTypes.json#/moa.normalize.disease.ncit:C3171"
  },
  {
    "id": "moa.assertion:859",
    "description": "The U.S. Food and Drug Administration (FDA) has granted approval to Rezlidhia (olutasidenib) for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible IDH1 mutation as detected by an FDA-approved test.",
    "type": "VariantTherapeuticResponseStudy",
    "predicate": "predictsSensitivityTo",
    "direction": "none",
    "qualifiers": {
      "alleleOrigin": "somatic",
      "geneContext": {
        "id": "moa.normalize.gene:IDH1",
        "label": "IDH1",
        "extensions": [
          {
            "type": "Extension",
            "name": "gene_normalizer_id",
            "value": "hgnc:5382"
          }
        ],
        "type": "Gene"
      }
    },
    "variant": "variants.json#/moa.variant:311",
    "specifiedBy": "methods.json#/moa.variant:311",
    "isReportedIn": [
      "documents.json#/moa.source:254"
    ],
    "strength": "strengths.json#/vicc.e000002",
    "therapeutic": "therapeutics.json#/moa.normalize.therapy.ncit:C129687",
    "tumorType": "tumorTypes.json#/moa.normalize.disease.ncit:C3171"
  },
  {
    "id": "moa.assertion:860",
    "description": "The U.S. Food and Drug Administration (FDA) has granted approval to Rezlidhia (olutasidenib) for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible IDH1 mutation as detected by an FDA-approved test.",
    "type": "VariantTherapeuticResponseStudy",
    "predicate": "predictsSensitivityTo",
    "direction": "none",
    "qualifiers": {
      "alleleOrigin": "somatic",
      "geneContext": {
        "id": "moa.normalize.gene:IDH1",
        "label": "IDH1",
        "extensions": [
          {
            "type": "Extension",
            "name": "gene_normalizer_id",
            "value": "hgnc:5382"
          }
        ],
        "type": "Gene"
      }
    },
    "variant": "variants.json#/moa.variant:310",
    "specifiedBy": "methods.json#/moa.variant:310",
    "isReportedIn": [
      "documents.json#/moa.source:254"
    ],
    "strength": "strengths.json#/vicc.e000002",
    "therapeutic": "therapeutics.json#/moa.normalize.therapy.ncit:C129687",
    "tumorType": "tumorTypes.json#/moa.normalize.disease.ncit:C3171"
  },
  {
    "id": "moa.assertion:861",
    "description": "The U.S. Food and Drug Administration (FDA) has granted approval to Rezlidhia (olutasidenib) for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible IDH1 mutation as detected by an FDA-approved test.",
    "type": "VariantTherapeuticResponseStudy",
    "predicate": "predictsSensitivityTo",
    "direction": "none",
    "qualifiers": {
      "alleleOrigin": "somatic",
      "geneContext": {
        "id": "moa.normalize.gene:IDH1",
        "label": "IDH1",
        "extensions": [
          {
            "type": "Extension",
            "name": "gene_normalizer_id",
            "value": "hgnc:5382"
          }
        ],
        "type": "Gene"
      }
    },
    "variant": "variants.json#/moa.variant:861",
    "specifiedBy": "methods.json#/moa.variant:861",
    "isReportedIn": [
      "documents.json#/moa.source:254"
    ],
    "strength": "strengths.json#/vicc.e000002",
    "therapeutic": "therapeutics.json#/moa.normalize.therapy.ncit:C129687",
    "tumorType": "tumorTypes.json#/moa.normalize.disease.ncit:C3171"
  },
  {
    "id": "moa.assertion:862",
    "description": "The U.S. Food and Drug Administration (FDA) has granted approval to Rezlidhia (olutasidenib) for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible IDH1 mutation as detected by an FDA-approved test.",
    "type": "VariantTherapeuticResponseStudy",
    "predicate": "predictsSensitivityTo",
    "direction": "none",
    "qualifiers": {
      "alleleOrigin": "somatic",
      "geneContext": {
        "id": "moa.normalize.gene:IDH1",
        "label": "IDH1",
        "extensions": [
          {
            "type": "Extension",
            "name": "gene_normalizer_id",
            "value": "hgnc:5382"
          }
        ],
        "type": "Gene"
      }
    },
    "variant": "variants.json#/moa.variant:862",
    "specifiedBy": "methods.json#/moa.variant:862",
    "isReportedIn": [
      "documents.json#/moa.source:254"
    ],
    "strength": "strengths.json#/vicc.e000002",
    "therapeutic": "therapeutics.json#/moa.normalize.therapy.ncit:C129687",
    "tumorType": "tumorTypes.json#/moa.normalize.disease.ncit:C3171"
  },
  {
    "id": "moa.assertion:863",
    "description": "The U.S. Food and Drug Administration (FDA) has granted approval to Rezlidhia (olutasidenib) for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible IDH1 mutation as detected by an FDA-approved test.",
    "type": "VariantTherapeuticResponseStudy",
    "predicate": "predictsSensitivityTo",
    "direction": "none",
    "qualifiers": {
      "alleleOrigin": "somatic",
      "geneContext": {
        "id": "moa.normalize.gene:IDH1",
        "label": "IDH1",
        "extensions": [
          {
            "type": "Extension",
            "name": "gene_normalizer_id",
            "value": "hgnc:5382"
          }
        ],
        "type": "Gene"
      }
    },
    "variant": "variants.json#/moa.variant:863",
    "specifiedBy": "methods.json#/moa.variant:863",
    "isReportedIn": [
      "documents.json#/moa.source:254"
    ],
    "strength": "strengths.json#/vicc.e000002",
    "therapeutic": "therapeutics.json#/moa.normalize.therapy.ncit:C129687",
    "tumorType": "tumorTypes.json#/moa.normalize.disease.ncit:C3171"
  },
  {
    "id": "moa.assertion:864",
    "description": "The U.S. Food and Drug Administration (FDA) has granted approval to adagrasib for adult patients with KRAS G12C mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), as determined by an FDA approved test, who have received at least one prior systemic therapy.",
    "type": "VariantTherapeuticResponseStudy",
    "predicate": "predictsSensitivityTo",
    "direction": "none",
    "qualifiers": {
      "alleleOrigin": "somatic",
      "geneContext": {
        "id": "moa.normalize.gene:KRAS",
        "label": "KRAS",
        "extensions": [
          {
            "type": "Extension",
            "name": "gene_normalizer_id",
            "value": "hgnc:6407"
          }
        ],
        "type": "Gene"
      }
    },
    "variant": "variants.json#/moa.variant:372",
    "specifiedBy": "methods.json#/moa.variant:372",
    "isReportedIn": [
      "documents.json#/moa.source:255"
    ],
    "strength": "strengths.json#/vicc.e000002",
    "therapeutic": "therapeutics.json#/moa.normalize.therapy.ncit:C157493",
    "tumorType": "tumorTypes.json#/moa.normalize.disease.ncit:C2926"
  },
  {
    "id": "moa.assertion:867",
    "description": "The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of pediatric patients 1 year of age or older with low-grade glioma (LGG) with a BRAF V600E mutation who require systemic therapy.",
    "type": "VariantTherapeuticResponseStudy",
    "predicate": "predictsSensitivityTo",
    "direction": "none",
    "qualifiers": {
      "alleleOrigin": "somatic",
      "geneContext": {
        "id": "moa.normalize.gene:BRAF",
        "label": "BRAF",
        "extensions": [
          {
            "type": "Extension",
            "name": "gene_normalizer_id",
            "value": "hgnc:1097"
          }
        ],
        "type": "Gene"
      }
    },
    "variant": "variants.json#/moa.variant:144",
    "specifiedBy": "methods.json#/moa.variant:144",
    "isReportedIn": [
      "documents.json#/moa.source:258"
    ],
    "strength": "strengths.json#/vicc.e000002",
    "therapeutic": "therapeutics.json#/moa.ctid:mm4iftPYmDnZsAZWZwRW5l7p9lbvwqOJ",
    "tumorType": "tumorTypes.json#/moa.normalize.disease.oncotree:LGGNOS"
  },
  {
    "id": "moa.assertion:911",
    "description": "The U.S. Food and Drug Administration approved ivosidenib for adult patients with relapsed or refractory myelodysplastic syndromes (MDS) with a susceptible IDH1 mutation, as detected by an FDA-approved test.",
    "type": "VariantTherapeuticResponseStudy",
    "predicate": "predictsSensitivityTo",
    "direction": "none",
    "qualifiers": {
      "alleleOrigin": "somatic",
      "geneContext": {
        "id": "moa.normalize.gene:IDH1",
        "label": "IDH1",
        "extensions": [
          {
            "type": "Extension",
            "name": "gene_normalizer_id",
            "value": "hgnc:5382"
          }
        ],
        "type": "Gene"
      }
    },
    "variant": "variants.json#/moa.variant:310",
    "specifiedBy": "methods.json#/moa.variant:310",
    "isReportedIn": [
      "documents.json#/moa.source:268"
    ],
    "strength": "strengths.json#/vicc.e000002",
    "therapeutic": "therapeutics.json#/moa.normalize.therapy.rxcui:2049873",
    "tumorType": "tumorTypes.json#/moa.normalize.disease.ncit:C3247"
  },
  {
    "id": "moa.assertion:912",
    "description": "The U.S. Food and Drug Administration approved ivosidenib for adult patients with relapsed or refractory myelodysplastic syndromes (MDS) with a susceptible IDH1 mutation, as detected by an FDA-approved test.",
    "type": "VariantTherapeuticResponseStudy",
    "predicate": "predictsSensitivityTo",
    "direction": "none",
    "qualifiers": {
      "alleleOrigin": "somatic",
      "geneContext": {
        "id": "moa.normalize.gene:IDH1",
        "label": "IDH1",
        "extensions": [
          {
            "type": "Extension",
            "name": "gene_normalizer_id",
            "value": "hgnc:5382"
          }
        ],
        "type": "Gene"
      }
    },
    "variant": "variants.json#/moa.variant:311",
    "specifiedBy": "methods.json#/moa.variant:311",
    "isReportedIn": [
      "documents.json#/moa.source:268"
    ],
    "strength": "strengths.json#/vicc.e000002",
    "therapeutic": "therapeutics.json#/moa.normalize.therapy.rxcui:2049873",
    "tumorType": "tumorTypes.json#/moa.normalize.disease.ncit:C3247"
  },
  {
    "id": "moa.assertion:913",
    "description": "The U.S. Food and Drug Administration (FDA) approved encorafenib in combination with binimetinib for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutation, as detected by an FDA-approved test.",
    "type": "VariantTherapeuticResponseStudy",
    "predicate": "predictsSensitivityTo",
    "direction": "none",
    "qualifiers": {
      "alleleOrigin": "somatic",
      "geneContext": {
        "id": "moa.normalize.gene:BRAF",
        "label": "BRAF",
        "extensions": [
          {
            "type": "Extension",
            "name": "gene_normalizer_id",
            "value": "hgnc:1097"
          }
        ],
        "type": "Gene"
      }
    },
    "variant": "variants.json#/moa.variant:144",
    "specifiedBy": "methods.json#/moa.variant:144",
    "isReportedIn": [
      "documents.json#/moa.source:269"
    ],
    "strength": "strengths.json#/vicc.e000002",
    "therapeutic": "therapeutics.json#/moa.ctid:Ghu43xXqJAxMIyWjnLPSz84j2Mav-wAL",
    "tumorType": "tumorTypes.json#/moa.normalize.disease.ncit:C2926"
  },
  {
    "id": "moa.assertion:946",
    "description": "The U.S. Food and Drug Administration (FDA) approved vemurafenib for the treatment of patients with Erdheim-Chester disease and whose tumors harbor a BRAF V600 mutation.",
    "type": "VariantTherapeuticResponseStudy",
    "predicate": "predictsSensitivityTo",
    "direction": "none",
    "qualifiers": {
      "alleleOrigin": "somatic",
      "geneContext": {
        "id": "moa.normalize.gene:BRAF",
        "label": "BRAF",
        "extensions": [
          {
            "type": "Extension",
            "name": "gene_normalizer_id",
            "value": "hgnc:1097"
          }
        ],
        "type": "Gene"
      }
    },
    "variant": "variants.json#/moa.variant:144",
    "specifiedBy": "methods.json#/moa.variant:144",
    "isReportedIn": [
      "documents.json#/moa.source:273"
    ],
    "strength": "strengths.json#/vicc.e000002",
    "therapeutic": "therapeutics.json#/moa.normalize.therapy.rxcui:1147220",
    "tumorType": "tumorTypes.json#/moa.normalize.disease.ncit:C53972"
  },
  {
    "id": "moa.assertion:947",
    "description": "The U.S. Food and Drug Administration (FDA) approved vemurafenib for the treatment of patients with Erdheim-Chester disease and whose tumors harbor a BRAF V600 mutation.",
    "type": "VariantTherapeuticResponseStudy",
    "predicate": "predictsSensitivityTo",
    "direction": "none",
    "qualifiers": {
      "alleleOrigin": "somatic",
      "geneContext": {
        "id": "moa.normalize.gene:BRAF",
        "label": "BRAF",
        "extensions": [
          {
            "type": "Extension",
            "name": "gene_normalizer_id",
            "value": "hgnc:1097"
          }
        ],
        "type": "Gene"
      }
    },
    "variant": "variants.json#/moa.variant:146",
    "specifiedBy": "methods.json#/moa.variant:146",
    "isReportedIn": [
      "documents.json#/moa.source:273"
    ],
    "strength": "strengths.json#/vicc.e000002",
    "therapeutic": "therapeutics.json#/moa.normalize.therapy.rxcui:1147220",
    "tumorType": "tumorTypes.json#/moa.normalize.disease.ncit:C53972"
  }
]